

部 局	大学院医学研究科
講 座	外科系講座 腎泌尿器科学分野

氏 名 ふりがな 三宅 秀明 みやけ ひであき

学 歴	年 月 日	事 項
	1987年4月1日	神戸大学医学部入学
	1993年3月31日	神戸大学医学部卒業
	1994年4月1日	神戸大学大学院医学研究科入学
	1998年3月31日	神戸大学大学院医学研究科修了
	1996年4月1日～1997年9月30日	熊本大学大学院医学研究科(病理学系腫瘍医学)特別研究生(兼任)

学 位	年 月 日	事 項
	1998年3月31日	医学博士(神戸大学大学院医学研究科外科系泌尿器科学)

免 許	年 月 日	事 項
	1993年4月28日	医師免許証

認定医等	年 月 日	事 項
	1998年4月	日本泌尿器科学会専門医
	2001年8月	日本癌治療学会臨床試験登録医
	2003年4月	日本泌尿器科学会指導医
	2005年4月	日本臨床腫瘍学会暫定指導医
	2007年8月	日本がん治療認定医機構暫定教育医
	2008年4月	日本がん治療認定医機構がん治療認定医
	2009年5月	日本泌尿器科学会・日本泌尿器内視鏡学会泌尿器腹腔鏡技術認定医
	2010年1月	日本内視鏡外科学会技術認定医(泌尿器腹腔鏡)
	2012年8月	日本移植学会移植認定医
	2015年8月	日本泌尿器科学会・日本泌尿器内視鏡学会泌尿器ロボット支援手術プロクター
	2018年10月	日本泌尿器科学会・日本泌尿器内視鏡学会泌尿器ロボット支援手術プロクター(認定術式追加:腎部分切除術・膀胱全摘除術)
	2019年4月	da Vinci robotic surgery 見学施設認定 console surgeon
	2022年4月	hinotori robotic surgery 見学施設認定 cockpit surgeon

職 歴	年 月 日	事 項
	1993年6月1日～1994年3月31日	兵庫県立尼崎病院泌尿器科研修医
	1998年4月1日～2000年3月31日	The Prostate Centre, Vancouver General Hospital, Postdoctoral fellow
	2000年4月1日～2000年9月30日	私立新須磨病院泌尿器科医員
	2000年10月1日～2002年1月31日	神戸大学医学部附属泌尿器科医員
	2002年2月1日～2006年3月31日	兵庫県立成人病センター医長
	2006年4月1日～2007年3月31日	神戸大学医学部附属病院泌尿器科助手
	2007年4月1日～2007年4月30日	神戸大学医学部附属病院泌尿器科助教
	2007年5月1日～2010年7月31日	神戸大学医学部附属病院泌尿器科講師
	2010年8月1日～2015年10月31日	神戸大学大学院医学研究科外科系講座腎泌尿器科学分野准教授
	2015年11月1日～2017年3月31日	浜松医科大学医学部泌尿器学講座准教授
	2017年4月1日～	浜松医科大学医学部泌尿器学講座教授
	2007年4月1日～2009年3月31日	神戸大学医学部附属病院泌尿器科病棟医長、リスクマネージャー、11階北病棟主任(兼任)

2010年6月1日～2015年10月31日 神戸大学医学部附属病院泌尿器科診療科長補佐（兼任）  
2010年11月1日～ Vancouver Prostate Centre, Vancouver General Hospital, Associate  
Member（兼任）  
2015年11月1日～2017年3月31日 浜松医科大学医学部附属病院泌尿器科副科長（兼任）  
2017年4月1日～ 浜松医科大学医学部附属病院泌尿器科科長（兼任）  
2018年4月1日～ 静岡大学浜松医科大学共同大学院光医工学共同専攻応用光医工学部門教授  
（兼任）  
2019年4月1日～2022年3月31日 浜松医科大学医学部附属病院副病院長（運営・管理担当）  
（兼任）  
2020年4月1日～2022年3月31日 浜松医科大学教育研究評議会評議員（兼任）  
2020年4月1日～2022年3月31日 浜松医科大学学長選考会議委員（兼任）  
2022年4月1日～ 浜松医科大学キャンサーバイオバンク委員会委員長（兼任）  
2022年4月1日～ 浜松医科大学医学部附属病院腎センター長（兼任）

---

# 業 績 目 録

## 1. 著書

No. 1

(英文：番号，著者名（掲載順に全員），著書名，発行所，発行年（西暦），頁の順に記入してください。)

(和文：番号，著書名，著者名（掲載順に全員），発行所，頁，発行年（西暦）の順に記入してください。)

(英文)

1. Prostate cancer: biology, genetics, and the new therapeutics, Chung LW, Isaacs WB, Simons JW (Edit), Gleave ME, Miyake H, Nelson C, Rennie P, Leung S. Prostate cancer: biology, genetics, and the new therapeutics. Targeting antiapoptotic genes upregulated by androgen withdrawal using antisense oligodeoxynucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Human Press, 2001; pp327-340
2. Prostate cancer, Denis L, Bartsch G, Khoury S, Murai M, Partin A (Edit), Bartsch G, Chi K, Cussenot O, Frenkel E, Gleave M, Klocker H, Logothetis C, Miyake H, Schanlken J. Prostate cancer. Innovative approaches in medical management of prostate cancer: other than hormonal therapies. Health Publications, 2003; pp161-216
3. Hot topics in urology, Kirby RS, O' Leary MP (Edit), Gleave ME, Miyake H, Jansen B. Hot topics in urology. Antisense therapy in oncology: current status. Elsevier, 2004; pp39-151
4. Prostate Cancer: A Comprehensive Perspective, Tewari AK (Edit), Miyake H, Takenaka A, Fujisawa M. Biomarkers of potential therapeutic value. Springer, 2013; Section 1, Chapter 15
5. Medical treatment of urological malignancies, Steif C, Fizazi SK, Evans C (Edit), Gleave M, Azad AA, Bishop J, Brown M, Carver BS, Clarke N, Chi KN, Dehm SM, Feng F, Joshua AM, Khoja L, Lamoureux F, Loriot Y, Massard C, Miyake H, Raj GV, Ravindranathan P, Reiter RE, Tombal B, Zoubeidi A. Medical treatment of urological malignancies. Androgen pathway-targeted agents. International Consultation on Urological Diseases and European Association of Urology, 2015; pp415-482

(和文)

1. レジデントコンパス 泌尿器科編，野々村祝夫，鈴木啓悦（編），側腹部痛・背部痛，三宅秀明，ライフ・サイエンス，pp36-40，2007
2. 2008年卒後教育テキスト，日本泌尿器科学会（編），局所進行性前立腺癌に対する手術療法，三宅秀明，日本泌尿器科学会，pp51-56，2008
3. 2009年卒後教育テキスト，日本泌尿器科学会（編），低・中リスク非セミノーマに対する治療戦略，三宅秀明，日本泌尿器科学会，pp178-185，2009
4. 若い医師のための泌尿器科学，三宅秀明（編），腫瘍，三宅秀明，ベクトル・コア，pp128-156，2009
5. 腎がんにおける分子標的薬使用患者への実践対応マニュアル，植村天受，富田善彦，大家基嗣（編），肝・膵障害，三宅秀明，藤澤正人，メディカルレビュー社，pp42-45，2009
6. 腎移植症例集 2009，高橋公太，相川厚（編），LCT・FCXM クロスマッチ陰性，PRA・DSA

陽性であった献腎移植の1例, 石村武志, 兵頭洋二, 竹田雅, 三宅秀明, 田中一志, 武中篤, 藤澤正人, 日本医学館, pp171-173, 2009

7. 臨床泌尿器科増刊号 膀胱全摘と尿路変向術, 大家基嗣(編), 結腸導管造設術, 三宅秀明, 藤澤正人, 医学書院, pp173-178, 2009
8. 前立腺癌診療 こんなときどうする Q&A, 笈善行(編), 臨床病期 T3N0M0 前立腺癌の前立腺全摘除術は有効なのでしょうか?また, 手術方法は通常の前立腺全摘除術と同じでよいのでしょうか?, 三宅秀明, 藤澤正人, 中外医学社, pp74-77, 2010
9. 新 Urologic Surgery シリーズ 8 外傷の手術と救急処置, 松田公志, 中川昌之, 富田善彦(編), 腎外傷の手術, 三宅秀明, 藤澤正人, メディカルビュー社, pp30-39, 2011
10. 泌尿器科診療ガイド, 勝岡洋治(編), 腎盂・尿管腫瘍, 三宅秀明, 金芳堂, pp. 130-132, 2011
11. 2011 年卒後教育テキスト, 日本泌尿器科学会(編), 高リスク精巣腫瘍の治療, 三宅秀明, 日本泌尿器科学会, pp168-176, 2011
12. 腹腔鏡手術スキルアップ・シリーズ 腎泌尿器 症例から学ぶ術者のための実践手術手技, 川端岳, 武中篤, 田中一志(編), 腎静脈からの出血を来し pure laparoscopic surgery から hand-assisted surgery への変更を要した腹腔鏡下根治的右腎摘除術, 三宅秀明, ベクトル・コア, pp88-99, 2011
13. がんの浸潤・転移, 高井義美(編), 前立腺がん, 三宅秀明, 藤澤正人, 南山堂, pp34-43, 2011
14. 臨床泌尿器科増刊号 泌尿器科ベッドサイドマニュアル, 大家基嗣(編), 尿道カテーテル留置, 三宅秀明, 藤澤正人, 医学書院, pp57-61, 2012
15. 泌尿器科悪性腫瘍の治療戦略, 三宅秀明(編), 副腎癌, 原田健一, 三宅秀明, ベクトル・コア, pp129-140, 2012
16. 泌尿器科悪性腫瘍の治療戦略, 三宅秀明(編), 総論, 三宅秀明, ベクトル・コア, pp1-7, 2012.
17. 泌尿器科悪性腫瘍の治療戦略, 三宅秀明(編), 腎細胞癌, 三宅秀明, ベクトル・コア, pp9-28, 2012.
18. 泌尿器科悪性腫瘍の治療戦略, 三宅秀明(編), 腎盂・尿管癌, 三宅秀明, ベクトル・コア, pp29-45, 2012
19. 泌尿器科悪性腫瘍の治療戦略, 三宅秀明(編), 精巣腫瘍, 楠田雄司, 三宅秀明, ベクトル・コア, pp87-108, 2012
20. 2012 年卒後教育テキスト, 日本泌尿器科学会(編), 膀胱全摘除術と尿路変向, 三宅秀明, 日本泌尿器科学会, pp88-94, 2012
21. Year Book of RCC 2013, 富田善彦, 金山博臣, 植村天受, 篠原信雄(編), テムシロリムス, 三宅秀明, 藤澤正人, メディカルレビュー社, pp139-146, 2013

22. 去勢抵抗性前立腺癌, 鈴木和浩(編), ドセタキセル, 三宅秀明, 藤澤正人, 先端医学社, pp70-75, 2014
23. 2015 年卒後教育テキスト, 日本泌尿器科学会(編), ホルモン療法, 三宅秀明, 日本泌尿器科学会, pp292-296, 2015
24. 後期研修医がおさえておきたい泌尿器疾患アトラス, 高橋悟, 原勲, 舛森直哉, 久米春喜, 高橋哲(編), 上部尿路上皮癌, 古川順也, 三宅秀明, 藤澤正人, 医学図書出版株式会社, pp78-85, 2015
25. 後期研修医がおさえておきたい泌尿器疾患アトラス, 高橋悟, 原勲, 舛森直哉, 久米春喜, 高橋哲(編), 膀胱癌, 三宅秀明, 藤澤正人, 医学図書出版株式会社, pp86-91, 2015
26. Year Book of RCC 2015, 富田善彦, 金山博臣, 植村天受, 篠原信雄(編), 薬物療法の QOL 評価, 三宅秀明, 藤澤正人, メディカルレビュー社, pp43-51, 2015
27. 癌化学療法と制吐薬使用マニュアル 婦人科癌・泌尿器科癌編, MVAC 療法, 三宅秀明, 藤澤正人, メディカルレビュー社, pp40-41, 2016
28. Q & A でスッキリわかる前立腺癌, 鈴木啓悦(編), PSA 以外に有効な診断(バイオ)マーカーはありますか?, 三宅秀明, メジカルビュー社, pp67-69, 2017
29. 浜松医科大学医学部附属病院の最新医療, 浜松医科大学医学部附属病院(編), 泌尿器科領域におけるロボット支援手術, 三宅秀明, バリューメディカル, pp10-11, 2019
30. 浜松医科大学医学部附属病院の最新医療, 浜松医科大学医学部附属病院(編), 膀胱がんに対する光学的診断を用いた内視鏡手術, 三宅秀明, バリューメディカル, pp94, 2019
31. 浜松医科大学医学部附属病院の最新医療, 浜松医科大学医学部附属病院(編), 間質性膀胱炎に対するジメチルスルホキシド(DMSO)を用いた膀胱内注入療法, 三宅秀明, 大塚篤史, バリューメディカル, pp95, 2019
32. Urologic Surgery Next オープンサージャリー, 土谷順彦(編), 横隔膜へのアプローチ, 三宅秀明, メジカルビュー社, pp29-34, 2019
33. 今日の治療指針, 福井次矢, 高木誠, 小室一成(編), 性感染症(尿道炎), 三宅秀明, 医学書院, pp1191, 2019
34. 泌尿器外科特別号 泌尿器科薬物療法, 赤座英之(編), mTORI 総論, 三宅秀明, 医学図書出版, pp 26-28, 2019
35. 泌尿器外科特別号 泌尿器科薬物療法, 赤座英之(編), テムシロリムス, 三宅秀明, 医学図書出版, pp 29-31, 2019
36. 第 45 回尿路悪性腫瘍研究会記録集, 尿路悪性腫瘍研究会(編), 筋層非浸潤性膀胱がんの診断および予後予測における FISH 法の意義, 三宅秀明, 協和企画, pp19-23, 2019
37. 歯科衛生士のための全身疾患ハンドブック, 橋本賢二, 増本一真(編), 頻尿・尿失禁, 三宅秀明, 医歯薬出版株式会社, pp83-84, 2020
38. 今日の診断指針, 永井良三(編), 尿路の内視鏡診断, 三宅秀明, 医学書院, pp453-455, 2020

39. 今日の治療指針，福井次矢，高木誠，小室一成（編），精巣上体炎，精巣炎，三宅秀明，医学書院，pp1236-1237，2020
  40. 第46回尿路悪性腫瘍研究会記録集，尿路悪性腫瘍研究会（編），浸潤がん基準に準ずる治療を要するハイリスク非浸潤がんに対する取り組み，杉山貴之，三宅秀明，協和企画，pp24-29，2021
  41. 今日の治療指針，福井次矢，高木誠，小室一成（編），血尿（特発性腎出血を含む），三宅秀明，医学書院，pp1252-1253，2021
  42. 今日の治療指針，福井次矢，高木誠，小室一成（編），腎細胞癌，腎血管筋脂肪腫，三宅秀明，医学書院，pp1206-1208，2022
  43. 泌尿器科のくすり，影山慎二（編），前立腺癌（ホルモン感受性），松下雄登，三宅秀明，日本醫事新報社，pp193-202，2022
  44. 浜松医科大学医学部附属病院最新医療のいま，浜松医科大学医学部附属病院（編），体にやさしいロボット支援手術，三宅秀明，バリユーメディカル，pp98-99，2022
  45. 今日の治療指針，福井次矢，高木誠，小室一成（編），陰茎腫瘍，尖圭コンジローマ，三宅秀明，医学書院，pp1208-1209，2023
  46. 2023 後期研修医がおさえておきたい泌尿器手術 TOP30，菊地栄次，木村高弘，高木敏男，宮嶋哲（編），腎部分切除術（開放手術），三宅秀明，医学図書出版株式会社，pp2-6，2023
-

# 業 績 目 録

## 2. 論文 (原著)

No. 1

(英文：番号，著者名 (掲載順に全員)，論文題目，発行雑誌名，発行年 (西暦)，巻，頁，(IF= ， CI= ) の順に記入してください。 corresponding author(s)には，著者名の左に\*を付してください。)

(和文：番号，論文題目，著者名 (掲載順に全員)，発行雑誌名，巻，頁，発行年 (西暦) の順に記入してください。) [ 総説，その他も同様 (IF, CI は不要) ]

---

(英文)

- ① \*Miyake H, Hara I, Yoshimura K, Eto H, Arakawa S, Wada S, Chihara K, Kamidono S. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. *Cancer Res.* 1996; 56: 2440-5 (IF=13.312, CI=51)
2. \*Yoshimura K, Eto H, Miyake H, Hara I, Arakawa S, Kamidono S. Messenger ribonucleic acids for fibroblast growth factors and their receptor in human bladder and renal cell carcinoma cell lines. *Cancer Lett.* 1996; 103: 91-7 (IF=9.756, CI=24)
3. \*Miyake H, Hara I, Fujisawa M, Eto H, Okada H, Arakawa S, Kamidono S. Prognostic variables in patients with upper urinary tract cancers. *Int J Clin Oncol.* 1996; 1: 135-8 (IF=3.85, CI=0)
4. \*Miyake H, Hara I, Fujisawa M, Eto H, Okada H, Arakawa S, Kamidono S. A comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostatic cancer. *Int J Urol.* 1996; 3: 472-7 (IF=2.896, CI=0)
5. \*Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. *J Urol.* 1997; 157: 2351-5 (IF=7.641, CI=83)
6. \*Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Expression patterns of CD44 adhesion molecule in testicular germ cell tumors and normal testes. *Am J Pathol.* 1998; 152: 1157-60 (IF=5.77, CI=19)
7. \*Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. *Cancer Lett.* 1998; 123: 121-6 (IF=9.756, CI=50)
8. \*Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. *Int J Oncol.* 1998; 12: 469-73 (IF=5.884, CI=31)
9. \*Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. *Br J Urol.* 1998; 82: 494-8 (IF=1.69, CI=93)
10. \*Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S. Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant in the detection and monitoring of bladder cancer. *J Urol.* 1998; 160: 2004-8 (IF=7.641, CI=20)

11. Miyake H, Okamoto I, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S, \*Saya H. Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8-10/CD44v10 competitive RT-PCR. *Int J Cancer*. 1998; 79: 560-4 (IF=7.316, CI=14)
12. Nakamura H, Sudo T, Tsuiki H, Miyake H, Morisaki T, Sasaki J, Masuko N, Kochi M, Ushio Y, \*Saya H. Identification of a novel human homolog of the Drosophila dlq, P-dlg, specifically expressed in the gland tissues and interacting with p55. *FEBS Lett*. 1998; 433: 63-7 (IF=3.864, CI=43)
13. Miyake H, Nakamura H, Hara I, Gohji K, Arakawa S, Kamidono S, \*Saya H. Multifocal renal cell carcinoma: evidence for a common clonal origin. *Clin Cancer Res*. 1998; 4: 2491-4 (IF=13.801, CI=24)
14. \*Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H, Kamidono S. Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. *J Urol*. 1998; 160: 1562-6 (IF=7.641, CI=30)
15. \*Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. *Anticancer Res*. 1998; 18: 3087-92 (IF=2.435, CI=34)
16. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S, \*Saya H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. *Oncogene*. 1998; 16: 933-43 (IF=8.756, CI=112)
17. \*Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. Expression of MAGE genes in renal cell carcinoma. *Int J Mol Med*. 1998; 2: 57-60 (IF=5.314, CI=29)
18. \*Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S, Nakajima M. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. *Int J Cancer*. 1998; 79: 96-101 (IF=7.316, CI=106)
19. Okamoto I, Morisaki T, Sasaki J, Miyake H, Matsumoto M, Suga M, Ando M, \*Saya H. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. *J Nat Cancer Inst*. 1998; 90: 307-315 (IF=11.816, CI=57)
20. \*Gohji K, Hara I, Gotoh A, Eto H, Miyake H, Sugiyama T, Okada H, Arakawa S, Kamidono S. Multifocal renal cell carcinoma in Japanese patients with tumors with maximal diameters of 50 mm or less. *J Urol*. 1998; 159: 1144-7 (IF=7.641, CI=52)
21. \*Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Increased angiogenin expression in the tumor tissue and serum in urothelial carcinoma patients is related to disease progression and recurrence. *Cancer*. 1999; 86: 316-24 (IF=6.921, CI=72)
22. \*Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. Expression of fibroblast growth factors in human non-papillary renal cell carcinoma: Correlation with tumor progression. *Int J Clin Oncol*. 1999; 4: 74-7 (IF=3.85, CI=0)



23. \*Miyake H, Gohji K, Hara I, Eto H, Yamanaka K, Arakawa S, Kamidono S. Long-term results of neoadjuvant treatment with M-VAC (Methotrexate, Vinblastine, Doxorubicin, and Cisplatin) for locally invasive transitional cell carcinoma of the urothelium. *Int J Clin Oncol*. 1999; 4: 32-5 (IF=3.85, CI=0)
24. \*Hara I, Hara S, Miyake H, Yamanaka K, Nagai H, Gohji K, Arakawa S, Kamidono S. Expression of MAGE genes in testicular germ cell tumors. *Urology*. 1999; 53: 843-7 (IF=2.633, CI=21)
25. \*Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. *Int J Oncol*. 1999; 14: 535-41 (IF=5.884, CI=60)
26. \*Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. *Prostate*. 1999; 39: 123-9 (IF=4.012, CI=129)
27. \*Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. *Br J Cancer*. 1999; 79: 1651-6 (IF=9.082, CI=47)
28. \*Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. *Urology*. 1999; 53: 302-7 (IF=2.633, CI=38)
29. \*Miyake H, Hara I, Gohji K, Yamanaka K, Hara S, Arakawa S, Nakajima M, Kamidono S. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. *Clin Cancer Res*. 1999; 5: 2824-9 (IF=13.801, CI=30)
30. \*Miyake H, Hara I, Takechi Y, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Long-term follow-up in patients with bilateral testicular germ cell tumors: A report of 10 cases. *Int J Clin Oncol*. 1999; 4: 244-7 (IF=3.85, CI=0)
31. \*Hara I, Miyake H, Yamanaka K, Hara S, Arakawa S, Kamidono S. Expression of CD44 adhesion molecule in non-papillary renal cell carcinomas and normal kidneys. *Urology*. 1999; 54: 562-6 (IF=2.633, CI=15)
32. Yamanaka K, \*Hara I, Nagai H, Miyake H, Gohji K, Micellef MJ, Kurimoto M, Arakawa S, Kamidono S. Synergistic anti-tumor effects of interleukin 12 gene transfer and systemic administration of interleukin 18 in a mouse bladder cancer model. *Cancer Immunol Immunother*. 1999; 48: 297-302 (IF=6.63, CI=50)
33. \*Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. *J Urol*. 1999; 162: 916-21 (IF=7.641, CI=19)
34. Miyake H, Tolcher A, \*Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit

progression to androgen-independence after castration in the Shionogi tumor model. *Cancer Res.* 1999; 59: 4030-4 (IF=13.312, CI=129)

35. Nickerson T, Miyake H, Gleave ME, \*Pollak M. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins. *Cancer Res.* 1999; 59: 3392-5 (IF=13.312, CI=54)
36. \*Miyake H, Hara I, Arakawa S, Kamidono S. Utility of competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNA for detecting upper urinary tract transitional cell carcinoma. *Mol Urol.* 1999; 3: 365-70 (IF=1.452, CI=7)
37. \*Hara I, Yamada Y, Miyake H, Nomi M, Hara S, Yamanaka K, Takechi Y, Oka Y, Nakamura I, Gotoh A, Gohji K, Arakawa S, Kamidono S. Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors. *Anticancer Drugs.* 1999; 10: 711-8 (IF=2.389, CI=10)
38. \*Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. *J Urol.* 1999; 162: 2176-81 (IF=7.641, CI=29)
39. \*Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldi, J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. *Clin Cancer Res.* 1999; 5: 2891-8 (IF=13.801, CI=161)
40. \*Miyake H, Hara I, Arakawa S, Kamidono S. Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin but not by glycosylation inhibitor, tunicamycin in human prostate cancer cells. *J Cell Biochem.* 2000; 77: 396-408 (IF=4.481, CI=96)
41. \*Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micellef MJ, Kurimoto M, Gohji K, Arakawa S, Ichihashi M, Kamidono S. Effectiveness of cancer vaccine therapy using cells transduced with interleukin-12 gene combined with systemic interleukin-18 administration. *Cancer Gene Ther.* 2000; 7: 83-90 (IF=5.854, CI=43)
- ④2. Miyake H, Nelson C, Rennie PS, \*Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen-independence in prostate cancer. *Cancer Res.* 2000; 60: 170-6 (IF=13.312, CI=219)
- ④3. Miyake H, Tolcher A, \*Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. *J Nat Cancer Inst.* 2000; 92: 34-41 (IF=11.816, CI=163)
44. \*Miyake H, Hara I, Arakawa S, Kamidono S. A clinicopathological study of bladder cancer associated with upper urinary tract cancer. *BJU Int.* 2000; 85: 37-41 (IF=5.969, CI=20)
45. Miyake H, Pollak M, \*Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen-independence in prostate cancer models. *Cancer Res.* 2000; 60: 3058-64 (IF=13.312, CI=124)

46. Leung SY, Jackson JK, Miyake H, Burt H, \*Gleave ME. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. *Prostate*. 2000; 44: 156-63 (IF=4.012, CI=49)
47. \*Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated p53 gene transfer in human bladder cancer model. *Urology*. 2000; 56: 332-6 (IF=2.633, CI=37)
48. Miyake H, Monia BP, \*Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense Bcl-xL and antisense Bcl-2 oligodeoxynucleotides plus taxol after castration in the Shionogi tumor model. *Int J Cancer*. 2000; 86: 855-62 (IF=7.316, CI=61)
49. Miyake H, Nelson C, Rennie PS, \*Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. *Endocrinology*. 2000; 141: 2257-65 (IF=5.051, CI=122)
50. Miyake H, Nelson C, Rennie PS, \*Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. *Cancer Res*. 2000; 60: 2547-54 (IF=13.312, CI=189)
51. Miyake H, Chi KN, \*Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. *Clin Cancer Res*. 2000; 6: 1655-63 (IF=13.801, CI=144)
52. \*Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. *Int J Cancer*. 2001; 93: 26-32 (IF=7.316, CI=16)
53. \*Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumor model. *Br J Cancer*. 2001; 84: 859-63 (IF=9.082, CI=6)
54. \*Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. *J Urol*. 2001; 165: 1769-72 (IF=7.641, CI=45)
55. \*Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Differential involvement of the Fas receptor/ligand system in p53-dependent apoptosis in human prostate cancer cells. *Prostate*. 2000; 45: 341-9 (IF=4.012, CI=8)
56. \*Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. *Int J Oncol*. 2000; 17: 1213-8 (IF=5.884, CI=35)
57. Hara S, Miyake H, Fujisawa M, Okada H, Arakawa S, Kamidono S, \*Hara I. Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. *Jap J Clin Oncol*. 2001; 31: 399-402 (IF=2.925, CI=34)

58. \*Hara I, Miyake H, Hara S, Arakawa S, Hanioka K, Kamidono S. Role of percutaneous image-guided biopsy in the evaluation of renal masses. *Urol Int.* 2001; 67: 199-202 (IF=1.934, CI=43)
59. Hara S, Nagai H, Miyake H, Yamanaka K, Arakawa S, Ichihashi M, Kamidono S, \*Hara I. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. *J Urol.* 2001; 165: 2039-43 (IF=7.641, CI=17)
60. Hara S, Miyake H, Nakamura I, Arakawa S, Kamidono S, \*Hara I. Increased Fas ligand expression in the tumor tissue and serum in patients with testicular germ cell tumors with seminomatous element. *Urology.* 2001; 58: 471-6 (IF=2.633, CI=15)
61. Leung S, Miyake H, Zellweger T, Tolcher A, \*Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. *Int J Cancer.* 2001; 91: 846-50 (IF=7.316, CI=86)
62. \*Hara I, Hara S, Miyake H, Arakawa S, Kamidono S. Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines. *Int J Oncol.* 2001; 18: 1181-5 (IF=5.884, CI=10)
63. \*Hara I, Miyake H, Hara S, Yamanaka K, Ono Y, Eto H, Takechi Y, Arakawa S, Kamidono S. Value of serum prostate specific antigen-alpha1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. *BJU Int.* 2001; 88: 53-7 (IF=5.969, CI=14)
64. Okamoto M, \*Hara I, Miyake H, Hara S, Gotoh A, Arakawa S, Kamidono S. Synergistic antitumor effect of ionomycin and cisplatin against renal cell carcinoma in vitro and in vivo. *Urology.* 2001;57: 188-92 (IF=2.633, CI=11)
65. \*Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. *Clin Cancer Res.* 2001; 7: 4245-52 (IF=13.801, CI=116)
66. \*Hara I, Miyake H, Gleave ME, Kamidono S. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. *Jap J Cancer Res.* 2001; 92: 1220-4 (IF=2.225, CI=34)
67. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, \*Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. *Neoplasia.* 2001; 3: 360-7 (IF=6.218, CI=106)
68. \*Hara I, Hara S, Miyake H, Nomi M, Gotoh A, Kawabata G, Arakawa S, Kamidono S. Usefulness of ureteropyeloscopy for diagnosis of upper urinary tract tumors. *J Endourol.* 2001; 15: 601-5 (IF=2.619, CI=15)
69. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, \*Gleave ME. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by

incorporation of 2' -o-(2-methoxy) ethyl chemistry. *J Pharmacol Exp Ther.* 2001; 298: 934-40 (IF=4.404, CI=122)

70. Hara S, Miyake H, Arakawa S, Kamidono S, \*Hara I. Over expression of inhibitor of caspase 3-activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo. *J Urol.* 2001; 166: 2491-4 (IF=7.641, CI=13)
71. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, \*Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal cell carcinoma cells. *Mol Urol* 2001; 5: 105-11 (IF=1.452, CI=36)
72. Miyake H, Hara S, Nomi M, Arakawa S, Kamidono S, \*Hara I. Value of prostate specific antigen (PSA)-alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1 to 10.0 ng/mL: comparison with PSA-related parameters. *Int J Urol.* 2001; 8: 589-93 (IF=2.896, CI=4)
73. \*Hara I, Miyake H, Hara S, Yamada Y, Takechi Y, Fujisawa M, Okada H, Arakawa S, Kamidono S. Significance of prostate-specific antigen-alpha 1-antichymotrypsin complex for diagnosis and staging of prostate cancer. *Jap J Clin Oncol.* 2001; 78: 506-9 (IF=2.925, CI=5)
74. \*Hara I, Taguchi I, Miyake H, Hara S, Gotoh A, Kamidono S. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma. *Int J Oncol.* 2001; 19: 959-62 (IF=3.85, CI=0)
75. Miyake H, Hara S, Yamanaka K, Ono Y, Eto H, Yamada Y, Takechi Y, Arakawa S, Kamidono S, \*Hara I. Predicting the extent of prostate cancer using a combination of serum prostate specific antigen-alpha1-antichymotrypsin complex and systematic biopsy. *Urol Int.* 2002; 68: 232-6 (IF=1.934, CI=2)
76. \*Hara I, Miyake H, Hara S, Gotoh A, Nakamura I, Okada H, Arakawa S, Kamidono S. Health-related quality of life after radical cystectomy for bladder cancer: comparison of ileal conduit and orthotopic bladder replacement. *BJU Int.* 2002; 89: 10-13 (IF=5.969, CI=67)
77. \*Hara I, Yamada Y, Miyake H, Hara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S. Detection of  $\beta$ -human chorionic gonadotropin expressing cells by nested reverse transcriptase-polymerase chain reaction in the peripheral blood stem cells of patients with advanced germ cell tumor. *J Urol.* 2002; 167: 1487-91 (IF=7.641, CI=4)
78. \*Miyake H, Eto H, Arakawa S, Kamidono S, Hara I. Over expression of CD44v8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. *J Urol.* 2002; 167: 1282-7 (IF=7.641, CI=48)
79. Miyake H, Gleave M, Kamidono S, \*Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. *Urology.* 2002; 59: 150-4 (IF=2.633, CI=86)
80. Miyake H, Hara S, Arakawa S, Kamidono S, \*Hara I. Over expression of clusterin is an independent prognostic factor for non-papillary renal cell carcinoma. *J Urol.* 2002;

167: 703-6 (IF=7.641, CI=54)

81. \*Hara I, Miyake H, Yamada Y, Takechi Y, Hara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Soejima T, Sugimura K, Kamidono S. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate: experimental and clinical outcomes. *Int J Urol.* 2002; 9: 322-7 (IF=2.896, CI=7)
82. \*Hara I, Miyake H, Yamanaka K, Hara S, Kamidono S. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. *Oncol Rep.* 2002; 9: 1379-83 (IF=4.136, CI=18)
83. Miyake H, Nakamura I, Eto H, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S, \*Hara I. An evaluation of quality of life in patients who underwent orthotopic bladder replacement after cystectomy: comparison of ileal neobladder versus colon neobladder. *Urol Int.* 2002; 69: 195-9 (IF=1.934, CI=10)
84. \*Hara I, Miyake H, Hara S, Gotoh A, Okada H, Arakawa S, Kamidono S. Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder. *Jap J Clin Oncol.* 2002; 32: 14-8 (IF=2.925, CI=26)
85. Miyake H, Gleave ME, Arakawa S, Kamidono S, \*Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. *J Urol.* 2002; 167: 2203-8 (IF=7.641, CI=53)
86. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, \*Gleave ME. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. *Clin Cancer Res.* 2002; 8: 3276-84 (IF=13.801, CI=134)
87. \*Miyake H, Eto H, Hara S, Okada H, Kamidono S, Hara I. Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. *Int J Urol.* 2002; 9: 677-80 (IF=2.896, CI=23)
88. \*Hara I, Kawabata G, Miyake H, Hara S, Fujisawa M, Okada H, Arakawa S, Kamidono S. Feasibility and usefulness of laparoscopic radical prostatectomy. *Int J Urol.* 2002; 9: 635-40 (IF=2.896, CI=17)
89. Hara S, Miyake H, Okada H, Arakawa S, Kamidono S, \*Hara I. D-xylose absorption after urinary orthotopic bladder replacement: colon neobladder compared with ileal neobladder. *Int J Urol.* 2002; 9: 628-31 (IF=2.896, CI=2)
90. \*Hara I, Hara S, Miyake H, Muramaki M, Hikosaka S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S. Clinical outcome of surgical resection for renal cell carcinoma. *Jap J Clin Oncol.* 2002; 32: 291-5 (IF=2.925, CI=0)
91. \*Hara I, Miyake H, Hara S, Takechi Y, Eto H, Fujisawa M, Okada H, Arakawa S, Kamidono S. Increased serum carcinoembryonic antigen level in patients undergoing colon neobladder replacement compared with ileal neobladder replacement. *Urology.* 2002; 60: 363-7 (IF=2.633, CI=4)
92. Miyake H, Kawabata G, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S, \*Hara I. Comparison of surgical stress between laparoscopy and open surgery in the field of

urology by measurement of humoral mediators. *Int J Urol.* 2002; 9: 329-33 (IF=2.896, CI=52)

93. \*Miyake H, Hara I, Eto H. Prediction of the extent of prostate cancer by the combined use of systematic biopsy and serum level of cathepsin D. *Int J Urol.* 2003; 10: 196-200 (IF=2.896, CI=11)
94. Park SJ, \*Miyake H, Hara I, Eto H. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. *Int J Urol.* 2003; 10: 68-71 (IF=2.896, CI=30)
95. \*Miyake H, Hara I, Kamidono S, Gleave ME, Eto H. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. *Oncol Rep.* 2003; 10: 469-73 (IF=4.136, CI=42)
96. \*Hara I, Miyake H, Takechi Y, Eto H, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. *Int J Urol.* 2003; 10: 19-24 (IF=2.896, CI=18)
97. \*Hara I, Kawabata G, Miyake H, Nakamura I, Hara S, Okada H, Kamidono S. Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. *J Urol.* 2003; 169: 2045-8 (IF=7.641, CI=68)
98. \*Okada H, Shirakawa T, Miyake H, Gotoh A, Fujisawa M, Arakawa S, Kamidono S. Establishment of a prostatic small-cell carcinoma cell line (S0-MI). *Prostate.* 2003; 56: 231-8 (IF=4.012, CI=7)
99. \*Miyake H, Ono Y, Park SJ, Hara I, Eto H. Pathological findings of the radical prostatectomy specimens in Japanese men diagnosed on single core positive prostate biopsy in eight with a Gleason score  $\leq$  4. *Int J Urol.* 2003; 10: 383-6 (IF=2.896, CI=1)
100. \*Muramaki M, Miyake H, Hara S, Kamidono S, Hara I. Predicting factors for collection of peripheral blood stem cells in patients with advanced germ cell tumors after cisplatin-based combination chemotherapy. *Oncol Rep.* 2003; 110: 1545-9 (IF=4.136, CI=4)
101. \*Miyake H, Eto H, Takechi Y, Kamidono S, Hara I. Increased urinary 8-hydroxy-2'-deoxyguanosine excretion after ileal neobladder replacement compared with colon neobladder replacement. *BJU Int.* 2003; 91: 657-60 (IF=5.969, CI=8)
102. \*Miyake H, Sakai I, Ishimura T, Hara I, Eto H. Clinicopathological features of incidentally detected renal cell carcinoma in Japan. *UroOncology.* 2003; 3: 95-8 (IF=0, CI=0)
103. \*Muramaki M, Miyake H, Hara I, Kamidono S. Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. *Clin Cancer Res.* 2003; 9: 5152-60 (IF=13.801, CI=32)
104. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, \*Gleave ME. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP

prostate tumor model. *BJU Int.* 2003; 92: 463-9 (IF=5.969, CI=56)

105. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, \*Gleave ME. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. *Cancer Res.* 2003; 63: 3575-84 (IF=13.312, CI=97).
106. \*Muramaki M, Hara I, Miyake H, Yamada Y, Okada H, Kamidono S. Long-term cryopreservation of peripheral blood stem cells in patients with advanced germ cell tumors using the dump-freezing method in a -80°C mechanical freezer. *Oncol Rep.* 2003; 10: 1993-8 (IF=4.136, CI=3)
107. \*Miyake H, Hara I, Gleave ME, Eto H. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. *Prostate.* 2004; 61: 318-23 (IF=4.012, CI=66)
108. \*Muramaki M, Miyake H, Kamidono S, Hara, I. Over expression of CD44v8-10 in human bladder cancer cells decreases their interaction with hyaluronic acid and potentiates their malignant progression. *J Urol.* 2004; 171: 426-30 (IF=7.641, CI=17)
109. Ishimura T, Sakai I, Hara I, Eto H, \*Miyake H. Clinical outcome of transrectal ultrasound guided prostate biopsy targeting eight cores for detecting prostate cancer in Japanese men. *Int J Clin Oncol.* 2004; 9: 47-50 (IF=3.85, CI=0)
110. \*Miyake H, Hara S, Eto H, Arakawa S, Kamidono S, Hara I. Significance of renal function in changes in acid-base metabolism after orthotopic bladder replacement: colon neobladder compared with ileal neobladder. *Int J Urol.* 2004; 11: 83-7 (IF=2.896, CI=20)
111. \*Miyake H, Sakai I, Ishimura T, Hara I, Eto H. Significance of cancer detection in the anterior lateral horn on systematic prostate biopsy: impact on pathological findings of radical prostatectomy specimens. *BJU Int.* 2004; 93: 57-9 (IF=5.969, CI=17)
112. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. *Int J Urol.* 2004; 11: 397-401 (IF=2.896, CI=8)
113. Ishimura T, Sakai I, Hara I, Eto H, \*Miyake H. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery. *Int J Urol.* 2004; 11: 264-8 (IF=2.896, CI=28)
114. \*Miyake H, Sakai I, Harada K, Eto H, Hara I. Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan. *Acta Urol Jap.* 2004; 50: 151-6 (IF=0, CI=0)
115. \*Miyake H, Hara I, Kamidono S, Eto H. Oxidative DNA damage in patients with prostate cancer and its response to treatment. *J Urol.* 2004; 171: 1533-6 (IF=7.641, CI=81)
116. Sakai I, Harada K, Hara I, Eto H, \*Miyake H. Prognostic significance of capsular invasion and capsular penetration in Japanese men with prostate cancer undergoing radical retropubic prostatectomy. *UroOncology.* 2004; 4: 27-30 (IF=0, CI=0)



117. Sakai I, Harada K, Hara I, Eto H, \*Miyake H. Limited usefulness of the free-to-total prostate-specific antigen ratio for diagnosis and staging of prostate cancer in Japanese men. *Int J Clin Oncol*. 2004; 9: 64-7 (IF=3.85, CI=0)
118. \*Miyake H, Hara I, Kamidono S, Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. *J Urol*. 2004; 172: 1127-9 (IF=7.641, CI=45)
119. Ishimura T, Sakai I, Hara I, Eto H, \*Miyake H. Clinicopathological features of recurrence after radical surgery for nonmetastatic renal cell carcinoma. *Int J Clin Oncol*. 2004; 9: 369-72 (IF=3.85, CI=0)
120. Hikosaka S, \*Hara I, Miyake H, Hara S, Kamidono S. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. *Int J Urol*. 2004; 11: 647-52 (IF=2.896, CI=17)
121. \*Miyake H, Muramaki M, Eto H, Kamidono S, Hara I. Health-related quality of life after chemotherapy for advanced germ cell tumors: a comparison of standard-dose and high-dose chemotherapy. *Int J Urol*. 2004; 11: 542-6 (IF=2.896, CI=6)
122. \*Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer KoTCC-1 cells. *J Urol*. 2004; 171: 2477-81 (IF=7.641, CI=34)
123. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy. *Int J Urol*. 2004; 11: 402-6 (IF=2.896, CI=5)
124. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Prognostic significance of bone metastasis patterns in patients with prostate cancer. *UroOncology*. 2004; 4: 135-8 (IF=0, CI=0)
125. \*Miyake H, Hara I, Kamidono S, Eto H. Prognostic significance of oxidative DNA damage evaluated by 8-hydroxy-2'-deoxyguanosine in patients undergoing radical nephrectomy for renal cell carcinoma. *Urology*. 2004; 64: 1057-61 (IF=2.633, CI=31)
126. \*Muramaki M, Miyake H, Hara I, Kawabata G, Kamidono S. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model. *J Urol*. 2004; 172: 1485-9 (IF=7.641, CI=18)
127. \*Miyake H, Hara I, Eto H. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. *Anticancer Res*. 24: 2573-7 (IF=2.435, CI=25)
128. \*Miyake H, Muramaki M, Eto H, Kamidono S, Hara I. Health-related quality of life in patients with testicular cancer: a comparative analysis according to therapeutic modalities. *Oncol Rep*. 2004; 12: 867-70 (IF=4.136, CI=12)
129. \*Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S. Introduction of 65 kDa antigen of mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of

BCG therapy. *Microbiol Immunol.* 2004; 48: 289-95 (IF=2.962, CI=5)

130. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer. *Int J Urol.* 2005; 12: 182-6 (IF=2.896, CI=1)
131. \*Miyake H, Sakai I, Harada K, Takechi Y, Hara I, Eto H. Prognostic significance of tumor volume in radical prostatectomy specimens after neoadjuvant hormonal therapy. *Urol Int.* 2005; 74: 27-31 (IF=1.934, CI=6)
132. \*Miyake H, Hara S, Eto H, Kamidono S, Hara I. Global analysis of gene expression profiles in ileum in a rat bladder augmentation model using cDNA microarrays. *Int J Urol.* 2004; 11: 1009-12 (IF=2.896, CI=0)
133. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Long-term outcome of adjuvant chemotherapy with MVP-CAB regimen (methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin) for locally advanced bladder cancer. *UroOncology.* 2004; 4: 151-6 (IF=0, CI=0)
134. \*Muramaki M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience. *Int J Urol.* 2004; 11: 768-73 (IF=2.896, CI=6)
135. \*Muramaki M, Hara I, Miyake H, Yamada Y, Okada H, Kamidono S. Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic nonseminomatous germ cell tumors *Int J Urol.* 2004; 11: 763-7 (IF=2.896, CI=6)
136. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. *Int J Urol.* 2005; 12: 270-4 (IF=2.896, CI=17)
137. Harada K, Sakai I, Hara I, Eto H, \*Miyake H. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy. *Int J Urol.* 2005; 12: 250-5 (IF=2.896, CI=16)
138. Yamanaka K, Gleave ME, Hara I, Muramaki M, \*Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. *Mol Cancer Ther.* 2005; 4: 187-95 (IF=6.011, CI=23)
139. \*Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. *Oncol Rep.* 2005; 13: 341-5 (IF=4.136, CI=26)
140. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Clinicopathological features of prostate cancer in Japanese men diagnosed on repeat transrectal ultrasound-guided biopsy. *Int J Clin Oncol.* 2005; 10: 30-4 (IF=3.85, CI=0)
141. Yamanaka K, Gleave M, Muramaki M, Hara I, \*Miyake H. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide

in a human bladder cancer model. *Oncol Rep.* 2005; 13: 885-90 (IF=4.136, CI=15)

142. \*Miyake H, Hara I, Yamanaka K, Muramaki M, Eto H. Prognostic significance of insulin-like growth factor binding protein-2 to insulin-like growth factor binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder. *BJU Int.* 2005; 95: 987-91 (IF=5.969, CI=11)
143. Sakai I, Harada K, Hara I, Eto H, \*Miyake H. Significance of the percentage of prostate needle biopsy cores with cancer as a predictor of disease extension in radical prostatectomy specimens in Japanese men. *Int Urol Nephrol.* 2005; 37: 305-10 (IF=2.266, CI=0)
144. \*Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. *Neoplasia.* 2005; 7: 171-9 (IF=6.218, CI=30)
145. Sakai I, Harada K, Hara I, Eto H, \*Miyake H. Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nerve-sparing radical retropubic prostatectomy. *Int J Urol.* 2005; 12: 275-9 (IF=2.896, CI=18)
146. Sakai I, Harada K, Hara I, Eto H, \*Miyake H. A comparison of biological features between prostate cancers arising in the transition zone and in the peripheral zone. *BJU Int.* 2005; 96: 528-32 (IF=5.969, CI=41)
147. Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, \*Miyake H. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase polymerase chain reaction for cytokeratine 19 and uroplakin II. *Clin Cancer Res.* 2005; 11: 3773-7 (IF=13.801, CI=64)
148. \*Miyake H, Hara I, Yamazaki H, Eto H. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. *Oncol Rep.* 2005; 14: 673-6 (IF=4.136, CI=7)
149. \*Miyake H, Sakai I, Harada K, Hara I, Eto H. Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy? *Int J Urol.* 2005; 12: 739-44 (IF=2.896, CI=2)
150. \*Muramaki M, Miyake H, Hara I, Kamidono S. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. *Int J Oncol.* 2005; 26: 623-8 (IF=5.884, CI=15)
151. \*Miyake H, Sakai I, Harada K, Eto H, Hara I. Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer. *Acta Urol Jap.* 2005; 51: 241-6 (IF=0, CI=0)
152. Maeda T, \*Miyake H, Miyake M, Hara I, Inoue T, Fujisawa M. Renal mass formation after bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. *Jap J Endourol ESWL.* 2005; 18: 252-5 (IF=0, CI=0)

153. \*Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. *Oncol Rep.* 2005; 14: 1371-5 (IF=4.136, CI=30)
154. \*Miyake H, Hara I, Sakai I, Harada K, Inoue T, Eto H, Takechi Y, Fujisawa M. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon- $\alpha$  for Japanese patients with metastatic renal cell carcinoma who underwent radical nephrectomy: a preliminary report. *Int J Clin Oncol.* 2005; 10: 338-41 (IF=3.85, CI=0)
155. \*Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression. *Anticancer Res.* 2005; 25: 3645-9 (IF=2.435, CI=6)
156. \*Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone refractory prostate cancer. *BJU Int.* 2005; 96: 791-5 (IF=5.969, CI=52)
157. Kurahashi T, Muramaki M, Yamanaka K, Hara I, \*Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. *BJU Int.* 2005; 96: 895-9 (IF=5.969, CI=58)
158. \*Miyake H, Kurahashi T, Muramaki M, Yamanaka K, Hara I. Significance of routine transition zone biopsies in Japanese men undergoing transrectal ultrasound-guided prostate biopsy. *Int J Urol.* 2005; 12: 964-8 (IF=2.896, CI=14)
159. \*Muramaki M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S. Clinical study of six cases showing late relapse of germ cell tumors. *Int J Urol.* 2005; 12: 855-8 (IF=2.896, CI=3)
160. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessela B, Zangemeister-Wittke U, \*Gleave ME. A novel bispecific antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. *Mol Cancer Ther.* 2005; 4: 1689-98 (IF=6.011, CI=84)
161. \*Miyake H, Hara I, Yamanaka K, Inoue T, Fujisawa M. Limited significance of routine excretory urography in follow-up of patients with superficial bladder cancer after transurethral resection. *BJU Int.* 2006; 97: 720-3 (IF=5.969, CI=7)
162. Sakai I, Harada K, Kurahashi T, Muramaki M, Yamanaka K, Hara I, Inoue T, \*Miyake H. Usefulness of the nadir value of serum prostate specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. *Urol Int.* 2006; 76: 227-31 (IF=1.934, CI=16)
163. Harada K, Sakai I, Kurahashi T, Muramaki M, Yamanaka K, Hara I, Eto H, \*Miyake H. Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder. *Int Urol Nephrol.* 2006; 38: 49-55 (IF=2.266, CI=7)

164. Sakai I, Harada K, Kurahashi T, Yamanaka K, Hara I, \*Miyake H. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zone. *Int J Urol*. 2006; 13: 368-72 (IF=2.896, CI=26)
165. Harada K, Sakai I, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Inoue T, \*Miyake H. Reconstruction of urinary tract combined with surgical management of locally advanced non-urological cancer involving the genitourinary organs. *Urol Int*. 2006; 76: 82-6 (IF=1.934, CI=12)
166. Harada K, Sakai I, Ishimura T, Inoue T, Hara I, \*Miyake H. Clinical symptoms in localized renal cell carcinoma reflect its invasive potential: comparative study between incidentally detected and symptomatic diseases. *Urol Oncol*. 2006; 24: 201-6 (IF=2.954, CI=14)
167. \*Miyake H, Hara I, Kurahashi T, Muramaki M, Yamanaka K, Inoue T, Fujisawa M. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate specific antigen. *Urol Int*. 2006; 77: 200-4 (IF=1.934, CI=1)
168. \*Miyake H, Sakai I, Inoue T, Hara I, Fujisawa M. Limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high risk prostate cancer in Japanese men. *Urol Int*. 2006; 77: 122-6 (IF=1.934, CI=2)
169. Yamanaka K, \*Miyake H, Hara I, Inoue T, Hanioka K, Fujisawa M. Papillary renal cell carcinoma: a clinicopathological study of 35 cases. *Int J Urol*. 2006; 13: 1049-52 (IF=2.896, CI=14)
170. \*Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. *Anticancer Res*. 2006; 26: 1583-7 (IF=2.435, CI=28)
171. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister- Wittke U, \*Gleave ME. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. *BJU Int*. 2006; 97: 1300-8 (IF=5.969, CI=54)
172. \*Muramaki M, Miyake H, Yamada Y, Hara I. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. *Oncol Rep*. 2006; 15: 253-7 (IF=4.136, CI=16)
173. \*Hara I, Miyake H, Yamada Y, Yamanaka K, Furukawa J, Kumano M, Takenaka A, Fujisawa M. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience. *Anticancer Drugs*. 2006; 17: 1057-66 (IF=2.389, CI=6)
174. Sakai I, \*Miyake H, Harada K, Hara I, Inoue T, Fujisawa M. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. *Int J Urol*. 2006; 13: 1389-92 (IF=2.896, CI=16)

175. \*Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Gleave M, Fujisawa M. Expression of clusterin in prostate cancer is correlated with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. *Urology*. 2006; 68: 609-14 (IF=2.633, CI=30)
176. Yamanaka K, \*Miyake H, Hara I, Inoue T, Fujisawa M. Significance of radical cystectomy for bladder cancer in patients over eighty years old. *Int Urol Nephrol*. 2007; 39: 209-14 (IF=2.266, CI=24)
177. \*Miyake H, Hara I, Nakano Y, Takenaka A, Fujisawa M. Hand-assisted laparoscopic radical nephrectomy: comparative study with conventional open radical nephrectomy. *J Endourol*. 2007; 21: 429-32 (IF=2.619, CI=11)
178. \*Miyake H, Kurahashi T, Hara I, Takenaka A, Fujisawa M. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy following neoadjuvant hormonal therapy. *BJU Int*. 2007; 99: 315-20 (IF=5.969, CI=21)
179. Nakano Y, \*Miyake H, Inoue T, Takenaka A, Hara I, Fujisawa M. Elevated urinary cytokine levels in patients undergoing ileal neobladder replacement compared with sigmoid neobladder replacement. *Int Urol Nephrol*. 2007; 39: 467-72 (IF=2.266, CI=5)
180. \*Miyake H, Hara I, Kurahashi T, Inoue T, Eto H, Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase polymerase chain reaction targeting prostate-specific antigen and prostate-specific membrane antigen genes. *Clin Cancer Res*. 2007; 13: 1192-7 (IF=13.801, CI=50)
181. Kurahashi T, \*Miyake H, Hara I, Fujisawa M. Significance of Aurora-A expression in renal cell carcinoma. *Urol Oncol*. 2007; 25: 128-33 (IF=2.954, CI=30)
182. \*Terakawa T, Miyake H, Nakano Y, Tanaka K, Takenaka A, Hara I, Fujisawa M. Transurethral drainage for prostatic abscess in a patient with metastatic testicular cancer undergoing systematic chemotherapy. *Acta Urol Jap*. 2007; 53: 725-8 (IF=0, CI=0)
183. Furukawa J, \*Miyake H, Hara I, Takenaka A, Fujisawa M. Clinical outcome of orthotopic neobladder replacement in patients with a solitary functioning kidney. *Int J Urol*. 2007; 14: 398-401 (IF=2.896, CI=7)
184. Kumano M, \*Miyake H, Hara I, Furukawa J, Takenaka A, Fujisawa M. First-line high-dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors. *Int J Urol*. 2007; 14: 336-8 (IF=2.896, CI=6)
185. Kurahashi T, \*Miyake H, Nakano Y, Shinozaki M, Oka N, Tanaka K, Takenaka A, Hara I, Arakawa S, Fujisawa M. A comparison of clinical features between chlamydial and non-chlamydial urethritis in men negative for gonococcal infection who attended a urological outpatient clinic in Japan. *Int Urol Nephrol*. 2007; 39: 809-13 (IF=2.266, CI=1)
186. Kumano M, \*Miyake H, Hara I, Furukawa J, Takenaka A, Fujisawa M. Stable hematopoietic

recovery after peripheral blood stem cell transplantation in patients receiving high-dose chemotherapy for advanced germ cell tumors. *Anticancer Res.* 2007; 26: 4965-8 (IF=2.435, CI=0)

187. Kurahashi T, \*Miyake H, Hara I, Fujisawa M. Expression of major heat shock protein in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. *J Urol.* 2007; 177: 757-61 (IF=7.641, CI=41)
188. \*Hara I, Kawabata G, Tanaka K, Kanomata N, Miyake H, Takenaka A, Fujisawa M. Oncological outcome of laparoscopic prostatectomy. *Int J Urol.* 2007; 14: 515-20 (IF=2.896, CI=12)
189. \*Hara I, Tanaka K, Yamada Y, Miyake H, Takenaka A, Fujisawa M. Usefulness of laparo- or retroperitoneoscopic biopsy for retroperitoneal lymph node swelling of unknown origin. *Int J Urol.* 2007; 14: 466-9 (IF=2.896, CI=7)
190. Kurahashi T, \*Miyake H, Oka N, Shinozaki M, Takenaka A, Hara I, Fujisawa M. Clinical outcome of ureteroscopic lithotripsy for 2129 patients with ureteral stones. *Urol Res.* 2007; 35: 149-53 (IF=1.364, CI=13)
191. Furukawa J, \*Miyake H, Takenaka A, Hara I, Fujisawa M. Persistent expression of Aurora-A following neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. *BJU Int.* 2007; 100: 310-4 (IF=5.969, CI=13)
192. \*Miyake H, Harada K, Inoue T, Takenaka A, Hara I, Fujisawa M. Additional sampling of the dorsal apex on systematic prostate biopsy: impact on early detection of prostate cancer. *Urology.* 2007; 69: 738-42 (IF=2.633, CI=9)
193. Furukawa J, \*Miyake H, Hara I, Takenaka A, Fujisawa M. Upper urinary tract recurrence following radical cystectomy for bladder cancer. *Int J Urol.* 2007; 14: 496-9 (IF=2.896, CI=25)
194. Terakawa T, \*Miyake H, Takenaka A, Hara I, Fujisawa M. Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava. *Int J Urol.* 2007; 14: 781-4 (IF=2.896, CI=27)
195. Kurahashi T, \*Miyake H, Kumano M, Muramaki M, Takenaka A, Fujisawa M. Brain metastases from malignant germ cell tumors of the testis: our experience of 5 cases with a review of the literature. *Curr Urol.* 2007; 1: 169-73 (IF=0, CI=0)
196. Kumano M, \*Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. *Acta Urol Jap.* 2007; 53: 851-6 (IF=0, CI=0)
197. \*Miyake H, Kurahashi T, Takenaka A, Hara I, Fujisawa M. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores. *Urol Int.* 2007; 79: 302-6 (IF=1.934, CI=21)
198. Kumano M, \*Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor

response in mouse renal cell carcinoma. *J Urol.* 2007; 178: 1504-9 (IF=7.641, CI=16)

199. \*Takenaka A, Yamada Y, Kurahashi T, Soga H, Miyake H, Fujisawa M. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. *Int J Urol.* 2008; 15: 106-9 (IF=2.896, CI=9)
200. Muramaki M, \*Miyake H, Kurahashi T, Takenaka A, Inoue T, Fujisawa M. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. *Int J Urol.* 2008; 15: 314-8 (IF=2.896, CI=8)
201. Kumano M, \*Miyake H, Kurahashi T, Yamanaka K, Fujisawa M. Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle. *Br J Cancer.* 2008; 98: 356-62 (IF=9.082, CI=15)
202. Kurahashi T, \*Miyake H, Oka N, Shinozaki M, Takenaka A, Hara I, Fujisawa M. Health-related quality of life in patients undergoing lithotripsy for urinary stone. *Int Urol Nephrol.* 2008; 40: 39-43 (IF=2.266, CI=14)
203. Furukawa J, \*Miyake H, Hara I, Takenaka A, Fujisawa M. Clinical outcome of radical cystectomy for patients with pT4 bladder cancer. *Int J Urol.* 2008; 15: 58-61 (IF=2.896, CI=8)
204. Terakawa T, \*Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. Risk factors for intravesical recurrence following surgical management of transitional cell carcinoma of the upper urinary tract. *Urology.* 2008; 71: 123-7 (IF=2.633, CI=73)
205. Terakawa T, \*Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawa M. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. *Urology.* 2008; 72: 1194-7 (IF=2.633, CI=29)
206. Terakawa T, \*Miyake H, Hara I, Takenaka A, Fujisawa M. Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy. *J Endourol.* 2008; 22: 1693-9 (IF=2.619, CI=16)
207. \*Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. *J Urol.* 2008; 180: 921-7 (IF=7.641, CI=112)
208. \*Miyake H\*, Furukawa J, Takenaka A, Yamanaka N, Fujisawa M. Long-term functional outcomes in patients with various types of orthotopic intestinal neobladder. *Int J Urol.* 2008; 15: 612-5 (IF=2.896, CI=17)
209. \*Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. *Int J Urol* 2008; 15: 309-13 (IF=2.896, CI=38)
210. Terakawa T, \*Miyake H, Tanaka K, Takenaka A, Inoue T, Fujisawa M. Surgical margin status



of open versus laparoscopic radical prostatectomy specimens. *Int J Urol.* 2008; 15: 704-7 (IF=2.896, CI=23)

211. Yamanaka K, \*Miyake H, Sakai I, Tamada H, Inoue T, Fujisawa M. Oncological outcome following radical prostatectomy in patients with pT3 prostate cancer. *Curr Urol.* 2008; 2: 87-91 (IF=0, CI=0)
212. Kumano M, \*Miyake H, Tanaka K, Takenaka A, Fujisawa M. Prognostic significance of surgical margin status after laparoscopic radical prostatectomy: early experience in a single institution in Japan. *Curr Urol.* 2008; 2: 67-72 (IF=0, CI=0)
213. Soga H, \*Takenaka A, Ooba T, Nakano Y, Miyake H, Takeda M, Tanaka K, Hara I, Fujisawa M. A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization. *Urol Int.* 2009; 82: 222-6 (IF=1.934, CI=15)
214. \*Takenaka A, Soga H, Kurahashi T, Miyake H, Tanaka K, Fujisawa M. Early recovery of urinary continence after laparoscopic versus retropubic radical prostatectomy: evaluation of preoperative erectile function and nerve-sparing procedure as predictors. *Int Urol Nephrol.* 2009; 41: 587-93 (IF=2.266, CI=13)
215. \*Takenaka A, Soga H, Terakawa T, Kumano M, Furukawa J, Muramaki M, Kurahashi T, Miyake H, Tanaka K, Yamanaka N, Fujisawa M. Assessment of voiding function of orthotopic neobladders in elderly patients with long-term survival. *BJU Int.* 2009; 103: 927-30 (IF=5.969, CI=9)
216. Yanagiuchi A, \*Miyake H, Nomi M, Takenaka A, Fujisawa M. Modulation of microenvironment by growth factors regulates in vivo growth of skeletal myoblasts. *BJU Int.* 2009; 103: 1569-73 (IF=5.969, CI=20)
217. Terakawa T, \*Miyake H, Kurahashi T, Furukawa J, Takenaka A, Fujisawa M. Improved sensitivity for the detection of micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer who underwent radical prostatectomy. *BJU Int.* 2009; 103: 1074-8 (IF=5.969, CI=16)
218. Kumano M, \*Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Adverse prognostic impact of capsular incision at radical prostatectomy for Japanese men with clinically localized prostate cancer. *Int Urol Nephrol.* 2009; 41: 581-6 (IF=2.266, CI=14)
219. \*Miyake H, Kurahashi T, Takenaka A, Inoue T, Fujisawa M. Clinical outcome of combined immunotherapy with interferon- $\alpha$  and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. *Urol Oncol.* 2009; 27: 598-603 (IF=2.954, CI=25)
220. Sakai I, \*Miyake H, Muramaki M, Takenaka A, Fujisawa M. Oncological outcome following radical prostatectomy in Japanese men with clinical stage T1c prostate cancer. *Curr Urol.* 2009; 3: 62-6 (IF=0, CI=0)
221. \*Takenaka A, Soga H, Sakai I, Nakano Y, Miyake H, Tanaka K, Fujisawa M. Influence of nerve-sparing procedure on early recovery of urinary continence after laparoscopic

radical prostatectomy. *J Endourol.* 2009; 23: 1115-9 (IF=2.619, CI=25)

222. \*Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Prediction of response to combined immunotherapy with interferon- $\alpha$  and low-dose interleukin-2 in metastatic renal cell carcinoma based on expression patterns of potential molecular markers in radical nephrectomy specimens. *Int J Urol.* 2009; 16: 465-71 (IF=2.896, CI=13)
223. Kumano M, \*Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. *Urol Oncol.* 2009; 27: 180-6 (IF=2.954, CI=42)
224. Hyodo Y, \*Miyake H, Kondo Y, Fujisawa M. Down-regulation of lectin-like oxidized low-density lipoprotein receptor-1 following ischemic preconditioning in ischemia-reperfused rat kidneys. *Urology.* 2009; 73: 906-10 (IF=2.633, CI=3)
225. Sakai I, \*Miyake H, Takenaka A, Fujisawa M. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. *BJU Int.* 2009; 104: 942-6 (IF=5.969, CI=26)
226. Terakawa T, \*Miyake H, Furukawa J, Ettinger SL, Gleave M, Fujisawa M. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. *Br J Cancer.* 2009; 101: 1731-9 (IF=9.082, CI=14)
227. Haraguchi T, \*Takenaka A, Yamazaki T, Nakano Y, Miyake H, Tanaka K, Kuwayama M, Takechi Y, Fujisawa M. The relationship between the reproducibility of holmium laser enucleation of the prostate and prostate size over the learning curve. *Prostate Cancer Prostatic Dis.* 2009; 12: 281-4 (IF=5.455, CI=11)
228. \*Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. *Urol Oncol.* 2010; 28: 145-51 (IF=2.954, CI=49)
229. \*Miyake H, Fujimoto H, Komiyama M, Fujisawa M. Development of "extended radical retropubic prostatectomy": a surgical technique for improving margin positive rates in prostate cancer. *Eur J Sur Oncol.* 2010; 36: 281-6 (IF=4.037, CI=13)
230. \*Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. *Urology.* 2010; 75: 454-9 (IF=2.633, CI=25)
231. Kurahashi T, \*Miyake H, Furukawa J, Kumano M, Takenaka A, Fujisawa M. Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens from Japanese men with bladder cancer. *Int Urol Nephrol.* 2010; 42: 73-9 (IF=2.896, CI=12)
232. \*Miyake H, Furukawa J, Takenaka A, Inoue T, Yamanaka N, Fujisawa M. Experience with various types of orthotopic neobladder in Japanese men: long-term follow-up. *Urol Int.* 2010; 84: 34-9 (IF=1.934, CI=1)

233. \*Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue T, Fujisawa M. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. *Urol Oncol*. 2010; 28: 515-9 (IF=2.954, CI=39)
234. \*Miyake H, Furukawa J, Muramaki M, Takenaka A, Fujisawa M. Orthotopic sigmoid neobladder after radical cystectomy: assessment of complications, functional outcomes and quality of life in 82 Japanese patients. *BJU Int*. 2010; 106: 412-6 (IF=5.969, CI=16)
235. Kumano M, \*Miyake H, Terakawa T, Furukawa J, Fujisawa M. Suppressed tumor growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model. *BJU Int*. 2010; 106: 121-7 (IF=5.969, CI=10)
236. Terakawa T, \*Miyake H, Kumano M, Sakai I, Fujisawa M. Antiandrogen bicalutamide activates androgen receptor with a mutation in codon 741 through the mitogen activated protein kinase pathway in human prostate cancer PC3 cells. *Oncol Rep*. 2010; 24: 1395-9 (IF=4.136, CI=8)
237. Muramaki M, \*Miyake H, Kurahashi T, Takenaka A, Fujisawa M. Characterization of anatomical extension pattern of localized prostate cancer arising in the peripheral zone. *BJU Int*. 2010; 105: 1514-8 (IF=5.969, CI=3)
238. Furukawa J, \*Miyake H, Terakawa T, Sakai I, Muramaki M, Takenaka A, Fujisawa M. Predictors of cancer-specific survival following radical cystectomy in patients with node-positive bladder cancer. *Curr Urol*. 2010; 4: 188-92 (IF=0, CI=0)
239. \*Miyake H, Muramaki M, Tanaka K, Takenaka A, Fujisawa M. Impact of body mass index on perioperative outcomes of laparoscopic radical nephrectomy in Japanese patients with clinically localized renal cell carcinoma. *Int J Urol*. 2010; 17: 522-6 (IF=2.896, CI=10)
240. \*Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue T, Fujisawa M. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. *BJU Int*. 2010; 106: 1643-7 (IF=5.969, CI=16)
241. Terakawa T, \*Miyake H, Muramaki M, Takenaka A, Fujisawa M. Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report. *Int J Urol*. 2010; 17: 881-5 (IF=2.896, CI=11)
242. Sakai I, \*Miyake H, Terakawa T, Muramaki M, Takenaka A, Fujisawa M. Oncological outcomes following surgical treatment for Japanese men with squamous cell carcinoma of the penis. *Curr Urol*. 2010; 4: 125-30 (IF=0, CI=0)
243. \*Miyake H, Muramaki M, Ishimura T, Nakano Y, Tanaka K, Fujisawa M. Comparison of the impact of body mass index on perioperative outcomes between open and laparoscopic radical nephrectomies for clinically localized renal cell carcinoma. *Jap J Endourol*. 2011; 24: 99-103 (IF=0, CI=0)

244. Soga H, \*Takenaka A, Murakami G, Haraguchi T, Miyake H, Tanaka K, Fujisawa M. Distribution of the lymphatic vessels in the prostatic fascia. *Prostate*. 2011; 71: 1294-8 (IF=4.012, CI=2)
245. Sakai I, \*Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. *Cancer Sci*. 2011; 102: 769-75 (IF=6.518, CI=16)
246. Kusuda Y, \*Miyake H, Terakawa T, Furukawa J, Muramaki M, Fujisawa M. Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience of 5 cases with a review of the literature. *Int J Urol*. 2011; 18: 326-9 (IF=2.896, CI=0)
247. Muramaki M, \*Miyake H, Sakai I, Kondo Y, Kusuda Y, Yamada Y, Fujisawa M. Age at diagnosis as a powerful predictor for disease recurrence following radical nephrectomy in Japanese patients with pT1 renal cell carcinoma. *Int J Urol*. 2011; 18: 121-5 (IF=2.896, CI=7)
248. \*Takenaka A, Hara I, Soga H, Sakai I, Terakawa T, Muramaki M, Miyake H, Tanaka K, Fujisawa M. Assessment of long-term quality of life in patients with orthotopic neobladder followed for more than 5 years. *Int Urol Nephrol*. 2011; 43: 749-54 (IF=2.266, CI=18)
249. \*Miyake H, Muramaki M, Sakai I, Terakawa T, Kusuda Y, Yamada Y, Yamanaka K, Fujisawa M. Oncological outcome of contemporary radical nephrectomy for pT1 renal cell carcinoma: comparison of open versus laparoscopic approach. *Curr Urol*. 2011; 5: 145-50 (IF=0, CI=0)
250. Behnsawy HM, \*Miyake H, Abdalla MA, Sayed MA, Ahmed AI, Fujisawa M. Expression of integrin proteins in non-muscle invasive bladder cancer: significance of intravesical recurrence following transurethral resection. *BJU Int*. 2011; 107: 240-6 (IF=5.969, CI=14)
251. Behnsawy HM, \*Miyake H, Abdalla MA, Sayed MA, Ahmed AI, Fujisawa M. Expression of cell cycle-associated proteins in non-muscle invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. *Urol Oncol*. 2011; 29: 495-501 (IF=2.954, CI=28)
252. Muramaki M, \*Miyake H, Terakawa T, Kusuda Y, Fujisawa M. Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy. *Urology*. 2011; 78: 1443.e7-12 (IF=2.633, CI=21)
253. \*Takenaka A, Soga H, Hinata N, Honda M, Sejima T, Muramaki M, Miyake H, Tanaka K, Fujisawa M. Classification of the distribution of cavernous nerve fibers around the prostate by intraoperative electrical stimulation during laparoscopic radical prostatectomy. *Int J Impot Res*. 2011; 23: 56-61 (IF=2.408, CI=6)
254. Terakawa T, \*Miyake H, Kumano M, Fujisawa M. Growth inhibition and enhanced chemosensitivity induced by downregulation of Aurora-A in human renal cell carcinoma

Caki-2 cells using short hairpin RNA. *Oncol Lett.* 2011; 2: 713-7 (IF=3.111, CI=6)

255. \*Kitajima K, Takahashi S, Ueno Y, Yoshikawa T, Ohno Y, Obara M, Miyake H, Fujisawa M, Sugimura K. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: Comparison between ultra-high b-value (2000 s/mm<sup>2</sup>) and standard high b-value (1000 s/mm<sup>2</sup>). *J Magn Reson Imaging.* 2012; 36: 198-205 (IF=5.119, CI=56)
256. Harada K, \*Miyake H, Terakawa T, Fujisawa M. Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladder. *Curr Urol.* 2012; 6: 27-32 (IF=0, CI=0)
257. \*Ando M, Yamaguchi K, Chiba K, Miyake H, Fujisawa M. Expression of VASA mRNA in testis as a significant predictor of sperm recovery by microdissection testicular sperm extraction inpatient with non-obstructive azoospermia. *J Androl.* 2012; 33: 711-6 (IF=2.473, CI=18)
258. \*Chiba K, Kondo Y, Yamaguchi K, Miyake H, Fujisawa M. Inhibition of claudin-11 and occludin expression in rat Sertoli cells by mono-(2-ethylhexyl) phthalate through p44/42 mitogen-activated protein kinase pathway. *J Androl.* 2012; 33: 368-74 (IF=2.473, CI=20)
259. Sakai I, \*Miyake H, Muramaki M, Kondo Y, Kusuda Y, Yamada Y, Fujisawa M. Significant impact of age at diagnosis on the prognosis of Japanese patients with pT1 renal cell carcinoma following surgical resection. *BJU Int.* 2012; 109: 695-9 (IF=5.969, CI=5)
260. Muramaki M, \*Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M. Expression profile of E-cadherin and N-cadherin in non-muscle invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. *Urol Oncol.* 2012; 30: 161-6 (IF=2.954, CI=38)
261. \*Miyake H, Furukawa J, Muramaki M, Takenaka A, Fujisawa M. Orthotopic bladder substitution following radical cystectomy in women: comparative study between sigmoid and ileal neobladders. *Urol Oncol.* 2012; 30: 38-43 (IF=2.954, CI=8)
262. \*Chiba K, Yamaguchi K, Ando M, Miyake H, Fujisawa M. Expression pattern of testicular claudin-11 in infertile men. *Urology.* 2012; 80: 1161.e13-7 (IF=2.633, CI=20)
263. \*Miyake H, Sakai I, Harada K, Muramaki M, Fujisawa M. Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over seventy-five years old. *Int Urol Nephrol.* 2012; 44: 1697-703 (IF=2.266, CI=16)
264. Kusuda Y, \*Miyake H, Gleave ME, Fujisawa M. Clusterin inhibition using OGX-011 synergistically enhances antitumor activity of sorafenib in a human renal cell carcinoma model. *Br J Cancer.* 2012; 106: 1945-52 (IF=9.082, CI=29)
265. \*Miyake H, Terakawa T, Furukawa J, Muramaki M, Fujisawa M. Prognostic significance of tumor extension into venous system in patients undergoing surgical treatment for renal cell carcinoma with venous tumor thrombus. *Eur J Sur Oncol.* 2012; 38: 630-6 (IF=4.037, CI=24)

266. Harada K, \*Miyake H, Kusuda Y, Fujisawa M. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. *BJU Int.* 2012; 110: E1131-7 (IF=5.969, CI=64)
267. \*Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function. *Eur J Radiol.* 2012; 81: 2060-5 (IF=4.531, CI=14)
268. \*Shigemura K, Tanaka K, Yamamichi F, Shirakawa T, Miyake H, Fujisawa M. Does mutation in *gyrA* and/or *parC* or efflux pump expression play the main role in fluoroquinolone resistance in *Escherichia coli* urinary tract infections?: A statistical analysis study. *Int J Antimicrob Agents.* 2012; 40: 516-20 (IF=15.441, CI=24)
269. Matsumoto M, \*Shigemura K, Shirakawa T, Nakano Y, Miyake H, Tanaka K, Kinoshita S, Arakawa S, Kawabata M, Fujisawa M. Mutations in the *gyrA* and *parC* genes and in vitro activities of fluoroquinolones in 114 clinical isolates of *Pseudomonas aeruginosa* derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography. *Int J Antimicrob Agents.* 2012; 40: 440-4 (IF=15.441, CI=16)
270. \*Miyake H, Furukawa J, Muramaki M, Inoue T, Fujisawa M. Health related quality of life after radical cystectomy: Comparative study between orthotopic sigmoid versus ileal neobladders. *Eur J Sur Oncol.* 2012; 38: 1089-94 (IF=4.037, CI=7)
271. \*Miyake H, Kusuda Y, Harada K, Sakai I, Fujisawa M. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma. *Int J Clin Oncol.* 2013; 18: 81-6 (IF=3.85, CI=8)
272. Terakawa T, \*Miyake H, Kusuda Y, Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. *Urol Oncol.* 2013; 31: 493-8 (IF=2.954, CI=39)
273. Behnsawy HM, \*Miyake H, Kusuda Y, Fujisawa M. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells. *Urol Oncol.* 2013; 31: 843-8 (IF=2.954, CI=13)
274. Kusuda Y, \*Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. *Urol Oncol.* 2013; 31: 899-903 (IF=2.954, CI=18)
275. \*Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. *Urol Oncol.* 2013; 31: 733-8 (IF=2.954, CI=15)
276. Muramaki M, \*Miyake H, Sakai I, Fujisawa M. Prognostic factors influencing postoperative development of chronic kidney disease in patients with small renal tumors who underwent partial nephrectomy. *Curr Urol.* 2013; 6: 129-35 (IF=0, CI=0)

277. Behnsawy HM, \* Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. *BJU Int.* 2013; 111: 30-7 (IF=5.969, CI=54)
278. \* Miyake H, Muramaki M, Furukawa J, Tanaka H, Inoue T, Fujisawa M. Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy. *Urol Oncol.* 2013; 31: 1511-6 (IF=2.954, CI=6)
279. \* Miyake H, Harada K, Kusuda Y, Fujisawa M. Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib. *Int J Clin Oncol.* 2013; 18: 220-5 (IF=3.85, CI=4)
280. \* Miyake H, Furukawa J, Muramaki M, Sakai I, Yamashita M, Inoue T, Fujisawa M. Orthotopic sigmoid versus ileal neobladders in Japanese patients: A comparative assessment of complications, functional outcomes and quality of life. *Urol Oncol.* 2013; 31: 1155-60 (IF=2.954, CI=7)
281. \* Ueno Y, Kitajima K, Sugimura K, Kawakami F, Miyake H, Obara M, Takahashi S. Ultra-high b-value diffusion-weighted MR imaging for the detection of prostate cancer with 3-Tesla MRI. *J Magn Reson Imaging.* 2013; 38: 154-60 (IF=5.119, CI=53)
282. \* Miyake H, Harada K, Kusuda Y, Fujisawa M. Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis. *Int J Clin Oncol.* 2013; 18: 1054-9 (IF=3.85, CI=8)
283. Yasufuku T, \* Shigemura K, Tanaka K, Arakawa S, Miyake H, Fujisawa M. Risk factors for refractory febrile neutropenia in urological chemotherapy. *J Infec Chemother.* 2013; 19: 211-6 (IF=2.065, CI=8)
284. Sakai I, \* Miyake H, Fujisawa M. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumor cell proliferation. *BJU Int.* 2013; 112: E211-20 (IF=5.969, CI=39)
285. Kusuda Y, \* Miyake H, Behnsawy HM, Fukuhara T, Inoue T, Fujisawa M. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. *Urol Oncol.* 2013; 31: 42-50 (IF=2.954, CI=14)
286. Furukawa J, \* Miyake H, Sakai I, Fujisawa M. Significance of ureteroscopic biopsy grade in patients with upper tract urothelial carcinoma. *Curr Urol.* 2013; 6: 156-9 (IF=0, CI=0)
287. \* Kitajima K, Takahashi S, Ueno Y, Miyake H, Fujisawa M, Kawakami F, Sugimura K. Do apparent diffusion coefficient (ADC) values obtained using high b-values with a 3-T MRI correlate better than a transrectal ultrasound (TRUS)-guided biopsy with true Gleason scores obtained from radical prostatectomy specimens for patients with prostate cancer? *Eur J Radiol.* 2013; 82: 1219-26 (IF=4.531, CI=30)
288. Ando M, \* Yamaguchi K, Chiba K, Miyake H, Fujisawa M. Outcome of microdissection

testicular sperm extraction in azoospermic patients with Klinefelter syndrome and other sex-chromosomal anomalies. *Syst Biol Reprod Med.* 2013; 59: 210-3 (IF=2.958, CI=4)

289. Yamamichi F, \*Shigemura K, Morishita S, Yamanaka K, Tanaka K, Miyake H, Fujisawa M. Significance of neoadjuvant hormonal therapy in radical retropubic prostatectomy: a retrospective single-surgeon study. *Yonsei Med J.* 2013; 54: 410-5 (IF=3.052, CI=1)
290. \*Shirakawa T, Haraguchi T, Shigemura K, Morishita S, Minayoshi K, Miyazaki J, Yamada Y, Miyake H, Tanaka K, Fujisawa M. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized multicenter study. *Int J Urol.* 2013; 20: 903-10 (IF=2.896, CI=13)
291. Kusuda Y, \*Miyake H, Kurahashi T, Fujisawa M. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction. *Urol Oncol.* 2013; 31: 615-21 (IF=2.954, CI=1)
292. Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, \*Naito S. STAT3 polymorphism can predict the response to interferon- $\alpha$  therapy in patients with metastatic renal cell carcinoma. *Eur Urol.* 2013; 63: 745-52 (IF=24.344, CI=24)
293. Kumano M, \*Miyake H, Nakano Y, Fujisawa M. Significance of selected-site mucosal biopsies in non-muscle invasive bladder cancer. *Curr Urol.* 2013; 7: 57-61 (IF=0, CI=0)
294. Kumano M, \*Miyake H, Abolghait SK, Behnsawy HM, Fujisawa M.  $\beta$ 4-integrin-mediated cytotoxic activity of AexU in human prostate cancer PC3 cells. *Oncol Lett.* 2013; 6: 1482-6 (IF=3.111, CI=1)
295. \*Shigemura K, Tanaka K, Osawa K, Arakawa S, Miyake H, Fujisawa M. Clinical factors associated with shock in bacteremic UTI. *Int Urol Nephrol.* 2013; 45: 653-7 (IF=2.266, CI=15)
296. \*Shigemura K, Tanaka K, Haraguchi T, Yamamichi F, Muramaki M, Miyake H, Fujisawa M. Postoperative infectious complications in our early experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia. *Korean J Urol.* 2013; 54: 189-93 (IF=0, CI=0)
297. \*Tanaka K, Shigemura K, Muramaki M, Takahashi S, Miyake H, Fujisawa M. Efficacy of using three-tesla magnetic resonance imaging diagnosis of capsule invasion for decision-making about neurovascular bundle preservation in robotic-assisted radical prostatectomy. *Korean J Urol.* 2013; 54: 437-41 (IF=0, CI=0)
298. Behnsawy HM, \*Shigemura K, Meligy FY, Yamamichi F, Yamashita M, Haung WC, Li X, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression. *Korean J Urol.* 2013; 54: 547-54 (IF=0, CI=0)
299. Harada K, \*Miyake H, Kumano M, Fujisawa M. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways through mTORC2. *Br J Cancer.* 2013; 109: 2389-95 (IF=9.082, CI=30)



300. Kumano M, \*Miyake H, Harada K, Fujisawa M. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors. *Med Oncol.* 2013; 30: 745 (IF=3.738, CI=7)
301. Tei H, \*Miyake H, Harada K, Fujisawa M. Expression profile of CD44s, CD44v6 and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy. *Urol Oncol* 2014; 32: 694-700 (IF=2.954, CI=14)
302. Nishikawa M, \*Miyake H, Harada K, Fujisawa M. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. *Med Oncol.* 2014; 31: 792 (IF=3.738, CI=19)
303. Ko YH, \*Miyake H, Behnsawy HM, Cheon J, Fujisawa M. Limited significance of activated Akt- mammalian target of rapamycin signaling pathway in prostate cancer progression. *Urol Int* 2014; 93: 146-51 (IF=1.934, CI=3)
304. \*Miyake H, Harada K, Kumano M, Fujisawa M. Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: A single-center experience in Japan. *Int J Clin Oncol.* 2014; 19: 679-85 (IF=3.85, CI=4)
305. Sakai I, \*Miyake H, Hinata N, Fujisawa M. Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. *Int J Clin Oncol.* 2014; 19: 674-8 (IF=3.85, CI=14)
306. Nishikawa M, \*Miyake H, Harada K, Fujisawa M. Expression of molecular markers associated with the mammalian target of rapamycin pathway in non-metastatic renal cell carcinoma: impact on prognostic outcomes following radical nephrectomy. *Urol Oncol.* 2014; 32: 49.e15-21 (IF=2.954, CI=4)
307. \*Shigemura K, Tanaka K, Yamamichi F, Muramaki M, Arakawa S, Miyake H, Fujisawa M. Comparison of postoperative infection between robotic-assisted laparoscopic prostatectomy and open radical prostatectomy. *Urol Int.* 2014; 92: 15-9 (IF=1.934, CI=9)
308. \*Hinata N, Miyake H, Kurahashi T, Ando M, Furukawa J, Ishimura T, Tanaka K, Fujisawa M. Novel telementoring system for robot-assisted radical prostatectomy: Impact on the learning curve. *Urology.* 2014; 83: 1088-92 (IF=2.633, CI=35)
309. Furukawa J, \*Miyake H, Tanaka K, Sugimoto M, Fujisawa M: Console-integrated real-time three-dimensional image overlay navigation for robot-assisted partial nephrectomy with selective arterial clamping: Early single-center experience with 17 cases. *Int J Med Robot.* 2014; 10: 385-90 (IF=2.483, CI=28)
310. Nishikawa M, \*Miyake H, Yamashita M, Inoue T, Fujisawa M. Long-term changes in renal function outcomes following radical cystectomy and urinary diversion. *Int J Clin Oncol.* 2014; 19: 1105-11 (IF=3.85, CI=29)
311. Muramaki M, \*Miyake H, Behnsawy HM, Furukawa J, Harada K, Fujisawa M. Assessment of postoperative quality of life: comparative study between laparoscopic and minimum

- incision endoscopic radical prostatectomies. *Int J Clin Oncol.* 2014; 19: 1092-7 (IF=3.85, CI=4)
312. Harada K, \*Miyake H, Kusuda Y, Fujisawa M. Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model. *Clin Transl Oncol.* 2014; 16: 801-6 (IF=3.34, CI=9)
313. Yamamichi F, \*Shigemura K, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. *Scand J Urol.* 2014; 48: 523-32 (IF=1.899, CI=19)
314. \*Miyake H, Behnsawy HM, Hinata N, Fujisawa M. Objective assessment of residual nerve tissues in radical prostatectomy specimens by immunohistochemical staining of neuronal nitric oxide synthase-positive nerves and its impact on postoperative erectile function. *Urology.* 2014; 84: 1395-401 (IF=2.633, CI=5)
315. \*Kitajima K, Takahashi S, Ueno Y, Miyake H, Fujisawa M, Sugimura K. Visualization of periprostatic nerve fibers before and after radical prostatectomy using diffusion tensor magnetic resonance imaging with tractography. *Clin Imaging.* 2014; 38: 302-6 (IF=2.42, CI=14)
316. Okada K, Miyake H, Yamaguchi K, Chiba K, Maeta K, Bilasy SE, Edamatsu H, Kataoka T, \*Fujisawa M. Critical function of RA-GEF-2/Rapgef6, a guanine nucleotide exchange factor for Rap1, in mouse spermatogenesis. *Biochem Biophys Res Commun.* 2014; 445: 89-94 (IF=3.322, CI=8)
317. \*Miyake H, Nishikawa M, Tei H, Furukawa J, Harada K, Fujisawa M. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. *Urol Oncol.* 2014; 32: 584-8 (IF=2.954, CI=11)
318. Nakano Y, \*Miyake H, Chiba K, Fujisawa M. Impact of penile rehabilitation with low-dose vardenafil on recovery of erectile function in Japanese men following nerve-sparing radical prostatectomy. *Asian J Androl.* 2014; 16: 892-6 (IF=3.054, CI=8)
319. Yanagiuchi A, \*Miyake H, Tanaka K, Fujisawa M. Significance of preoperatively observed detrusor overactivity as a predictor of continence status early after robot-assisted radical prostatectomy. *Asian J Androl.* 2014; 16: 869-72 (IF=3.054, CI=18)
320. \*Tanaka K, Shigemura K, Hinata N, Muramaki M, Miyake H, Fujisawa M. Histological evaluation of nerve sparing technique in robotic assisted radical prostatectomy. *Indian J Urol.* 2014; 30: 268-72 (IF=0, CI=0)
321. \*Miyake H, Harada K, Inoue TA, Fujisawa M. Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors. *Med Oncol.* 2014; 31: 190 (IF=3.738, CI=6)
322. Nishikawa M, \*Miyake H, Muramaki M, Fujisawa M. Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors. *Med Oncol.* 2014;

31: 296 (IF=3.738, CI=3)

323. \*Hinata N, Hieda K, Sasaki H, Kurokawa T, Miyake H, Fujisawa M, Murakami G, Fujimiya M. Nerves and fascia in and around the paracolpium or paravaginal tissue: an immunohistochemical study using elderly donated cadavers. *Anat Cell Biol.* 2014; 47: 44-54 (IF=0, CI=0)
324. \*Hinata N, Hieda K, Sasaki H, Murakami G, Abe S, Matsubara A, Miyake H, Fujisawa M. Topohistology of sympathetic and parasympathetic nerve fibers in branches of the pelvic plexus: an immunohistochemical study using donated elderly cadavers. *Anat Cell Biol.* 2014; 47: 55-65 (IF=0, CI=0)
325. \*Hinata N, Murakami G, Miyake H, Tanaka K, Abe S, Fujimiya M, Takenaka A, Fujisawa M. Urethral sphincter fatigue after robot-assisted radical prostatectomy: descriptive questionnaire-based study and anatomic basis. *Urology.* 2014; 84: 144-8 (IF=2.633, CI=9)
326. \*Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. *Med Oncol.* 2014; 31: 978 (IF=3.738, CI=27)
327. \*Ishimura T, Muramaki M, Kishikawa H, Miyake H, Tanaka K, Nishimura K, Nojima M, Yamamoto S, Ichikawa Y, Fujisawa M. The impact of donor factors on early graft function in kidney transplantation from donation after cardiac death. *Transplant Proc.* 2014; 46: 1064-6 (IF=1.014, CI=3)
328. \*Terakawa T, Miyake H, Yokoyama N, Miyazaki A, Tanaka H, Inoue T, Fujisawa M. Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin. *Urol Int.* 2014; 92: 180-5 (IF=1.934, CI=8)
329. \*Shigemura K, Tanaka K, Arakawa S, Miyake H, Fujisawa M. Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement. *J Antibiot.* 2014; 67: 143-5 (IF=3.424, CI=2)
330. \*Tanaka K, Shigemura K, Ishimura T, Muramaki M, Miyake H, Fujisawa M. Evaluation of a 3D system based on a high-quality flat screen and polarized glasses for use by surgical assistants during robotic surgery. *Indian J Urol.* 2014; 30: 13-6 (IF=0, CI=0)
331. \*Okada K, Yamaguchi K, Chiba K, Miyake H, Fujisawa M. Comprehensive evaluation of androgen replacement therapy in aging Japanese men with late-onset hypogonadism. *Aging Male.* 2014; 17: 72-5 (IF=2.398, CI=14)
332. \*Enatsu N, Yamaguchi K, Chiba K, Miyake H, Fujisawa M. Clinical outcome of microsurgical varicocelectomy in infertile men with severe oligozoospermia. *Urology.* 2014; 83: 1071-4 (IF=2.633, CI=15)
333. Nishikawa M, \*Miyake H, Kitajima K, Takahashi S, Sugimura K, Fujisawa M. Preoperative differentiation between benign and malignant renal masses smaller than 4 cm treated with partial nephrectomy. *Int J Clin Oncol.* 2015; 20: 150-5 (IF=3.85, CI=2)

334. Furukawa J, \*Miyake H, Kusuda Y, Fujisawa M. Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor. *Int J Clin Oncol* 2015; 20: 351-7 (IF=3.85, CI=10)
335. \*Tanaka K, Furukawa J, Shigemura K, Hinata N, Ishimura T, Muramaki M, Miyake H, Fujisawa M. Surgery-related outcomes and postoperative split renal function by scintigraphy evaluation in robot-assisted partial nephrectomy in complex renal tumors: an initial case series. *J Endourol.* 2015; 29: 29-34 (IF=2.619, CI=6)
336. \*Hinata N, Murakami G, Miyake H, Abe SI, Fujisawa M. Histological study of the cavernous nerve mesh outside the periprostatic region: anatomical basis for erectile function after nonnerve sparing radical prostatectomy. *J Urol.* 2015; 193: 1052-9 (IF=7.641, CI=11)
337. Liu B, \*Miyake H, Nishikawa M, Fujisawa M. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: Correlation with intravesical recurrence following transurethral resection. *Urol Oncol* 2015; 33: 110.e11-8 (IF=2.954, CI=20)
338. Liu B, \*Miyake H, Nishikawa M, Tei H, Fujisawa M. Expression profile of autophagy-related markers in localized prostate cancer: Correlation with biochemical recurrence after radical prostatectomy. *Urology.* 2015; 85: 1424-30 (IF=2.633, CI=9)
339. Nishikawa M, \*Miyake H, Fujisawa M. Enhanced sensitivity to sunitinib by inhibition of Akt1 expression in human castration-resistant prostate cancer PC3 cells both in vitro and in vivo. *Urology.* 2015; 85: 1215.e1-7 (IF=2.633, CI=5)
340. Miyazaki A, \*Miyake H, Harada K, Fujisawa M. No significant correlation of clinical outcomes between first- and second-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. *Anticancer Res.* 2015; 35: 3067-73 (IF=2.435, CI=9)
341. Miyazaki A, \*Miyake H, Harada K, Inoue T, Fujisawa M. Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. *Mol Clin Oncol.* 2015; 3: 601-6 (IF=0, CI=0)
342. Fukuda T, \*Miyake H, Enatsu N, Matsushita K, Fujisawa M. Assessment of time-dependent changes in semen parameters in infertile men following microsurgical varicocelectomy. *Urology.* 2015; 86: 48-51 (IF=2.633, CI=14)
343. \*Hinata N, Miyake H, Miyazaki A, Nishikawa M, Tei H, Fujisawa M. Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy. *Int J Urol.* 2015; 22: 742-6 (IF=2.896, CI=18)
344. \*Miyake H, Harada K, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. *Med Oncol* 2015; 32: 78 (IF=3.738, CI=29)
345. Harada K, \*Miyake H, Ogawa T, Inoue T, Fujisawa M. Oncological outcomes in Japanese men undergoing orchiectomy for stage I testicular germ cell tumor. *Curr Urol.* 2015; 8: 84-90 (IF=0, CI=0)

346. \*Miyake H, Harada KI, Imai S, Miyazaki A, Fujisawa M. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib. *Int J Clin Oncol.* 2015; 20: 796-801 (IF=3.85, CI=6)
347. \*Miyake H, Hinata N, Imai S, Furukawa J, Tanaka K, Fujisawa M. Partial nephrectomy for hilar tumors: comparison of conventional open and robot-assisted approaches. *Int J Clin Oncol.* 2015; 20: 808-13 (IF=3.85, CI=17)
348. \*Ueno Y, Takahashi S, Ohno Y, Kitajima K, Yui M, Kassai Y, Kawakami F, Miyake H, Sugimura K. Computed diffusion-weighted MR imaging for prostate cancer detection: the influence of the combinations of b-values. *Br J Radiol.* 2015; 88: 20140738 (IF=3.629, CI=25)
349. Tei H, \*Miyake H, Fujisawa M. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo. *Human Cell.* 2015; 28: 114-21 (IF=4.374, CI=9)
350. \*Miyake H, Furukawa J, Hinata N, Muramaki M, Tanaka K, Fujisawa M. Significant impact of R. E. N. A. L. nephrometry score on changes in postoperative renal function early after robot-assisted partial nephrectomy. *Int J Clin Oncol.* 2015; 20: 586-92 (IF=3.85, CI=14)
351. \*Hinata N, Suzuki R, Ishizawa A, Miyake H, odriguez-Vazquez JF, Murakami G, Fujisawa M. Fetal development of the mesonephric artery in humans with reference to replacement by the adrenal and renal arteries. *Ann Anat.* 2015; 202: 8-17 (IF=2.976, CI=12)
352. Nishikawa M, \*Miyake H, Behnsawy HM, Fujisawa M. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder. *Urol Oncol.* 2015; 33: 166.e9-15 (IF=2.954, CI=3)
353. Nishikawa M, \*Miyake H, Liu B, Fujisawa M. Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: Association with disease recurrence following radical nephrectomy. *J Cancer Res Clin Oncol.* 2015; 141: 1585-91 (IF=4.322, CI=17)
354. Tei H, \*Miyake H, Harada K, Fujisawa M. Detection of significant prostate cancer according to anatomical areas of sampling cores obtained with transrectal systematic 12-core biopsy. *Curr Urol.* 2015; 8: 91-5 (IF=0, CI=0)
355. \*Enatsu N, Miyake H, Chiba K, Fujisawa M. Predictive factors of successful sperm retrieval on microdissection testicular sperm extraction in Japanese men. *Reprod Med Biology.* 2015; 15: 29-33 (IF=0, CI=0)
356. \*Enatsu N, Miyake H, Chiba K, Fujisawa M. Candesartan mediated amelioration of cisplatin-induced testicular damage is associated with alterations in expression patterns of nephrin and podocin. *BioMed Res Int.* 2015; 2015: 273784 (IF=3.246, CI=4)
357. Nishikawa M, \*Miyake H, Bing L, Fujisawa M. UNC-51-like kinase 1 expression in radical nephrectomy specimens as a predictive factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. *Urol Oncol.* 2015; 33: 506.e1-7 (IF=2.954, CI=1)
358. \*Enatsu N, Miyake H, Chiba K, Fujisawa M. Identification of spermatogenically active

regions in rat testes by using narrow band imaging system. *Urology*. 2015; 86: 929-35 (IF=2.633, CI=2)

359. \*Yamamoto K, Shinomiya K, Ioroi T, Hirata S, Harada K, Suno M, Nishioka T, Kume M, Makimoto H, Nakagawa T, Hirano T, Bito T, Nishigori C, Miyake H, Fujisawa M, Hirai M. Association of single nucleotide polymorphisms in STAT3 with hand-foot skin reactions in patients with metastatic renal cell carcinoma treated with multiple tyrosine kinase inhibitors: a retrospective analysis in Japanese patients. *Target Oncol*. 2016; 11: 93-9 (IF=4.897, CI=10)
360. \*Miyake H, Muramaki M, Imai S, Harada K, Fujisawa M. Changes in renal function of patients with metastatic renal cell carcinoma during treatment with molecular-targeted agents. *Target Oncol*. 2016; 11: 329-35 (IF=4.897, CI=6)
361. \*Miyake H, Miyazaki A, Imai S, Harada K, Fujisawa M. Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multiinstitutional study in Japan. *Target Oncol*. 2016; 11: 175-82 (IF=4.897, CI=21)
362. \*Sumii K, Miyake H, Enatsu N, Matsushita K, Fujisawa M. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy. *Andrologia*. 2016; 48: 198-202 (IF=2.532, CI=3)
363. \*Matsushita K, Miyake H, Chiba K, Fujisawa M. Clusterin produced by Sertoli cells inhibits heat stress-induced apoptosis in the rat testis. *Andrologia*. 2016; 48: 11-9 (IF=2.532, CI=14)
364. Furukawa J, \*Miyake H, Hinata N, Muramaki M, Tanaka K, Fujisawa M. Renal functional and perioperative outcomes of selective versus complete renal arterial clamping during robot-assisted partial nephrectomy: early single-center experience with 39 cases. *Surg Innov*. 2016; 23: 242-8 (IF=2.532, CI=14)
365. Furukawa J, \*Miyake H, Inoue T, Ogawa T, Tanaka H, Fujisawa M. Oncologic outcome of radical prostatectomy as monotherapy for men with high-risk prostate cancer. *Curr Urol* 2016; 9: 67-72 (IF=0, CI=0)
366. Imai S, \*Miyake H, Fujisawa M. Acceleration of proteinuria without significant impact on renal function and its protection by angiotensin II receptor blocker in rats treated with axitinib. *Target Oncol*. 2016; 11: 309-15 (IF=4.897, CI=2)
367. \*Hinata N, Miyake H, Murakami G, Abe SI, Fujisawa M. Bladder neck muscle degeneration in patients with prostatic hyperplasia. *J Urol*. 2016; 195: 206-12 (IF=7.641, CI=0)
368. Nishikawa M, \*Miyake H, Fujisawa M. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies. *Int J Clin Oncol*. 2016; 21: 162-7 (IF=3.85, CI=2)
369. Momozono H, \*Miyake H, Tei H, Harada K, Fujisawa M. Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. *Mol Clin Oncol*. 2016;

4: 839-44 (IF=0, CI=0)

370. \*Yamamoto K, Ioroi T, Kanaya K, Shinomiya K, Komoto S, Hirata S, Harada K, Watanabe A, Suno M, Nishioka T, Kume M, Makimoto H, Nakagawa T, Hirano T, Miyake H, Fujisawa M, Hirai M. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population. *Med Oncol.* 2016; 33: 24 (IF=3.738, CI=9)
371. Furukawa J, \*Miyake H, Fujisawa M. Expression levels of GLI2 in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma treated with sunitinib. *Mol Clin Oncol.* 2016; 5: 186-92 (IF=0, CI=0)
372. Kawano Y, Takahashi W, \*Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Prognosis of metastatic renal cell carcinoma with first-line Interferon- $\alpha$  therapy in the era of molecular-targeted therapy. *Cancer Sci.* 2016; 107: 1013-7 (IF=6.528, CI=7)
373. \*Sumii K, Miyake H, Yoshiya K, Enatsu N, Matsushita K, Hara S, Fujisawa M. Erectile function and its impact on quality of life in Japanese men on hemodialysis. *Cogent Med.* 2016; 3: 1211594 (IF=0, CI=0)
374. \*Miyake H, Imai S, Harada K, Fujisawa M. Absence of significant correlation of adverse events between first- and second-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. *Clin Genitourin Cancer.* 2016; 14: e19-24 (IF=3.121, CI=3)
375. \*Miyake H, Miyazaki A, Furukawa J, Hinata N, Fujisawa M. Prospective assessment of time-dependent changes in quality of life of Japanese patients with prostate cancer following robot-assisted radical prostatectomy. *J Robot Surg.* 2016; 10: 201-7 (IF=2.484, CI=0)
376. Nishikawa M, \*Miyake H, Fujisawa M: De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. *Urol Oncol.* 2016; 34: 417. e9-15 (IF=2.954, CI=25)
377. \*Enatsu N, Miyake H, Haraguchi T, Chiba K, Fujisawa M. Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes. *Andrologia.* 2016; 48: 1195-201 (IF=2.532, CI=2)
378. Fukuda T, \*Miyake H, Enatsu N, Matsushita K, Fujisawa M. Seminal level of clusterin in infertile men as a significant biomarker reflecting spermatogenesis. *Andrologia.* 2016; 48: 1188-94 (IF=2.532, CI=14)
379. Momozono H, \*Miyake H, Miyazaki A, Fujisawa M. Significance of urethral fibrosis evaluated by preoperative magnetic resonance imaging as a predictor of continence status after robot-assisted radical prostatectomy. *Int J Med Robot.* 2016; 12: 496-501 (IF=2.483, CI=4)
380. \*Miyake H, Harada K, Ozono S, Fujisawa M. Efficacy and safety of axitinib in elderly

patients with metastatic renal cell carcinoma. *Med Oncol.* 2016; 33: 95 (IF=3.738, CI=9)

381. Momozono H, \*Miyake H, Fujisawa M. Impact of periurethral inflammation on continence status early after robot-assisted radical prostatectomy. *J Endourol.* 2016; 30: 1207-13 (IF=2.619, CI=4)
382. \*Sumii K, Miyake H, Enatsu N, Chiba K, Fujisawa M. Characterization of urocortin as an anti-apoptotic protein in experimental ischemia-reperfusion model of the rat testis. *Biochem Biophys Res Commun.* 2016; 479: 387-92 (IF=3.322, CI=5)
383. Miyazaki A, \*Miyake H, Fujisawa M. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. *Clin Transl Oncol.* 2016; 18: 893-900 (IF=3.34, CI=9)
384. \*Miyake H, Miyazaki A, Yao A, Hinata N, Fujisawa M. Significance of erection hardness score as a diagnostic tool to assess erectile function recovery in Japanese men after robot-assisted radical prostatectomy. *J Robot Surg.* 2016; 10: 221-6 (IF=2.484, CI=0)
385. \*Miyake H, Harada K, Ozono S, Fujisawa M. Prognostic significance of early tumor shrinkage under second-line targeted therapy for metastatic renal cell carcinoma: a retrospective multiinstitutional study in Japan. *Mol Diagn Ther.* 2016; 20: 385-92 (IF=4.476, CI=7)
386. Hara T, \*Miyake H, Fujisawa M. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. *Urol Oncol.* 2017; 35: 363-9 (IF=2.954, CI=16)
387. \*Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. *Urol Oncol.* 2017; 35: 432-7 (IF=2.954, CI=7)
388. \*Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naïve metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. *Clin Genitourin Cancer.* 2017; 15: 313-9 (IF=3.121, CI=23)
389. \*Miyake H, Hara T, Ozono S, Fujisawa M. Impact of prior use of an androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer.* 2017; 15: e217-22 (IF=3.121, CI=0)
390. \*Miyake H, Harada K, Ozono S, Fujisawa M. Assessment of efficacy, safety and quality of life of 124 patients treated with axitinib as second-line therapy for metastatic renal cell carcinoma: Experience in real world clinical practice in Japan. *Clin Genitourin Cancer.* 2017; 15: 122-8 (IF=3.121, CI=23)
391. Nishikawa M, \*Miyake H, Fujisawa M. Effect of targeting clusterin using OGX-011 on



antitumor activity of temsirolimus in a human renal cell carcinoma model. *Target Oncol.* 2017; 12: 69-79 (IF=4.897, CI=2)

392. \*Nishikawa M, Miyake H, Fujisawa M. Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy. *Int J Urol.* 2017; 24: 449-53 (IF=2.896, CI=6)
393. Watanabe A, \*Yamamoto K, Ioroi T, Hirata S, Harada K, Miyake H, Fujisawa M, Nakagawa T, Yano I, Hirai M. Association of single nucleotide polymorphisms in STAT3, ABCB1, and ABCG2 with stomatitis in patients with metastatic renal cell carcinoma treated with sunitinib: a retrospective analysis in Japanese patients. *Biol Pharm Bull.* 2017; 40: 458-64 (IF=2.264, CI=13)
394. \*Ogawa S, Ishimura T, Miyake H, Fujisawa M. Expression profile of mammalian target of rapamycin-related proteins in graft biopsy specimens: Significance for predicting interstitial fibrosis after renal transplantation. *Int J Urol.* 2017; 24: 223-9 (IF=2.896, CI=3)
395. \*Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Comparison of tyrosine kinase inhibitor versus mammalian target of rapamycin inhibitor as second-line molecular-targeted therapy for patients with poor-risk metastatic renal cell carcinoma. *Anticancer Res.* 2017; 37: 1523-8 (IF=2.435, CI=4)
396. \*Miyake H, Tei H, Fujisawa M. Geriatric nutrition risk index is an important predictor of cancer-specific survival, but not recurrence-free survival, in patients undergoing surgical resection for non-metastatic renal cell carcinoma. *Curr Urol.* 2017; 10: 26-31 (IF=0, CI=0)
397. \*Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer. *Med Oncol.* 2017; 34: 141 (IF=3.738, CI=10)
398. Tanaka U, \*Ueno Y, Morinaga Y, Miyake H, Kyotani K, Ueda Y, Kitajima K, Sofue K, Suenaga Y, Sugimura K, Takahashi S. Value of three-dimensional T2-weighted turbo spin-echo imaging with tissue-specific variable refocusing flip angle for 3-T magnetic resonance imaging of prostate cancer: comparison with conventional two- and three-dimensional T2-weighted turbo spin-echo imaging. *Jap J Radiol.* 2017; 35: 707-17 (IF=2.701, CI=6)
399. \*Miyake H, Imai S, Ozono S, Fujisawa M. The inverse association between baseline renal function and overall survival in patients with metastatic renal cell carcinoma who were treated with molecular-targeted agents. *Curr Urol.* 2017; 10: 186-92 (IF=0, CI=0)
400. \*Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer.* 2017; 15: e591-7 (IF=3.121, CI=30)
401. \*Oda T, Ishimura T, Yokoyama N, Ogawa S, Miyake H, Fujisawa M. Hypoxia-inducible factor-1 $\alpha$  expression in kidney transplant biopsy specimens after reperfusion is

associated with early recovery of graft function after cadaveric kidney transplantation: *Transplant Proc.* 2017; 49: 68-72 (IF=1.014, CI=12)

402. \*Miyake H, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. *Med Oncol.* 2017; 34: 200 (IF=3.738, CI=3)
403. \*Nishikawa M, Miyake H, Kurahashi T, Fujisawa M. Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy. *Int J Clin Oncol.* 2018; 23: 151-7 (IF=3.85, CI=7)
404. \*Okada K, Miyake H, Ishida T, Sumii K, Enatsu N, Chiba K, Matsushita K, Fujisawa M. Improved lower urinary tract symptoms associated with testosterone replacement therapy in Japanese men with late-onset hypogonadism. *Am J Mens Health.* 2018; 12: 1403-8 (IF=0, CI=0)
405. \*Kitahama Y, Koga H, Kawaoka T, Minami M, Miyake H, Yamamoto S. Posterolateral percutaneous endoscopic discectomy with partial pediculotomy for the L1-L2 high-grade downward migrated disc herniation. *J Head Neck Spine Surg.* 2018; 3: 555596 (IF=0, CI=0)
406. Suzuki T, \*Otsuka A, Ito Y, Yamada S, Miyake H, Ozono S. Isosamidin, an extract of *Peucedanum japonicum*, inhibits phenylephrine-mediated contractions of the human prostate in vitro. *Phytother Res.* 2018; 32: 949-52 (IF=6.388, CI=2)
407. \*Ioroi T, Furukawa J, Kume M, Hirata S, Utsubo Y, Mizuta N, Miyake H, Fujisawa M, Hirai M. Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy. *Support Care Cancer.* 2018; 26: 1419-23 (IF=3.359, CI=4)
408. \*Yamamoto K, Hara T, Nakagawa T, Hirai M, Miyake H, Fujisawa M, Yano I. Association of expression levels or activation status of STAT3 with treatment outcomes of sunitinib in patients with renal cell carcinoma. *Target Oncol.* 2018; 13: 371-8 (IF=4.897, CI=4)
409. \*Miyake H, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Significance of age in Japanese patients receiving sunitinib as first-line systemic therapy for metastatic renal cell carcinoma: comparative assessment of efficacy and safety between patients aged <75 and ≥ 75 years. *Anticancer Res.* 2018; 38: 3593-9 (IF=2.435, CI=3)
410. \*Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus. *Int J Clin Oncol.* 2018; 23: 553-8 (IF=3.85, CI=5)
411. \*Miyake H, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant

prostate cancer. *Int J Clin Oncol*. 2018; 23: 576-83 (IF=3.85, CI=2)

412. \*Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Comparison of alternative androgen receptor-axis-targeted agent (ARATA) versus docetaxel as second-line therapy for patients with metastatic castration-resistant prostate cancer progressing after initial ARATA in real-world clinical practice in Japan. *Clin Genitourin Cancer*. 2018; 16: 219-25 (IF=3.121, CI=9)
413. \*Miyake H, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Motoyama D, Ito T, Sugiyama T, Otsuka A. Significance of De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant prognostic but not predictive biomarker in Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. *Anticancer Res*. 2018; 38: 4179-85 (IF=2.435, CI=12)
414. \*Miyake H, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Motoyama D, Ito T, Sugiyama T, Otsuka A. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma. *Med Oncol*. 2018; 35: 133 (IF=3.738, CI=6)
415. Suzuki T, Shimizu T, Kwon J, Takaoka E, Yoshikawa S, Sumino Y, Kitta T, Miyazato M, Miyake H, \*Yoshimura N. Role of the serotonergic system in urethral continence reflexes during sneezing in rats. *Am J Physiol Renal Physiol*. 2018; 315: F79-85 (IF=4.097, CI=5)
416. Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, \*Quinn DI. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. *Ann Oncol*. 2018; 29: 2371-8 (IF=51.769, CI=120)
417. Takahashi S, Kinuya S, Nonomura N, Shinohara N, Suzuki K, Suzuki H, Nakamura K, Satoh T, Tateishi U, Yoneda T, Horikoshi H, Igawa T, Kamai T, Koizumi M, Kosaka T, Matsubara N, Miyake H, Mizokami A, Mizowaki T, Nakamura N, Nozawa M, Takahashi T, Uemura H, Uemura M, Yokomizo A, Yoshimura M, \*Kakehi Y. Japanese expert panel meeting on the management of prostate cancer with bone metastases. *Oncol Ther*. 2018; 6: 157-71 (IF=0, CI=0)
418. Tamura K, Horikawa M, Sato S, Miyake H, \*Setou M. Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry. *Oncotarget*. 2019; 10: 1688-703 (IF=5.168, CI=0)
419. \*Miyake H, Harada K, Matsushita Y, Hinata N, Sugimura H, Fujisawa M. Protocol for a prospective multicenter intervention study (URivo study) assessing biomarkers in patients with previously treated advanced clear cell renal cell carcinoma receiving nivolumab. *Int J Clin Trials*. 2019; 6: 63-8 (IF=0, CI=0)
420. \*Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Clinical outcomes of 42 renal cell carcinoma patients with metastases solely to the lung who received sorafenib as second-line systemic therapy. *Anticancer Res*. 2019; 39: 1067-72 (IF=2.435, CI=4)

421. \*Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer. *Anticancer Res.* 2019; 39: 1391-6 (IF=2.435, CI=22)
422. Ito T, Kanao K, Takahara K, Ando R, Yasui T, Shiroki R, Sumitomo M, \*Miyake H. Optimal timing of cabazitaxel introduction for Japanese patients with metastatic castration-resistant prostate cancer. *Anticancer Res.* 2019; 39: 3089-94 (IF=2.435, CI=2)
423. \*Otsuka A, Suzuki T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia. *Low Urin Tract Symptoms.* 2019; 11: 0141-6 (IF=1.374, CI=4)
424. \*Ohashi N, Isobe S, Matsuyama T, Ishigaki S, Suzuki T, Tsuji T, Otsuka A, Kato A, Miyake H, Yasuda H. The Intrarenal renin-angiotensin system is activated immediately after kidney donation in kidney transplant donors. *Intern Med.* 2019; 58: 643-8 (IF=1.282, CI=2)
425. \*Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer. *Int J Clin Oncol.* 2019; 24: 842-7 (IF=3.85, CI=6)
426. \*Otsuka A, Suzuki T, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Therapeutic endoscopic treatment plus maintenance dimethyl sulfoxide therapy prolongs recurrence-free time in patients with Hunner type interstitial cystitis: a pilot study. *Int Neurourol J.* 2019; 23: 327-33 (IF=3.038, CI=0)
427. \*Kanao K, Ito T, Takahara K, Ando R, Yasui T, Shiroki R, Miyake H, Sumitomo M. Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. *Jpn J Clin Oncol.* 2019; 49: 1043-8 (IF=2.925, CI=2)
428. \*Motoyama D, Aki R, Matsushita Y, Tamura K, Ito T, Sugiyama T, Otsuka A, Miyake H. Early single-center experience with robotic partial nephrectomy using the da Vinci Xi: comparative assessment with conventional open partial nephrectomy. *Curr Urol.* 2019; 13: 13-8 (IF=0, CI=0)
429. \*Ito T, Tamura K, Otsuka A, Shinbo H, Takada S, Kurita Y, Miyake H. Development of a complete en-bloc technique with direct bladder neck incision: A newly modified approach for holmium laser enucleation of the prostate. *J Endourol.* 2019; 33: 835-40 (IF=2.619, CI=12)
430. \*Motoyama D, Matsushita Y, Watanabe H, Tamura K, Ito T, Sugiyama T, Otsuka A, Miyake H. Significant impact of three-dimensional volumetry of perinephric fat on the console time during robot-assisted partial nephrectomy. *BMC Urol.* 2019; 19: 132 (IF=2.09, CI=6)

431. Hara T, \*Miyake H, Hinata N, Fujisawa M. Inhibition of tumor growth and sensitization to sunitinib by RNA interference targeting programmed death-ligand 1 in mouse renal cell carcinoma RenCa model. *Anticancer Res.* 2019; 39: 4737-42 (IF=2.435, CI=4)
432. \* Sugiyama T, Ozono S, Miyake H. Expression profile of S100A2 and its clinicopathological significance in renal cell carcinoma. *Anticancer Res.* 2020; 40: 6337-43 (IF=2.435, CI=2)
433. \*Otsuka A, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Predictive factors for persistence of preoperative overactive bladder symptoms after transvaginal mesh surgery in women with pelvic organ prolapse. *Low Urin Tract Symptoms.* 2020; 12: 167-72 (IF=1.374, CI=4)
434. Tamura K, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, \*Miyake H. Enhanced sensitivity to NVP-BEZ235 by inhibition of p62/SQSTM1 in human bladder cancer KoTCC-1 cells both in vitro and in vivo. *In Vivo.* 2020; 34: 1001-8 (IF=2.406, CI=3)
435. \*Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. *Cancer Sci.* 2020; 111: 907-23 (IF=6.518, CI=22)
436. \*Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer. *Mol Clin Oncol.* 2020; 12: 495-500 (IF=0, CI=0)
437. \*Miyake H, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Assessment of factors predicting disease progression in Japanese patients with non-metastatic castration-resistant prostate cancer. *Anticancer Res.* 2020; 40: 1101-6 (IF=2.435, CI=2)
438. \*Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy. *Urol Oncol.* 2020; 38: 6. e9-16 (IF=2.954, CI=7)
439. \*Motoyama D, Matsushita Y, Watanabe H, Tamura K, Ito T, Sugiyama T, Otsuka A, Miyake H. Improved perioperative outcomes by early unclamping prior to renorrhaphy compared with conventional clamping during robot-assisted partial nephrectomy: a propensity score matching analysis. *J Robot Surg.* 2020; 14: 47-53 (IF=2.484, CI=7)
440. \*Motoyama D, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Ito T, Sugiyama T, Otsuka A, Miyake H. Initial learning curve for robot-assisted partial nephrectomy performed by a single experienced robotic surgeon. *Asian J Endosc Surg.* 2020; 13: 59-64 (IF=0, CI=0)
441. \*Matsushita Y, Watanabe K, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Second transurethral resection for high-risk non-muscle invasive bladder

cancer patients: a propensity score matched analysis. *Jap J Clin Oncol.* 2020; 50: 718-21 (IF=2.925, CI=1)

442. Ikeda A, Kojima T, Kawai K, Hinotsu S, Keino N, Shiga K, Miyake H, Miyata Y, Enomoto Y, Shimizu F, Anai S, Matsuyama H, Suzuki C, Kanimoto Y, Shigeta K, Naito S, Akaza H, \*Nishiyama H. Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan. *Int J Clin Oncol.* 2020; 25: 1163-9 (IF=3.85, CI=9)
443. \*Ando R, Takahara K, Ito T, Kanao K, I Kobayashi, Shiroki R, Sumitomo M, Miyake H, Yasui T. Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: impact of disease progression vs. adverse events. *Urol Oncol.* 2020; 38: 937.e19-25 (IF=2.954, CI=2)
444. \*Takahara K, Ando R, Kanao K, Ito T, Miyake H, Sumitomo M, Yasui T, Shiroki R. Prognostic stratification of the IMDC intermediate risk group after treatment with first-line molecular-targeted therapy for metastatic renal cell carcinoma. *Anticancer Res.* 2020; 40: 4395-400 (IF=2.435, CI=1)
445. Hinata N, Yonese J, Masui S, Nakai Y, Shirotake S, Tatsugami K, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Ochi K, Kaneko H, \*Uemura H. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data. *Int J Clin Oncol.* 2020; 25: 1533-42 (IF=3.85, CI=15)
446. \*Matsushita Y, Watanabe K, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Comprehensive assessment of oncological outcomes in 186 patients with high-risk non-muscle-invasive bladder cancer: a single institution retrospective study. *Mol Clin Oncol.* 2020; 13: 16 (IF=0, CI=0)
447. Tamura K, Ando R, Takahara K, Ito T, Kanao K, Yasui T, Shiroki R, \*Miyake H. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy. *Urol Oncol.* 2021; 39: 78.e1-8 (IF=2.954, CI=7)
448. \*Sugiyama T, Terada H, Miyake H. Assessment of blood plasma free-amino acids levels in infertile men. *In Vivo.* 2021; 35: 1843-7 (IF=2.406, CI=0)
449. Takemura A, Matsushita Y, Tamura K, Sugiyama T, Nagata M, Otsuka A, \*Miyake H. Pembrolizumab versus combined chemotherapy with gemcitabine and paclitaxel: a comparative assessment of clinical outcomes in patients with platinum-refractory advanced urothelial cancer. *In Vivo.* 2021; 35: 1889-94 (IF=2.406, CI=1)
450. \*Mizutani K, Ito T, Takahara K, Ando R, Ishihara T, Yasui T, Shiroki R, Miyake H, Koie T. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. *Medicine.* 2021; 100: e25402 (IF=1.817, CI=1)
451. Furuhashi S, \*Morita Y, Ida S, Muraki R, Kitajima R, Suzuki K, Takeda M, Kikuchi H, Hiramatsu Y, Kurachi K, Shido Y, Sugimoto K, Ito H, Maekawa Y, Mineta H, Miyake H,

Takeuchi H. Risk factors for totally implantable central venous access port-related infection in patients with malignancy. *Anticancer Res.* 2021; 41: 1547-53 (IF=2.435, CI=1)

452. \*Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. *ESMO Open.* 2021; 6: 100101 (IF=6.883, CI=14)
453. \*Kitahama Y, Shizuka H, Kimura R, Suzuki T, Ohara Y, Miyake H, Sakai K. Fluid lubrication and cooling effects in diamond grinding of human iliac bone. *Medicina.* 2021; 57: 71 (IF=2.948, CI=0)
454. \*Ito T, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Miyake H. Impact of bladder neck angle measured by postoperative magnetic resonance imaging on mid-term recovery of urinary continence in prostate cancer patients undergoing robot-assisted radical prostatectomy. *J Endourol.* 2021; 35: 1610-5 (IF=2.619, CI=1)
455. \*Kitahama Y, Ohashi H, Namba H, Sakai K, Shizuka H, Miyake H. Finite element method for nerve root decompression in minimally invasive endoscopic spinal surgery. *Asian J Endosc Surg.* 2021; 14: 628-35 (IF=0, CI=0)
456. \*Motoyama D, Sato R, Watanabe K, Matsushita Y, Watanabe H, Matsumoto R, Ito T, Sugiyama T, Otsuka A, Miyake H. Perioperative outcomes in patients undergoing robot-assisted partial nephrectomy: Comparative assessments between complex and non-complex renal tumors. *Asian J Endosc Surg.* 2021; 14: 379-85 (IF=0, CI=0)
457. \*Tamura K, Osawa T, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Sugimoto M, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Komiyama M, Tanaka K, Yokomizo A, Kohei N, Shinohara N, Miyake H. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. *Jpn J Clin Oncol.* 2021; 51: 810-8 (IF=2.925, CI=0)
458. Watanabe H, Kawakami A, Sato R, Watanabe K, Matsushita Y, \*Miyake H. Molecular mechanism mediating cytotoxic activity of cabazitaxel in docetaxel-resistant human prostate cancer cells. *Anticancer Res.* 2021; 41: 3753-8 (IF=2.435, CI=0)
459. \*Miyake H, Sato R, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A. Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: Comparative assessments between cabazitaxel and other agents. *Int J Clin Oncol.* 2021; 26: 1745-51 (IF=3.85, CI=1)
460. \*Watanabe K, Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Significance of oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy following standard white light transurethral resection in accurate diagnosis of non-muscle invasive bladder cancer. *Cancer Diag Prog.* 2021; 1: 201-5 (IF=0, CI=0)

461. \*Watanabe H, Motoyama D, Watanabe K, Matsushita Y, Ito T, Sugiyama T, Otsuka A, Miyake H. Health-related quality of life in patients with small renal mass who underwent robot-assisted partial nephrectomy: a prospective evaluation. *J Endourol.* 2021; 35: 1644-9 (IF=2.619, CI=4)
462. \*Sato R, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Prognostic assessments in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy and systematic regional lymph node dissection. *Urologia.* 2021; 29: 3915603211034943 (IF=0, CI=0)
463. Matsushita Y, \*Iwashita Y, Ohtsuka S, Ohnishi I, Yamashita Y, Miyake H, Sugimura H. A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2'-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients. *Genes Environ.* 2021; 43: 52 (IF=2.627, CI=2)
464. \*Takahara K, Naiki T, Ito T, Nakane K, Koie T, Yasui T, Miyake H, Shiroki R. Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate. *Int J Urol.* 2022; 29: 229-34 (IF=2.896, CI=6)
465. \*Miyake H, Motoyama D, Kawakami A, Sato R, Watanabe K, Matsushita Y, Watanabe H, Ito T, Sugiyama T, Otsuka A. Initial experience of robot-assisted radical nephrectomy in Japan: Single institutional study of 12 cases. *Asian J Endosc Surg.* 2022; 15: 162-7 (IF=0, CI=0)
466. \*Abe K, Shibata K, Naito T, Otsuka A, Karayama M, Maekawa M, Miyake H, Suda T, Kawakami J. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients. *Eur J Clin Pharmacol.* 2022; 78: 77-87 (IF=3.064, CI=2)
467. \*Naiki T, Takahara K, Ito T, Nakane K, Sugiyama Y, Koie T, Shiroki R, Miyake H, Yasui T. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis. *Int J Clin Oncol.* 2022; 27: 592-601 (IF=3.85, CI=3)
468. \*Ito T, Mizutani K, Takahara K, Ando R, Yasui T, Shiroki R, Koie T, Miyake H. Prognostication in Japanese patients with previously treated metastatic renal cell carcinoma receiving nivolumab: An observational multi-institutional study. *Mol Clin Oncol.* 2022; 16: 17 (IF=0, CI=0)
469. \*Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Powles T, Yoshida M, Koide Y, Umeyama Y, di Pietro A, Uemura H. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. *Int J Clin Oncol.* 2022; 27: 383-95 (IF=3.85, CI=2)
470. \*Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Uemura H, Albiges L, Fujii Y, Umeyama Y, Wang J, Mariani M, Schmidinger M. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. *ESMO Open.* 2022; 7: 100450 (IF=6.883, CI=2)



471. \*Tomida R, Miyake M, Minato R, Sawada Y, Matsumura M, Iida K, Hori S, Fukui S, Ohyama C, Miyake H, Hongo F, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Hashine K. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette- Guérin therapy for non- muscle- invasive bladder cancer: a comparative analysis of large real- world data. *Int J Clin Oncol*. 2022; 7: 958-68 (IF=3.85, CI=0)
472. \*Motoyama D, Kawakami A, Sato R, Watanabe K, Matsushita Y, Watanabe H, Ito T, Sugiyama T, Otsuka A, Miyake H. Feasibility of inter-aortocaval clamping for renal artery during robot-assisted right partial nephrectomy: A propensity score matching analysis. *Asian J Endosc Surg*. 2022; 15: 531-8 (IF=0, CI=0)
473. Kobayashi K, \*Matsuyama H, Kawai T, Ikeda A, Miyake H, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H. Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). *Int J Urol*. 2022; 29: 632-8 (IF=2.896, CI=3)
474. \*Matsushita Y, Kawakami A, Sato R, Watanabe K, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer. *Jpn J Clin Oncol*. 2022; 52: 936-41 (IF=2.925, CI=0)
475. \*Sano A, Inoue Y, Kikuchi H, Fukuchi K, Funai K, Imai A, Matsushita Y, Tamura K, Kitagawa M, Miyake H. Development of a simple and objective prognostication model for patients with advanced solid malignant tumors treated with immune checkpoint inhibitors: A pan-cancer analysis. *Target Oncol*. 2022; 17: 583-9 (IF=4.897, CI=0)
476. Uemura H, Matsumoto R, Mizokami A, Miyake H, Uemura H, Matsuyama H, Nakamura K, Saito K, Kawakita M, Takeshita H, Koroki Y, Ono S, Murota M, Ito M, \*Kamoto T, Fujimoto K. Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study. *Int J Urol*. 2022; 29: 1061-70 (IF=2.896, CI=1)
477. Kimura K, \*Kitajima K, Kawanaka Y, Yokoyama H, Komoto H, Fujiwara M, Furukawa Y, Kanematsu A, Yamamoto S, Miyake H, Yamakado K. Evaluation of <sup>11</sup>C-choline PET/CT for determining treatment response in metastatic castration-resistant prostate cancer patients. *Int J Urol*. 2022; 29: 1072-8 (IF=2.896, CI=0)
478. \*Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Comparison of perioperative outcomes among patients with exophytic, mesophytic and endophytic renal tumors undergoing robot-assisted partial nephrectomy. *Int J Urol*. 2022; 29: 1026-30 (IF=2.896, CI=0)
479. \*Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Limited impact of erectile function on health-related quality of life in Japanese men undergoing robot-assisted radical prostatectomy. *Int J Urol*. 2022; 29: 956-61 (IF=2.896, CI=1)
480. \*Sato R, Sano A, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Sugiyama

T, Otsuka A, Miyake H. Effects of changes in erectile function after holmium laser enucleation of the prostate on postoperative outcomes in patients with benign prostatic hyperplasia. *In Vivo*. 2022; 36: 2960-4 (IF=2.406, CI=0)

481. \*Watanabe K, Otsuka A, Sano A, Sato R, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy. *Int J Urol*. 2023; 30: 57-61 (IF=2.896, CI=0)
482. \*Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S, Kono Y, Tamaki Y, Seko A, Ishiwata Y, Ito K, Toriihara A, Watabe S, Hosono M, Miyake H, Yamamoto S, Daimon T, Yamakado K. Novel nomogram developed for determining suitability of metastatic castration resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment - Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. *Eur J Nucl Med Mol Imaging*. 2023; 50: 1487-98 (IF=10.057, CI=0)
483. Watanabe K, Ishibashi M, Suzuki T, Otsuka A, Yoshimura N, Miyake H, \*Fukuda A. Therapeutic effects of KCC2 chloride transporter activation on detrusor overactivity in mice with spinal cord injury. *Am J Physiol Renal Physiol*. 2023; 324: F353-61 (IF=4.097, CI=0)
484. \*Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes. *BJUI Compass*. 2023; 4: 305-13 (IF=0, CI=0)
485. Miyake H, \*Kakei Y, Nakano Y, Terakawa T, Miyakoda K, Harada K, Fujisawa M. Efficacy and safety of apalutamide in metastatic castration-resistant prostate cancer patients (GENESIS): Protocol for a multicentre, open-label, single-arm clinical trial. *BMJ Open*. 2023; 13: e070173 (IF=3.007, CI=0)
486. \*Nakane K, Watanabe H, Naiki T, Takahara K, Yasui T, Miyake H, Shiroki R, Koie T. Trends in the use of second-generation androgen receptor axis-targeted agents for metastatic hormone-sensitive prostate cancer and clinical factors predicting biological recurrence. *Diagnostics*. 2023; 13: 1661 (IF=3.992, CI=0)
487. \*Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, Nishimura K, Yano Y, Nishio K, Kinoshita S, Fukushima T, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Miyake H, Azuma H. Optimal time point for evaluation of response to pembrolizumab treatment in Japanese patients with metastatic urothelial carcinoma. *Cancer Diagn Progn*. 2023; 3: 370-6 (IF=3.992, CI=0)
488. \*Kitajima K, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S, Kono Y, Tamaki Y, Seko-Nitta A, Ishiwata Y, Ito K, Toriihara A, Watanabe S, Hosono M, Miyake H, Yamamoto S, Sasaki R, Narita M, Yamakado K. Assessing therapeutic response to radium-223 with an automated bone scan index among metastatic castration-resistant prostate cancer patients: Data from patients in J-RAP-BSI trial. *Cancers*. 2023; 15: 2784 (IF=6.575, CI=0)

489. \*Sato R, Inamoto T, Matsushita Y, Takemura A, Uchimoto T, Sano A, Tanaka H, Ishikawa G, Watanabe K, Watanabe H, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Harada K, Azuma H, Miyake H. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab. *Int J Urol*. doi: 10.1111/iju.15133. Online ahead of print (IF=2.896, CI=0)
490. \*Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNIp-RCC trial. *Cancer Immunol Immunother*. doi: 10.1007/s00262-023-03367-w. Online ahead of print (IF=6.63, CI=0)
491. \*Harada K, Miyake H, Furukawa J, Fujimoto N, Fujisawa M. Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma. *Int J Urol*. doi: 10.1111/iju.15144. Online ahead of print (IF=2.896, CI=0)
492. Miyamoto T, \*Miyake M, Nakahama T, Nishimura N, Onishi K, Iida K, Yonemori M, Enokida H, Nakagame M, Matsumoto H, Matsuyama H, Matsushita Y, Miyake H, Fujii T, Shimada K, Baba S, Kinjyo M, Shimokama T, Okumura K, Fujimoto K. Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study. *Int J Urol*. doi: 10.1111/iju.15162. Online ahead of print (IF=2.896, CI=0)
493. \*Miyake H, Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M. Initial experience of robot-assisted partial nephrectomy using hinotori surgical robot system: Single institutional prospective assessment of perioperative outcomes in 30 cases. *J Endourol*. doi: 10.1089/end.2022.0775. Online ahead of print (IF=2.619, CI=0)
494. \*Uemura H, Yonese J, Hinata N, Masui S, Nakai Y, Shirotake S, Takeuchi A, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamada K, Miyake H, Fukasawa S, Morishima N, Ito H. Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review. *Int J Urol*. in press (IF=2.896, CI=0)
495. Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M, \*Miyake H. Perioperative outcomes of robot-assisted partial nephrectomy using hinotori versus da Vinci surgical robot system: A propensity score-matched analysis. *J Robot Surg*. in press (IF=2.484, CI=0)
496. Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M, \*Miyake H. Robot-assisted adrenalectomy using hinotori surgical robot system: Report of first series of 6 cases. *Asian J Endosc Surg*. in press (IF=0, CI=0)

(和文)

1. 単腎および両腎に発生した腎細胞癌に対する腎保存手術の検討, 江藤弘, 上野康一, 三宅秀明, 杉山武毅, 岡泰彦, 原勲, 中村一郎, 岡田弘, 荒川創一, 守殿貞夫, 日本泌尿器科学会雑誌, 86 巻, 1255-1260, 1995

2. 限局性前立腺癌に対する前立腺全摘除術の検討, 荒川創一, 原勲, 三宅秀明, 田口功, 山田裕二, 後藤章暢, 上野康一, 松井隆, 藤澤正人, 江藤弘, 郷司和男, 岡田弘, 守殿貞夫, 泌尿器科紀要, 42 巻, 811-815, 1996
3. 主腫瘍に随伴する微小癌: 随伴微小癌予測因子とその発生由来について, 郷司和男, 三宅秀明, 原勲, 江藤弘, 後藤章暢, 岡田弘, 荒川創一, 守殿貞夫, 泌尿器外科, 12 巻, 17-21, 1999
4. 術前内分泌療法を施行した根治的前立腺全摘出術症例の臨床病理学的検討, 原勲, 三宅秀明, 原章二, 後藤章暢, 江藤弘, 荒川創一, 守殿貞夫, 泌尿器科紀要, 47 巻, 453-458, 2001
5. 腹腔鏡下前立腺全摘除術: 初期 17 例の治療成績, 川端岳, 原勲, 原章二, 磯谷周治, 酒井豊, 和田義孝, 三宅秀明, 後藤章暢, 長久裕史, 藤澤正人, 岡田弘, 守殿貞夫, 荒川創一, 守殿貞夫, 日本泌尿器科学会雑誌, 92 巻, 647-655, 2001
6. 根治的前立腺全摘除術後の生化学的再発予測因子としての超高感度測定法を用いた PSA nadir 値の有用性, 酒井伊織, 原田健一, 三宅秀明, 江藤弘, 兵庫県立成人病センター紀要, 19 巻, 21-25, 2004
7. 前立腺癌における血清 Macrophage migration-inhibitory factor (MIF) の臨床的意義, 山中和樹, 原勲, 村蒔基次, 熊野晶文, 古川順也, 山田裕二, 三宅秀明, 藤澤正人, 日本腎泌尿器疾患予防医学研究会誌, 14 巻, 71-72, 2006
8. 再燃進行前立腺がんの治療の現状と展望 アンチアンドロゲン交替療法の臨床的意義, 鈴木啓悦, 沖原宏治, 三宅秀明, 藤澤正人, 三好進, 松本哲朗, 藤井元廣, 松田公志, 大園誠一郎, 武田正之, 碓井亜, 公文裕己, 市川智彦, 三木恒治, 泌尿器外科, 21 巻, 1023-1026, 2008
9. Maximum androgen blockade 中の PSA 再燃に対する非ステロイド性抗アンドロゲン剤交替療法 -NASA-PC 研究会報告を中心に-, 藤本直浩, 松本哲朗, 鈴木啓悦, 市川智彦, 沖原宏治, 三木恒治, 三宅秀明, 藤澤正人, 植村元秀, 三好進, 田丁貴俊, 矢野明, 藤井元廣, 滝花義男, 武田正之, 石光広, 松原昭郎, 碓井亜, 木下秀文, 松田公志, 麦谷莊一, 大園誠一郎, 那須保友, 雑賀隆史, 公文裕己, 西日本泌尿器科, 71 巻, 3-10, 2009
10. 経直腸的 12 箇所生検による部位別癌検出率の検討, 三宅秀明, 倉橋俊史, 寺川智章, 酒井伊織, 村蒔基次, 武中篤, 藤澤正人, 泌尿器外科, 22 巻, 1077-1079, 2009
11. 80 歳以上の超高齢者浸潤性膀胱癌に対する外科治療, 武中 篤, 酒井伊織, 寺川智章, 古川順也, 村蒔基次, 三宅秀明, 田中一志, 藤澤正人, 山中和樹, 井上隆朗, 西日本泌尿器科, 72 巻, 376-383, 2010
12. Stage C 前立腺がんに対する陽子線治療成績, 村上昌雄, 出水祐介, 丹羽康江, 寺島千貴, 有村 健, 美馬正幸, 三宅秀明, 藤澤正人, 菱川良夫, 泌尿器外科, 23 巻, 1075-1077, 2010
13. 小切開前立腺全摘除術の習得効率に関する検討, 石村武志, 中野雄造, 竹田 雅, 三宅秀明, 田中一志, 武中 篤, 藤澤正人, 日本ミニマム創泌尿器内視鏡外科学会雑誌, 2 巻, 125-129, 2010
14. 腹腔鏡下小切開前立腺全摘除術および腹腔鏡下前立腺全摘除術施行症例における QOL の比較, 村蒔基次, 寺川智章, 酒井伊織, 古川順也, 原田健一, 楠田雄司, 田中一志, 三宅秀明, 藤澤正人, 日本ミニマム創泌尿器内視鏡外科学会雑誌, 3 巻, 47-53, 2011

15. 小切開ドナー腎採取術, 田中一志, 石村武志, 竹田雅, 三宅秀明, 藤澤正人, 泌尿器外科, 24 巻, 1461-1465, 2011
16. 小児腎移植におけるバルガンシクロビルの使用経験, 竹田雅, 石村武志, 三宅秀明, 田中一志, 藤澤正人, 石森真吾, 橋村裕也, 貝藤裕史, 飯島一誠, 日本小児腎不全学会雑誌, 31 巻, 197-199, 2011
17. アシスタント用 3D モニターシステムを用いたロボット支援腹腔鏡下前立腺全摘除術, 田中一志, 山口耕平, 古川順也, 村蒔基次, 石村武志, 原口貴裕, 中野雄造, 三宅秀明, 藤澤正人, 内分泌外科, 28 巻, 212-217, 2011
18. シスプラチン分割投与に対するアプレピタントの効果に関する検討, 刈谷美里, 田中健太, 松本久美子, 久米学, 榎本博雄, 平野剛, 三宅秀明, 藤澤正人, 平井みどり, 癌と化学療法, 39 巻, 245-250, 2012
19. 当施設における内視鏡補助下小切開ドナー腎採取術, 竹田雅, 田中一志, 石村武志, 三宅秀明, 藤澤正人, 日本ミニマム創泌尿器内視鏡外科学会雑誌, 4 巻, 83-87, 2012
20. 転移性腎細胞癌に対するチロシンキナーゼ阻害剤の予後規定因子, 三宅秀明, 楠田勇司, 藤澤正人, 泌尿器外科, 26 巻, 17-19, 2013
21. 根治的腎摘除術を施行した静脈内腫瘍塞栓を伴う腎細胞癌症例の予後規定因子としての腫瘍塞栓進展レベルの意義, 三宅秀明, 寺川智章, 古川順也, 村蒔基次, 藤澤正人, 泌尿器外科, 26 巻, 73-74, 2013
22. 体重 15kg 前後の小児に対する腎移植術式に関する検討, 石村武志, 小川悟史, 貝藤裕史, 村蒔基次, 竹田雅, 三宅秀明, 田中一志, 西慎一, 飯島一誠, 藤澤正人, 日本小児腎不全学会雑誌, 33 巻, 241-243, 2013
23. 3 次元再構成画像システムを応用したロボット支援腎部分切除術 選択的動脈遮断における術中ナビゲーションの有用性, 古川順也, 三宅秀明, 田中一志, 藤澤正人, Urology Today, 21 巻, 149-153, 2014
24. 分子標的治療薬の皮膚障害における副作用マーカーのゲノム薬理学的解析, 山本和宏, 三宅秀明, 藤澤正人, 尾藤利憲, 錦織千佳子, 平野剛, 平井みどり, 医療の広場, 55 巻, 27-29, 2015
25. 浜松医大泌尿器科における 2nd TUR の治療成績, 松下雄登, 古瀬洋, 田村啓多, 本山大輔, 杉山貴之, 大塚篤史, 三宅秀明, 大園誠一郎, 泌尿器外科, 30 巻 (別冊), 436, 2017
26. 当科における High risk NMIBC 患者の臨床的検討, 松下雄登, 佐藤亮, 杉山桃子, 秋亮太, 田村啓多, 本山大輔, 伊藤寿樹, 杉山貴之, 大塚篤史, 三宅秀明, 泌尿器外科, 31 巻, 423-424, 2018
27. 検診施設における電撃がんの経験および 6 年間の前立腺がん検診の検討, 野畑俊介, 森厚嘉, 寺田央巳, 三宅秀明, 大園誠一郎, 日本腎泌尿器疾患予防医学研究会誌, 26 巻, 60-63, 2018
28. 喫煙行動に関する Genotype が BCG 注入療法の効果に及ぼす影響の検討, 松下雄登, 本山大輔, 伊藤寿樹, 杉山貴之, 大塚篤史, 三宅秀明, 梶村春彦, 泌尿器外科, 32 巻, 379-380, 2019
29. 人間ドック受診者における泌尿器がん (腎がん・膀胱がん・前立腺がん) 罹患率およびリス

ク因子に関する検討, 野畑俊介, 木内正太郎, 渡辺めぐみ, 森厚嘉, 武藤繁貴, 三宅秀明, 日本泌尿器科学会雑誌, 111 巻, 114-119, 2020

30. 人間ドック腹部超音波検査における泌尿器癌の成績及び多臓器癌との検討, 野畑俊介, 岩山高志, 山田薫, 木内正太郎, 渡辺めぐみ, 森厚嘉, 廣瀬和美, 齋藤晴義, 三宅秀明, 日本腎泌尿器疾患予防医学研究会誌, 30 巻, 43-45, 2022
-

# 業 績 目 録

## 3. 論文 (総説)

No. 1

(英文)

1. \*Gleave ME, Miyake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. *Urology*. 1999; 54(Supplement): 36-46
2. \*Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. *Urology*. 2001; 58(Supplement): 39-48
3. \*Miyake H, Hara I, Kamidono S, Gleave ME. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. *Int J Urol*. 2001; 8: 337-49
4. \*Zellweger T, Miyake H, Chi K, July L, Kiyama S, Gleave M. Targeting cell survival genes using antisense oligonucleotides to improve chemo- and hormonal-therapies in prostate cancer. *Eur Urol*. 2002; 1(Supplement): 7-14
5. \*Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: Current status in prostate cancer and other malignancies. *Cancer Metastasis Rev*. 2002; 21: 79-92
6. \*Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. *Invest New Drugs*. 2002; 20: 145-58
7. \*Duggan BJ, Gray S, Johnston SR, Williamson K, Miyake H, Gleave M. The role of antisense oligonucleotides in the treatment of bladder cancer. *Urol Res*. 2002; 30: 137-47
8. \*Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. *Cancer Chemother Pharmacol*. 2005; 56(Supplement 7): 47-57
9. \*Miyake H, Hara I, Fujisawa M, Gleave ME. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advance and future prospects. *Exp Rev Anticancer Ther*. 2005; 5: 1001-9
10. \*Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. *Int J Urol*. 2005; 12: 785-94
11. \*Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. *World J Urol*. 2005; 23: 1-9
12. \*Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligonucleotide therapy for prostate cancer. *Exp Opin Investig Drugs*. 2006;

15: 507-17

13. Nomi M, Miyake H, Sugita Y, Fujisawa M, \*Soker S. Role of growth factors and endothelial cells in therapeutic angiogenesis and tissue engineering. *Curr Stem Cell Res Ther.* 2006; 1: 395-410
14. \*Miyake H, Hara I, Fujisawa M, Gleave ME. Antisense oligodeoxynucleotide therapy for prostate cancer targeting antiapoptotic genes involved in the mechanism mediating progression to androgen independence. *Curr Signal Transduction Ther.* 2006; 1: 219-26
15. \*Hara I, Miyake H, Yamada Y, Takenaka A, Fujisawa M. High-dose chemotherapy for male germ cell tumor. *Int J Urol.* 2006; 13: 1037-44
16. \*Miyake H, Fujisawa M. Promise of antisense oligodeoxynucleotide-based therapy for bladder cancer. *Exp Rev Anticancer Ther.* 2008; 8: 1851-4
17. Fujisawa M, \*Miyake H. Significance of micrometastases in prostate cancer. *Surg Oncol.* 2008; 17: 247-52
18. \*Miyake H, Fujisawa M. Sigmoid neobladder as an ideal form of orthotopic urinary reconstruction. *Int J Urol.* 2012; 19: 184-6
19. \*Miyake H, Fujisawa M. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. *Int J Urol.* 2013; 20: 301-11
20. \*Miyake H. Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe? *Ann Transl Med.* 2019; 7: S347
21. \*Harada KI, Miyake H, Furukawa J, Fujimoto N, Fujisawa M. Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma. *Int J Urol.* 2022; 29: 816-22

(和文)

1. 尿路上皮癌患者における尿中 CD44 の発現, 原勲, 三宅秀明, 郷司和男, 荒川創一, 守殿貞夫, *泌尿器科紀要*, 45 巻, 589-592, 1999
2. 臨床医学の展望 2003 診断及び治療上の進歩 尿路上皮癌, 三宅秀明, *日本医事新報*, 4111 巻, 37-44, 2003
3. 前立腺癌に対する clusterin を標的にしたアンチセンスオリゴ療法, 三宅秀明, 村蒔基次, 山中和樹, 原勲, 藤澤正人, Marti E. Gleave, *西日本泌尿器科*, 68 巻, 239-243, 2006
4. 尿路上皮癌診断における CD44 分子の意義, 原勲, 三宅秀明, 武中篤, 藤澤正人, *日本腎泌尿器疾患予防医学研究会誌*, 15 巻, 26-29, 2007
5. 前立腺癌 再燃前立腺癌に対するドセタキセル療法 (1) : エストラムスチンとの併用, 山田裕二, 三宅秀明, 武中篤, 藤澤正人, *日本臨床*, 増刊号, 495-498, 2007
6. 前立腺癌 ハイリスク症例に対する長期術前内分泌療法, 三宅秀明, 藤澤正人, *日本臨床*,



増刊号, 472-476, 2007

7. 前立腺癌 抗アポトーシス遺伝子を標的としたアンチセンスオリゴ療法, 村蒔基次, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 158-162, 2007
8. 前立腺癌 抗アポトーシス遺伝子の発現亢進, 山中和樹, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 95-98, 2007
9. 前立腺癌に対するアンチセンス clusterin 療法, 三宅秀明, 藤澤正人, 臨床泌尿器科, 62 巻, 867-871, 2008
10. 拡大リンパ節郭清術の適応と問題点, 三宅秀明, 藤澤正人, Urology View, 6 巻, 76-81, 2008
11. 膀胱全摘除術後の上部尿路再発, 三宅秀明, 藤澤正人, Urology View, 6 巻, 77-81, 2008
12. oligo DNA, siRNA による治療の展望, 三宅秀明, 藤澤正人, Urology View, 6 巻, 98-104, 2008
13. 大容量 I-131 MIBG による悪性褐色細胞腫治療の試み, 萱野大樹, 稲木杏吏, 中村文音, 若林大志, 米山達也, 絹谷清剛, 三宅秀明, 坂口一彦, 日本内分泌学会雑誌, 85 巻 (Supplement), 149-151, 2009
14. 女性の新膀胱, 三宅秀明, 藤澤正人, 泌尿器外科, 22 巻, 23-29, 2009
15. S 状結腸利用新膀胱, 三宅秀明, 藤澤正人, 排尿障害プラクティス, 17 巻, 218-224, 2009
16. 腎細胞がんの治療をめぐって 2. 見落としのない検査のために—腎細胞がんを念頭においた読影 1) US, 三宅秀明, 藤澤正人, 臨床腫瘍プラクティス, 6 巻, 19-23, 2010
17. 分子標的薬治療 泌尿器癌 (腎細胞癌を中心に), 三宅秀明, 藤澤正人, 日本臨床, 68 巻, 1871-1875, 2010
18. 小径腎腫瘍に対する手術療法: 全摘と部分切除の比較を中心に, 三宅秀明, 藤澤正人, Urology View, 8 巻, 41-44, 2010
19. 外来化学療法の実際, 三宅秀明, 藤澤正人, Urology View, 8 巻, 46-51, 2010
20. 膀胱癌の手術 尿路変向術 新膀胱造設術を中心に, 三宅秀明, 泌尿器外科, 23 巻, 1774-1775, 2010
21. 腎・泌尿器癌 精巣癌 大量化学療法, 村蒔基次, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 523-526, 2010
22. 腎・泌尿器癌 膀胱癌 S 状結腸利用新膀胱, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 314-318, 2010
23. 腎・泌尿器癌 膀胱癌 膀胱全摘除術(女性), 藤澤正人, 三宅秀明, 日本臨床, 増刊号, 277-281, 2010
24. 去勢抵抗性前立腺癌に対する docetaxel 療法の意義, 三宅秀明, 寺川智章, 酒井伊織, 原田健一, 藤澤正人, 泌尿器外科, 24 巻, 1299-1301, 2011

25. 難治性精巣癌の化学療法：最適な救済化学療法を求めて，三宅秀明，藤澤正人，泌尿器紀要，57 巻，167-171，2011
26. 泌尿器科領域の結核，三宅秀明，藤澤正人，日本臨床，69 巻，1417-1421，2011
27. 前立腺癌（第 2 版）骨盤内微小リンパ節転移の検出とその意義，三宅秀明，藤澤正人，日本臨床，増刊号，651-655，2011
28. 前立腺癌（第 2 版）PSA 関連パラメーターの有用性，寺川智章，三宅秀明，藤澤正人，日本臨床，増刊号，250-253，2011
29. 前立腺癌（第 2 版）アンチセンスオリゴ療法，村蒔基次，三宅秀明，藤澤正人，日本臨床，増刊号，170-173，2011
30. 前立腺癌（第 2 版）抗アポトーシス遺伝子の発現亢進，古川順也，三宅秀明，藤澤正人，日本臨床，増刊号，117-120，2011
31. 新膀胱造設術の知識とポイント，三宅秀明，泌尿器ケア，17 巻，46-53，2012
32. 分子標的薬の副作用：Temsirrolimus，三宅秀明，藤澤正人，泌尿器科紀要，58 巻，651-654，2012
33. 進行精巣腫瘍に対する大量化学療法，三宅秀明，藤澤正人，泌尿器科紀要，58 巻，731-735，2012
34. 分子標的薬 腎細胞がんのチロシンキナーゼ阻害剤耐性化，三宅秀明，藤澤正人，日本臨床，増刊号，331-335，2012
35. 前立腺癌に対する腹腔鏡下前立腺全摘除術，三宅秀明，藤澤正人，臨床泌尿器科，67 巻，401-406，2013
36. ロボット支援手術による腎温存手術，古川順也，村蒔基次，三宅秀明，田中一志，藤澤正人，泌尿器外科，26 巻，1779-1784，2013
37. 前立腺癌と肥大症，三宅秀明，兵庫県医師会医学雑誌，56 巻，1-3，2013
38. 腎細胞癌のチロシンキナーゼ阻害剤に対する耐性獲得機序の解明とその克服を目指した新規治療の開発，三宅秀明，神緑会学術誌，29 巻，59-61，2013
39. 去勢抵抗性前立腺癌に対するアンチセンスオリゴ療法，三宅秀明，藤澤正人，日本臨床，72 巻，2121-2125，2014
40. 下部尿路再建術，三宅秀明，藤澤正人，泌尿器外科，28 巻，397-402，2015
41. 高齢者の泌尿器癌 膀胱癌，古川順也，三宅秀明，藤澤正人，腎と透析，78 巻，916-920，2015
42. 泌尿器領域の骨盤内感染症，上野嘉子，田中宇多留，高橋哲，三宅秀明，杉村 和朗，画像診断，36 巻，51-58，2015
43. 抗がん剤の副作用と支持療法 LH-RH 誘導体，三宅秀明，藤澤正人日本臨床，増刊号，313-316，

2015

44. 家族性腫瘍学 VHL, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 389-393, 2015
45. 前立腺癌に対する分子標的治療, 三宅秀明, 藤澤正人, 日本臨床, 74 巻, 2-5, 2016
46. ロボット支援前立腺全摘除術の現況と展望, 三宅秀明, 藤澤正人, 日本臨床, 74 巻, 98-102, 2016
47. 前立腺がんの手術ってどんな手術?, 三宅秀明, 藤澤正人, 泌尿器 Care & Cure Uro-L0, 21 巻, 57-62, 2016
48. 前立腺癌に対する治療標的としてのクラスタリンの同定とその臨床応用, 三宅秀明, 藤澤正人, Prostate Journal, 3 巻, 47-51, 2016
49. 腎がんの薬物療法 (分子標的療法), 三宅秀明, 大園誠一郎, 医学のあゆみ, 257 巻, 925-930, 2016
50. 腎盂尿管癌に対する腎尿管全摘除術-開放および鏡視下手術の比較, 三宅秀明, 大園誠一郎, 泌尿器外科, 29 巻, 455-460, 2016
51. CRPC に対する新規薬剤および治療体系開発の現況, 三宅秀明, 大園誠一郎, 泌尿器外科, 29 巻, 1351-1353, 2016
52. 新前立腺癌学 カバジタキセル, 原田健一, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 640-643, 2016
53. 新前立腺癌学 ロボット支援前立腺全摘除術, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 445-449, 2016
54. 新前立腺癌学 アンチセンスオリゴ療法, 村蒔基次, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 234-237, 2016
55. 新前立腺癌学 抗アポトーシス遺伝子の発現亢進, 古川順也, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 111-115, 2016
56. 新前立腺癌学 リガンド非依存性アンドロゲン受容体活性化, 寺川智章, 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 106-110, 2016
57. 去勢抵抗性前立腺癌に対する薬物療法の現況と展望, 三宅秀明, 大園誠一郎, 映像情報 Medical, 49 巻, 54-55, 2017
58. 禁制尿路変向術: 自己導尿型代用膀胱, 三宅秀明, 大園誠一郎, 泌尿器 Care & Cure Uro-L0, 22 巻, 38-40, 2017
59. 禁制尿路変向術: 自排尿型新膀胱, 三宅秀明, 大園誠一郎, 泌尿器 Care & Cure Uro-L0, 22 巻, 34-37, 2017
60. 腎細胞癌に対する薬物療法, 三宅秀明, 大園誠一郎, 日本臨床, 75 巻, 602-606, 2017
61. 前立腺癌診療ガイドライン 第 1~6 章 疫学と診断, 三宅秀明, 泌尿器外科, 30 巻, 1365-1370,

2017

62. 腎癌診療ガイドライン 総論, 大園誠一郎, 杉山貴之, 三宅秀明, 泌尿器外科, 30 巻, 1383-1386, 2017
63. 低活動膀胱, 大塚篤史, 鈴木孝尚, 三宅秀明, Modern Physician, 37 巻, 1267-1269, 2017
64. 新腎・泌尿器癌 上 診療ガイドラインの特徴: 欧米のガイドラインとの比較, 杉山貴之, 三宅秀明, 大園誠一郎, 日本臨床, 増刊号, 163-166, 2017
65. 新腎・泌尿器癌 上 下大静脈腫瘍塞栓に対する手術療法, 三宅秀明, 大園誠一郎, 藤澤正人 日本臨床, 増刊号, 247-251, 2017
66. 新腎・泌尿器癌 上 アキシチニブ, 三宅秀明, 大園誠一郎, 日本臨床, 増刊号, 320-324, 2017
67. 新腎・泌尿器癌 下 新膀胱 (Reddy 法), 三宅秀明, 藤澤正人, 日本臨床, 増刊号, 239-243, 2017
68. 新腎・泌尿器癌 下, 2nd-TUR, 古瀬洋, 松下雄登, 三宅秀明, 日本臨床, 増刊号, 185-189, 2017
69. 腎細胞癌の分子標的薬に対する耐性獲得—メカニズムの解明と克服に向けた取り組み, 原田健一, 三宅秀明, 藤澤正人, 臨床泌尿器科, 72 巻, 70-75, 2018
70. 本邦における腎癌薬物療法の動向—診療ガイドラインの改訂作業からみえてくる重要ポイント, 杉山貴之, 三宅秀明, 臨床泌尿器科, 72 巻, 12-16, 2018
71. 下大静脈腫瘍塞栓を伴う腎癌に対する手術: 塞栓レベル別の体系的アプローチ, 三宅秀明, 泌尿器外科, 31 巻, 361-366, 2018
72. 尿閉, 大塚篤史, 三宅秀明, 臨床泌尿器科, 72 巻, 234-238, 2018
73. 見逃してはならない泌尿器科疾患の初期症状 泌尿器がん・腫瘍 精巣がん, 杉山貴之, 三宅秀明, Uro-Lo: 泌尿器 Care & Cure, 23 巻, 283-286, 2018
74. 血管 IVR 四肢, その他 持続性陰茎勃起症, 神谷実佳, 牛尾貴輔, 甲斐文丈, 三宅秀明, 阪原晴海, 臨床放射線, 63 巻, 1510-1513, 2018
75. 後腹膜浸潤による痛み・苦痛の緩和, 三宅秀明, がん患者と対症療法, 27 巻, 30-35, 2018
76. ロボット支援下腎部分切除術における手術ナビゲーションシステムの有用性, 三宅秀明, 本山大輔, 医学のあゆみ, 267 巻, 40-45, 2018
77. 腎癌診療ガイドライン 2017 年版: 改訂のポイント, 三宅秀明, 杉山貴之, 大園誠一郎, Urology Today, 25 巻, 90-94, 2018
78. ロボット支援腎部分切除術のアウトカム, 三宅秀明, 本山大輔, 泌尿器外科, 31 巻, 1415-1421, 2018
79. 転移性腎細胞癌に対して腫瘍減量腎摘除術を推奨する, 三宅秀明, 泌尿器外科, 32 巻, 161-167,

2019

80. ロボット支援前立腺全摘除術における術前マルチパラメトリック MRI の意義, 三宅秀明, 臨床画像, 35 巻, 568-576, 2019
  81. 本邦における腎細胞癌の疫学的動向に変化はあるのか, 三宅秀明, 癌と化学療法, 46 巻, 36-39, 2019
  82. 既存のガイドラインを透析患者にどう活用するのか 腎癌, 三宅秀明, 臨床透析, 35 巻, 1031-1035, 2019
  83. BPH・B00 の診断および治療効果予測因子, 鈴木孝尚, 大塚篤史, 三宅秀明, Urology Today, 26 巻, 183-186, 2019
  84. 膀胱がんの全摘除術②新膀胱造設術, 三宅秀明, 泌尿器 Care & Cure Uro-Lo, 25 巻, 92-99, 2020
  85. 下大静脈腫瘍塞栓を伴う腎がんに対する外科治療の現状と展望, 三宅秀明, 泌尿器科, 11 巻, 274-281, 2020
  86. mCRPC に対する逐次治療におけるタキサン系抗がん薬の役割, 三宅秀明, 日本臨床, 78 巻, 1012-1018, 2020
  87. アキシチニブ・アベルマブ併用, 三宅秀明, Pharma Media, 38 巻, 45-48, 2020
  88. 前立腺肥大症: 薬物治療, 大塚篤史, 三宅秀明, 臨床泌尿器科, 74 巻, 184-187, 2020
  89. PD-L1 阻害薬+VEGFR-TKI, 三宅秀明, 臨床泌尿器科, 75 巻, 116-120, 2021
  90. 完全埋没型腫瘍に対する RAPN の有用性, 三宅秀明, 本山大輔, 泌尿器科, 13 巻, 239-244, 2021
  91. 腎癌の手術療法 (開放手術を中心に), 三宅秀明, 日本臨床, 79 巻, 684-689, 2021
  92. 急性尿閉, 大塚篤史, 三宅秀明, 臨床泌尿器科, 75 巻, 67-70, 2021
  93. 下部尿路機能障害 前立腺肥大症 薬物治療, 大塚篤史, 三宅秀明, 臨床泌尿器科, 74 巻, 184-187, 2021
  94. 転移性腎盂・尿管がんの化学療法と unmet need, 三宅秀明, 泌尿器科, 14 巻, 556-561, 2021
  95. 前立腺肥大症(BPH)薬物治療のニューノーマル"とりあえず"ではなくベストな処方を目指して 併用療法 新たな併用療法, 大塚篤史, 三宅秀明, 臨床泌尿器科, 75 巻, 510-513, 2021
  96. 高齢者の腎細胞癌に対する手術療法, 本山大輔, 三宅秀明, 日本臨床, 80 巻, 990-995, 2022
  97. ロボット支援根治的腎摘除術, 三宅秀明, 泌尿器外科, 35 巻, 960-967, 2022
-

# 業 績 目 録

## 4. 論文 (その他)

No. 1

(英文)

1. \*Hara I, Hara S, Miyake H, Kawabata G, Okada H, Kamidono S. Carcinoma in situ spread to mucosa of sigmoid colon neobladder. *Urology*. 2003; 62: 145
2. \*Hara I, Hikosaka S, Eto H, Miyake H, Yamada Y, Soejima T, Sugimura K, Kamidono S. Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. *Int J Urol*. 2004; 11: 678-82
3. \*Hashimoto N, Kawamura Y, Nakamura T, Murawaki A, Nishiumi T, Hirota Y, Sakagushi K, Kurahashi T, Miyake H, Fujisawa M, Sasano H, Takahashi Y. A case of primary aldosteronism caused by multiple adrenocortical macronodules. *Intern Med*. 2011; 50: 585-90
4. \*Miyake H, Haraguchi T, Takenaka A, Fujisawa M. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. *Int J Clin Oncol*. 2011; 16: 153-5
5. Harada K, \*Miyake H, Kurahashi T, Fujisawa M. Long-term complete response to very low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases. *Clin Exp Nephrol*. 2011; 15: 966-9
6. \*Hayakawa A, Shimotake N, Kubokawa I, Mitsuda Y, Mori T, Yanai T, Muramaki M, Miyake H, Fujisawa M, Iijima K. Primary pediatric stage III renal diffuse large B-cell lymphoma. *Am J Case Rep*. 2013; 14: 34-7
7. Nishikawa M, \*Miyake H, Fujisawa M. Concurrent occurrence of three renal cell carcinomas with different histological subtype in the same kidney. *Int J Urol*. 2014; 21: 222-3
8. \*Terakawa T, Miyake H, Tanaka H, Inoue T, Fujisawa M. Feasibility of a retroperitoneal approach as a surgical strategy for patients with situs inversus totalis: presentation of a case undergoing laparoscopic radical nephrectomy for renal cell carcinoma. *Int Cancer Conference J*. 2014; 92: 1800-5
9. \*Miyake H, Fujisawa M. Editorial comment to Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy. *Int J Urol*. 2014; 21: 270
10. \*Matsushita K, Yamaguchi K, Li F, Okada K, Ando M, Chiba K, Koshida M, Miyake H, Fujisawa M. Achieved pregnancy with the delivery of a healthy child by TESE-ICSI 7 years after bilateral adult orchidopexy: a case report. *Andrologia*. 2014; 46: 948-50
11. \*Miyake H, Fujisawa M. Editorial comment to Venous tumor thrombus consistency is not predictive of survival in patients with renal cell carcinoma: a retrospective study on 147 patients. *Int J Urol*. 2015; 22: 540
12. \*Miyake H, Fujisawa M. Editorial comment to Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors. *Int J Urol*. 2015; 22: 293

13. \*Matsushita Y, Miyake H, Motoyama D, Sugiyama T, Nagata M, Otsuka A, Furuse H, Ozono S. Contralateral pneumothorax during retroperitoneal laparoscopic donor nephrectomy: A case report. Asian J Endosc Surg. 2017; 10: 432-7
14. \*Miyake H, Harada K, Fujisawa M. Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases. Int Cancer Confer J. 2018; 7: 30-4
15. Matsushita Y, Nakamura K, Furuse H, Ichinohe K, \*Miyake H. Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases. Int Cancer Conf J. 2018; 8: 29-32
16. \*Wakabayashi K, Konishi K, Komatsu T, Ishiba R, Ota N, Ito T, Aki R, Tsuchida T, Miyake H, Nakamura K. Radiation-induced sarcoma after radiation therapy for prostate adenocarcinoma. IJU Case Rep. 2019; 2: 98-101
17. Watanabe K, Sugiyama T, Otsuka A, \*Miyake H. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. Int Cancer Conf J. 2019; 9: 32-5
18. \*Matsushita Y, Motoyama D, Ito T, Sugiyama T, Otsuka A, Sano M, Inuzuka K, Miyake H. Kidney transplantation from a living donor with renal artery fibromuscular dysplasia: a case report on arterial grafting of the donor renal artery. IJU Case Rep. 2020; 3: 201-3
19. \*Miyake H, Motoyama D, Matsushita Y, Watanabe H, Ito T, Sugiyama T, Otsuka A. Robot-assisted partial nephrectomy for patients with multifocal renal tumors arising in a solitary kidney: report of three cases. J Endourol Case Rep. 2020; 6: 370-3
20. Ishikawa G, Sugiyama T, Ito T, Otsuka A, \*Miyake H. Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma. Int Cancer Conf J. 2021; 10: 116-8
21. \*Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Robot-assisted radical nephrectomy and inferior vena cava tumor thrombectomy: Initial experience in Japan. IJU Case Rep 2022; 5: 145-8
22. \*Miyake H. New year's greetings. Int J Urol. 2022; 29: 5
23. Yamaguchi T, Sugiyama Y, Tanaka T, Kimura T, Yumura Y, Nakano M, Sugiyama T, Miura N, Goya M, Yamamoto A, Takahashi S, Miura Y, Tsuzuki T, Masumori N, Nishiyama H, Yao M, Koie T, Miyake H, Saika T, Saito S, Akimoto T, Tamada T, Ando Y, Takahashi S, Suzuki T, Hinotsu S, \*Kamba T. Summary of clinical practice guidelines for penile cancer 2021 by the Japanese Urological Association. Int J Urol. 2022; 29: 780-92
24. \*Miyake H. New year's greetings. Int J Urol. 2023; 30: 5

(和文)

1. 医師の立場から退院指導の補足説明（腎摘除術を受けた患者の退院指導），三宅秀明，藤澤正人，泌尿器ケア，12巻，41，2007

2. 進行性腎細胞癌 治療の転換期, 原勲, 木下秀文, 瀬川直樹, 野澤昌弘, 三宅秀明, Pharma Medica, 26 巻, 74-83, 2008
3. ナースのための前立腺癌の基礎知識, 三宅秀明, 藤澤正人, 泌尿器ケア, 13 巻, 15-20, 2008
4. 腎癌治療におけるスニチニブのベネフィットを最大化するために 臨床経験から考える最適な治療法とは, 笈善行, 江藤正俊, 三宅秀明, 矢尾正祐, 泌尿器外科, 22 巻, 1181-1191, 2009
5. 家族性巣状分節状糸体硬化症の 3 兄弟に対する生体腎移植の経験, 石村武志, 竹田 雅, 中野雄造, 三宅秀明, 田中一志, 藤澤正人, 腎移植・血管外科, 22 巻, 50-54, 2010
6. 当院にて 2007 年以降に経験した小児献腎移植の 4 例, 兵頭洋二, 石村武志, 竹田雅, 貝藤裕史, 神田杏子, 野津寛大, 三宅秀明, 田中一志, 武中 篤, 飯島一誠, 藤澤正人, 日本小児腎不全学会雑誌, 29 巻, 198-200, 2009
7. 転移性腎細胞癌に対する Neo-adjuvant 療法は有効か?, 植村天受, Wood C, 大家基嗣, 近藤恒徳, 篠原信雄, 野々村祝夫, 藤井靖久, 本郷文弥, 三宅秀明, 泌尿器外科, 24 巻, 1975-1983, 2011
8. 去勢抵抗性前立腺癌 (CRPC) 治療の現状と今後 ドセタキセル含有化学療法のあり方を中心に, 植村天受, 松山豪泰, 井手久満, 三宅秀明, 西村和郎, 久米春喜, 外来癌化学療法, 3 巻, 209-220, 2012
9. 嫌気性菌が関与したフルニエ壊疽 (Fournier's gangrene) の 1 症例, 荒川創一, 田中一志, 重村克巳, 三宅秀明, 藤澤正人, 日本外科感染症学会雑誌, 9 巻, 697-700, 2012
10. 敗血症, 感染性心内膜炎, 化膿性脊椎炎を合併した前立腺膿瘍の 1 例, 松本穰, 重村克巳, 山道深, 中野雄造, 三宅秀明, 田中一志, 荒川創一, 藤澤正人, 泌尿器科紀要, 58 巻, 565-568, 2012
11. GnRH アンタゴニストゴナックスを臨床で活かす, 堀江重郎, 鈴木和浩, 原勲, 三宅秀明, Prostate Journal, 1 巻, 73-82, 2014
12. 多臓器転移に対しパゾパニブを含む集学的治療を施行した前立腺原発滑膜肉腫の 1 例, 三宅秀明, 原田健一, 藤澤正人, Soft Tissue Sarcoma Journal, 6 巻, 9-10, 2014
13. 前立腺腫瘍のクリニカル・パール, 三宅秀明, 藤澤正人, 臨床泌尿器科, 68 巻, 850-855, 2014
14. 細菌性精巣上体炎に Epstein-Barr virus 感染を併発し免疫抑制剤減量で自然軽快した腎移植症例, 石村武志, 横山 直己, 小田 晃廉, 小川悟史, 日向 信之, 村蒔基次, 三宅秀明, 田中一志, 西慎一, 飯島一誠, 藤澤正人, 日本小児腎不全学会雑誌, 35 巻, 220-223, 2015
15. Meeting Report 第 53 回日本癌治療学会学術集会レポート, 三宅秀明, 藤澤正人, 泌尿器 Care & Cure Uro-L0, 21 巻, 138-139, 2016
16. 脊髄クモ膜嚢腫による下部尿路機能障害を認めた 1 例, 鈴木孝尚, 大塚篤史, 古瀬洋, 三宅秀明, 大園誠一郎, 泌尿器外科, 29 巻, 563-565, 2016
17. ゲフィチニブによるアレルギー性膀胱炎の 1 例, 鈴木孝尚, 大塚篤史, 古瀬洋, 三宅秀明,



大園誠一郎, 泌尿器外科, 29 巻, 1029-1032, 2016

18. 腎移植後ウイルス性食道炎の 2 例, 石村武志, 横山 直己, 小田 晃廉, 小川悟史, 日向 信之, 村蒔基次, 三宅秀明, 田中一志, 藤澤正人, 腎移植・血管外科, 26 巻, 102-106, 2016
  19. 座長の言葉, 三宅秀明, 泌尿器外科, 30 巻 (別冊), 452-453, 2017
  20. 去勢抵抗性前立腺癌 (CRPC) の逐次治療を再考する, 鈴木和浩, 鈴木啓悦, 小坂威雄, 土谷順彦, 三宅秀明, Prostate Journal, 4 巻, 209-217, 2017
  21. 腎癌に対する薬物療法—最新エビデンスを実臨床に活かす 企画にあたって, 三宅秀明, 臨床泌尿器科, 72 巻, 11, 2018
  22. ロボット支援腎部分切除術:さらなる進歩に向けた取り組み, 三宅秀明, 泌尿器外科, 31 巻, 1375, 2018
  23. IJU および和文誌の方向性, 矢尾正祐, 溝上敦, 三宅秀明, 伊藤一人, 河原崇司, 日本泌尿器科学会雑誌, 109 巻, S81-S85, 2018
  24. ガンシクロビル耐性サイトメガロウイルス血症を発症した脳死下腎移植レシピエントに対する治療経験, 伊藤寿樹, 松下雄登, 渡邊弘允, 田村啓多, 本山大輔, 杉山貴之, 大塚篤史, 三宅秀明, 日本臨床腎移植学会誌, 7 巻, 192-196, 2019
  25. ロボット支援下腎部分切除術における右腎動脈確保困難症例に対するトラブルシューティング—大動静脈間での右腎動脈クランプ—, 本山大輔, 三宅秀明, 泌尿器外科, 34 巻, 159-162, 2021
  26. イマチニブ治療中に乏精子症を呈した消化管間質腫瘍の 1 例, 杉山貴之, 寺田央巳, 三宅秀明, 泌尿器科外科, 34 巻, 885-888, 2021
  27. プロからプロへ CRPC の薬物治療について最近のトピックスを教えてください, 三宅秀明, 藤澤正人, 日本医事新報, 5083 巻, 48, 2021
  28. プロからプロへ 進行尿路上皮癌に対する一次化学療法後の維持療法とは?, 江藤正俊, 三宅秀明, 日本医事新報, 5086 巻, 51, 2021
  29. 化学療法導入の機会を逃さないための mCRPC 治療戦略とは, 鈴木和浩, 田中宣道, 三宅秀明, Prostate Journal, 8 巻, 113-118, 2021
  30. 腎移植後体外受精にて挙児を得た 1 例, 杉山貴之, 寺田央巳, 三宅秀明, 泌尿器科外科, 34 巻, 1005-1008, 2021
  31. 高齢者の泌尿器疾患 update 巻頭言:企画にあたって, 三宅秀明, 日本臨床, 80 巻, 908-909, 2022
  32. IJU の方向性, 三宅秀明, 篠原信雄, 古川順也, 河原崇司, 岡田淳志, 高木敏男, 日本泌尿器科学会雑誌, 113 巻, S146-S149, 2022
  33. 査読委員の確保と教育, 三宅秀明, 井上貴博, 白石晃司, 白石晃司, 田中一, 堀田記世彦, 日本泌尿器科学会雑誌, 113 巻, S150-S156, 2022
-

# 業 績 目 録

## 5. 学会発表(国内学会)

No. 1

(番号, 演題名, 発表者(共同発表者を含む), 学会名, 発行年の順に記入してください。)

### 特別講演

1. 泌尿器科腫瘍学とともに25年～私の歩んだ道とこれから, 三宅秀明, 第276回日本泌尿器科学会東海地方会総会, 2017
2. 本邦におけるCRPCに対する治療の現状と展望, 三宅秀明, 第60回千葉県泌尿器科医会学術集会, 2017
3. 進行前立腺癌に対する至適治療戦略確立に向けた取り組み, 三宅秀明, 平成31年度福岡県泌尿器科医会講演会, 2019
4. 腎癌診療に対する我々の取り組み, 三宅秀明, 第30回高槻市医師会泌尿器科専門部会講演会, 2019
5. 進行前立腺癌治療に関する最近の話題, 三宅秀明, 第106回日本泌尿器科学会四国地方会, 2020
6. mCSPCに対する至適治療戦略とは?, 三宅秀明, 第37回滋賀県泌尿器科集談会, 2020
7. 前立腺癌診療に関する最近の話題, 三宅秀明, 第80回大阪泌尿器科臨床医会学術集会, 2022

### 教育講演

1. 去勢抵抗性前立腺癌に対する新規治療, 三宅秀明, 第31回日本アンドロロジー学会総会, 2012
2. 進行前立腺癌に対する薬物療法の現況と展望, 三宅秀明, 第109回日本泌尿器科学会総会, 2021

### シンポジウム

1. 腎癌の新しい分類とバックグラウンド 腎癌におけるClusterin高発現の臨床病理学的意義, 三宅秀明, 原勲, 原章二, 和田義孝, 後藤章暢, 荒川創一, 守殿貞夫, 第21回腎癌研究会, 2001
2. 細胞増殖の制御: アポトーシスを中心として 前立腺癌とアポトーシス: プレクリニカルモデルでの解析からアンチセンスオリゴ療法の開発へ, 三宅秀明, 第21回日本アンドロロジー学会総会, 2002
3. 泌尿器科腫瘍の先端的治療 前立腺癌に対するアンチセンスClusterin療法: 網羅的遺伝子解析による標的遺伝子の同定から臨床試験実施に至るまでの経験, 三宅秀明, 原勲, Martin Gleave, 藤澤正人, 第95回日本泌尿器科学会総会, 2007
4. 進行精巣癌の治療戦略 末梢血幹細胞移植を用いた大量化学療法, 三宅秀明, 武中篤, 藤澤正人, 第57回日本泌尿器科学会中部総会, 2007
5. 尿路変向・尿路再建の治療成績: QOLを含む S状結腸利用新膀胱造設術の臨床成績, 三宅秀明, 藤澤正人, 第58回日本泌尿器科学会中部総会, 2008
6. 泌尿器科癌化学療法: 最新のレジメンの有効性と安全性 難治性精巣癌の化学療法: 最適な救済化学療法を求めて, 三宅秀明, 藤澤正人, 第59回日本泌尿器科学会中部総会, 2009

7. 前立腺癌のホルモン依存性喪失メカニズムと臨床的対応の可能性 前立腺癌の進展におけるIL-6の意義, 三宅秀明, 藤澤正人, 第28回日本アンドロロジー学会総会, 2009
8. がん分子標的薬の耐性化メカニズム: 基礎と臨床 腎細胞癌のチロシンキナーゼ阻害剤に対する耐性獲得機構とその克服の可能性, 三宅秀明, 藤澤正人, 第14回日本がん分子標的治療学会総会, 2010
9. 精巣腫瘍診療ガイドラインを検証する 進行性精巣腫瘍に対する大量化学療法, 三宅秀明, 藤澤正人, 第61回日本泌尿器科学会中部総会, 2011
10. 泌尿器科癌化学療法: 分子標的薬治療の副作用対 Temsirolimus, 三宅秀明, 藤澤正人, 第61回日本泌尿器科学会中部総会, 2011
11. 分子標的薬治療による予後因子 当科における進行腎細胞癌に対するチロシンキナーゼ阻害剤の使用成績, 三宅秀明, 楠田雄司, 藤澤正人, 第43回腎癌研究学会, 2012
12. Search for molecular targets of urological tumors Significance of molecular chaperone on molecular targeting therapy in prostate cancer, Miyake H, Muramaki M, Fujisawa M, 第72回日本癌学会総会, 2013
13. 前立腺全摘除術: 生き残るのはどれか? ロボット手術, 三宅秀明, 藤澤正人, 第27回日本泌尿器内視鏡学会総会, 2013
14. 10年以上経過した尿禁制型代用膀胱患者のアウトカム 腸管利用 neobladder の長期アウトカム: 小腸と結腸の比較 神戸大学での経験, 三宅秀明, 藤澤正人, 第102回日本泌尿器科学会総会, 2014
15. 前立腺全摘術後の排尿機能向上を目指した術前評価プログラムの構築 術前ウロダイナミックスタディの意義, 三宅秀明, 藤澤正人, 第102回日本泌尿器科学会総会, 2014
16. 泌尿器癌に対する根治的外科治療の最前線 ロボット支援腎部分切除術, 三宅秀明, 藤澤正人, 第52回日本癌治療学会総会, 2014
17. 進行腎癌 update Post-TKI としての分子標的治療戦略, 三宅秀明, 藤澤正人, 第64回日本泌尿器科学会中部総会, 2014
18. 前立腺がん治療と性機能 根治的前立腺全摘除術後の性機能と神経温存術式の客観的評価, 三宅秀明, 藤澤正人, 2014
19. 蛍光ナビゲーションを用いた内視鏡手術の現状と展望 泌尿器科領域のロボット支援手術における蛍光ナビゲーション, 三宅秀明, 藤澤正人, 第28回日本内視鏡外科学会総会, 2015
20. 腹腔鏡/ロボット支援手術におけるイメージナビゲーション ロボット支援腎部分切除術における3DCTを用いたイメージナビゲーション, 三宅秀明, 藤澤正人, 第28回日本内視鏡外科学会総会, 2015
21. 腎がん治療個別化の多様なアプローチ 小径腎がんの臨床的取り扱い—手術療法(ロボット支援腎部分切除術を中心に), 三宅秀明, 藤澤正人, 第53回日本癌治療学会総会, 2015
22. 転移性腎細胞癌に対する分子標的薬治療の選択と副作用マネジメント 腎機能障害患者に対する薬剤選択, 三宅秀明, 藤澤正人, 第65回日本泌尿器科学会中部総会, 2015

23. CRPC 治療の現状と今後の方向性 アビラテロン使用の実際と問題点, 三宅秀明, 藤澤正人, 第 65 回日本泌尿器科学会中部総会, 2015
24. 腎癌のバイオマーカー 転移性腎細胞癌に対する sunitinib の効果予測マーカーとしての血清 MMP-9/TIMP-2 ratio の意義, 三宅秀明, 西川昌友, 原田健一, 藤澤正人, 第 46 回腎癌研究学会, 2015
25. ロボットがもたらす手術療法のパラダイムシフト 泌尿器科領域におけるロボット支援手術の現状と将来展望, 三宅秀明, 藤澤正人, 第 29 回日本医学会総会, 2015
26. 進行前立腺癌の薬物療法の現状と展望 去勢抵抗性前立腺癌に対する新規治療開発の現況と展望, 三宅秀明, 大園誠一郎, 第 35 回日本アンドロロジー学会総会, 2016
27. mRCC に対する集学的治療戦略 当科における mRCC に対する集学的治療戦略, 三宅秀明, 藤澤正人, 第 104 回日本泌尿器科学会総会, 2016
28. Urological cancer: Year in review from Japan: renal cell carcinoma, Miyake H, Ozono S, 第 54 回日本癌治療学会総会, 2016
29. 腎癌薬物療法 転移性腎細胞癌に対する二次分子標的療法の早期腫瘍縮小効果が予後に及ぼす影響, 三宅秀明, 原田健一, 杉山貴之, 古瀬洋, 大園誠一郎, 藤澤正人, 第 54 回日本癌治療学会総会, 2016
30. CRPC の治療選択: わたしはこう考える 当科における CRPC に対する逐次治療戦略: その妥当性と問題点, 三宅秀明, 大園誠一郎, 第 105 回日本泌尿器科学会総会, 2017
31. 下大静脈腫瘍塞栓を伴う腎細胞癌の治療戦略 下大静脈腫瘍塞栓を伴う腎細胞癌に対する手術: 塞栓レベル別の体系的アプローチとその成績, 三宅秀明, 大園誠一郎, 藤澤正人, 第 105 回日本泌尿器科学会総会, 2017
32. ロボット手術の基本手技と Pit Fall 泌尿器科ロボット手術における基本と工夫, 三宅秀明, 第 11 回日本ロボット外科学会総会, 2019
33. 腎癌下大静脈塞栓摘除術における血管外科的手技を学ぶ レベルⅢの下大静脈腫瘍塞栓を有する腎癌に対する至適アプローチ, 三宅秀明, 第 35 回腎移植・血管外科研究会総会, 2019
34. 腎細胞癌の最新の話 転移性腎細胞癌に対する逐次薬物治療の考え方, 三宅秀明, 第 6 回日本泌尿器腫瘍学会総会, 2020
35. 複合免疫療法の時代における転移性腎癌の一次治療 転移性腎癌に対するアベルマブおよびアキシチニブ併用療法の現況と展望, 三宅秀明, 第 58 回日本日本癌治療学会総会, 2020
36. 泌尿器癌の転移・再発に対する治療戦略 Current status and future prospect of IO-TKI combined therapy for metastatic renal cell carcinoma, 三宅秀明, 第 59 回日本癌治療学会総会, 2021
37. RCC 治療戦略の新たなオプション 進行腎癌に対する一次治療における IO-TKI 併用療法の意義, 三宅秀明, 第 7 回日本泌尿器腫瘍学会総会, 2021
38. 進行腎癌に対する薬物療法の進歩と展望 進行腎癌に対する薬物療法の変遷, 三宅秀明, 第 72 回日本泌尿器科学会中部総会, 2022

39. 腎癌治療におけるロボット支援手術の可能性 ロボット支援根治的腎摘除術の初期経験～静脈腫瘍塞栓随伴例などの困難症例を中心に～, 三宅秀明, 第 52 回腎癌研究会, 2022
40. 泌尿器科ダビンチ手術の新しい取り組み ロボット支援根治的腎摘除術の初期経験～静脈腫瘍塞栓随伴例などの困難症例を中心に～, 三宅秀明, 第 37 回腎移植・血管外科研究会, 2022
41. 進行性前立腺癌薬物治療 Update mCRPC に対する逐次治療戦略の変遷と最新知見, 三宅秀明, 第 41 回日本アンドロロジー学会総会, 2022
42. Treatment strategy for mCRPC mCRPC に対する逐次治療戦略の変遷と最新知見, 三宅秀明, 第 8 回日本泌尿器腫瘍学会総会, 2022
43. 本音で語る進行性腎癌に対する一次治療選択 ペムブロリツマブおよびレンバチニブ併用療法, 三宅秀明, 第 8 回日本泌尿器腫瘍学会総会, 2022

#### ワークショップ

1. 腎癌の浸潤・転移における Basic fibroblast growth factor (FGF-2) の役割について, 三宅秀明, 原勲, 吉村光司, 荒川創一, 守殿貞夫, 第 55 回日本癌学会総会, 1996
2. 遺伝子診断の新しい展開 尿中剥離細胞における CD44 の alternative splicing を標的にした RT-PCR 法の尿路上皮癌診断および予後因子としての有用性, 三宅秀明, 原勲, 守殿貞夫, 第 38 回日本癌治療学会総会, 2000
3. Antisense oligodeoxynucleotide therapy for advanced prostate cancer targeting TRPM-2 gene to delay androgen-independent progression and enhance chemosensitivity, 三宅秀明, 原勲, 守殿貞夫, 第 11 回前立腺癌ワークショップ, 2000
4. 新しい分子標的 ヒト膀胱癌モデルにおける clusterin を標的にしたアンチセンスオリゴ療法の基礎的検討, 三宅秀明, 原勲, 原章二, 彦坂玲子, 村蒔基次, 後藤章暢, 荒川創一, 守殿貞夫, 第 39 回日本癌治療学会総会, 2001
5. 化学療法効果増強 進行性前立腺癌における clusterin を標的にしたアンチセンスオリゴと p53 発現アデノウイルスの併用療法による相乗的抗腫瘍効果, 三宅秀明, 原勲, 守殿貞夫, 江藤弘, 第 61 回日本癌学会総会, 2002
6. 進行性前立腺癌に対する新しい戦略 進行性前立腺癌に対する clusterin を標的にしたアンチセンスオリゴ療法, 三宅秀明, 江藤弘, 原勲, 守殿貞夫, 第 41 回日本癌治療学会総会, 2003
7. 臨床病理の役割 Real-time RT-PCR 法による前立腺癌骨盤内リンパ節微小転移の検出とその臨床的意義, 三宅秀明, 酒井伊織, 原田健一, 江藤弘, 第 42 回日本癌治療学会総会, 2004
8. Gene Therapy and Tissue Engineering Antisense oligodeoxynucleotide therapy targeting antiapoptotic genes for advanced prostate cancer, Miyake H, 第 92 回日本泌尿器科学会総会, 2004
9. 分子標的治療の最先端 Clusterin を標的にしたアンチセンスオリゴを用いた前立腺癌に対する第一相臨床試験の経験, 三宅秀明, 原勲, Gleave Martin, 藤澤正人, 第 44 回日本癌治療学会総会, 2006
10. 難治性精巣腫瘍 症例検討, 三宅秀明, 藤澤正人, 第 48 回日本癌治療学会, 2010

11. 腎細胞癌の分子標的薬：内科的マネジメント 分子標的薬治療による副作用，三宅秀明，藤澤正人，第 53 回日本腎臓学会総会，2010
12. 膀胱全摘除術および新膀胱造設術を施行した浸潤性膀胱癌症例の QOL 調査，三宅秀明，酒井伊織，古川順也，原田健一，楠田雄司，村蒔基次，藤澤正人，第 49 回日本癌治療学会総会，2011
13. 泌尿器ロボット支援手術におけるトラブルシューティング ロボット支援手術のトラブルシューティング：神戸大学における経験と対策，三宅秀明，藤澤正人，第 26 回日本内視鏡外科学会総会，2013
14. 前立腺の生検前 MRI の意義：有用性と問題点 前立腺癌検出における multiparametric MRI の意義：生検前後の癌検出能の比較，三宅秀明，北島一宏，上野嘉子，村蒔基次，高橋哲，杉村和朗，藤澤正人，第 102 回日本泌尿器科学会総会，2014
15. 腎がん分子標的治療の現況と将来展望 転移性腎細胞癌におけるチロシンキナーゼ阻害剤の早期腫瘍縮小効果が予後に及ぼす影響，三宅秀明，桃園宏之，今井聡士，宮崎 彰，西川昌友，古川順也，原田健一，日向信之，村蒔基次，藤澤正人，第 53 回日本癌治療学会総会，2015
16. 前立腺がんーリスク別・進行期別治療のトピックスー 進行前立腺癌の逐次薬物療法に関する最近の話題と将来展望，三宅秀明，第 60 回日本癌治療学会総会，2022
17. 腎摘除術、副腎摘除術、腎尿管全摘除術は腹腔鏡か？ロボットか？ 静脈腫瘍塞栓を随伴する腎癌に対するロボット支援手術，三宅秀明，第 35 回日本内視鏡外科学会総会，2022

#### パネルディスカッション

1. トランスレーショナルリサーチとバイオベンチャー 前立腺癌に対する Clusterin を標的にしたアンチセンスオリゴ療法，三宅秀明，第 57 回西日本泌尿器科学会総会，2005
2. 去勢抵抗性前立腺がん治療の現状と今後の展望 CRPC に対する新規薬剤および治療体系開発の現況，三宅秀明，大園誠一郎，藤澤正人，第 31 回前立腺シンポジウム，2015

#### 特別企画

1. 尿路性器癌における抗アポトーシス遺伝子を標的にしたアンチセンスオリゴ療法の基礎的検討，三宅秀明，第 90 回日本泌尿器科学会総会，2002
2. 分子標的治療 進行性前立腺癌に対する clusterin を標的にしたアンチセンスオリゴ療法，三宅秀明，原勲，守殿貞夫，江藤弘，第 40 回日本癌治療学会総会，2002
3. pT3b 前立腺癌進展メカニズムの解明：基礎的臨床的アプローチ，三宅秀明，第 56 回日本泌尿器科学会中部総会，2006
4. ケーススタディ 精巣腫瘍，三宅秀明，藤澤正人，第 96 回日本泌尿器科学会総会，2008
5. 泌尿器科医による知的財産と特許申請 知的財産としての OGX-011 の開発から臨床試験に至るまでの経験，三宅秀明，藤澤正人，第 99 回日本泌尿器科学会総会，2011
6. IJU への投稿・査読について，三宅秀明，第 61 回日本泌尿器科学会中部総会，2011
7. IJU の現状と将来展望，三宅秀明，第 62 回日本泌尿器科学会中部総会，2012

8. ロボット支援前立腺全摘除術の諸問題, 三宅秀明, 藤澤正人, 第 1 回 泌尿器画像診断・治療技術研究会, 2013
9. 技術認定医レクチャー (泌尿器科), 三宅秀明, 第 26 回近畿内視鏡外科研究会, 2013
10. 治療開発マップの作成: 腎癌 腎細胞癌を対象とした臨床試験において検討すべき課題のアンケート結果, 三宅秀明, 第 102 回日本泌尿器科学会総会, 2014
11. ロボット手術を究める ~ベーシックからアドバンスまで~ 腎・膀胱に対するロボット支援手術の現況, 三宅秀明, 大園誠一郎, 藤澤正人, 第 8 回日本ロボット外科学会総会, 2016
12. CRPC に対する薬物療法の現況と展望, 三宅秀明, 大園誠一郎, 第 4 回泌尿器画像診断・治療技術研究会, 2016
13. 前立腺特別企画 前立腺癌の診断・治療ー前立腺進行がん治療 ホルモン感受性癌に対する化学療法, 三宅秀明, 大園誠一郎, 第 66 回日本泌尿器科学会中部総会, 2016
14. T1b 腎細胞癌に対する手術 Overview, 三宅秀明, 第 107 回日本泌尿器科学会総会, 2019
15. 最先端と次世代へのメッセージ 2: 泌尿器癌を対象とした臨床研究: 目指すべき方向性とは, 三宅秀明, 第 107 回日本泌尿器科学会総会, 2019
16. 変わりゆく転移性前立腺癌治療: 転移性去勢感受性前立腺癌に対する薬物療法の現況と課題, 三宅秀明, 第 33 回日本老年泌尿器科学会総会, 2020
17. 第 1 回 CST 教育・研究助成金途中経過報告 CST による腹腔鏡下泌尿器手術体験実習およびその VR 遠隔履修モデルの構築, 三宅秀明, 第 35 回日本泌尿器内視鏡学会総会, 2021
18. 第 1 回 CST 教育・研究助成金報告 CST による腹腔鏡下泌尿器手術体験実習およびその VR 遠隔履修モデルの構築, 三宅秀明, 第 36 回日本泌尿器内視鏡・ロボティクス学会総会, 2022

#### 教育プログラム

1. 日本泌尿器科学会卒後教育プログラム: 局所進行性前立腺癌の治療 局所進行性前立腺癌に対する手術療法, 三宅秀明, 第 58 回日本泌尿器科学会中部総会, 2008
2. 日本泌尿器科学会卒後教育プログラム: 低~中間リスク精巣腫瘍の治療 低・中リスク非セミノーマに対する治療戦略, 三宅秀明, 第 97 回日本泌尿器科学会総会, 2009
3. 日本泌尿器科学会卒後教育プログラム: 高リスク精巣腫瘍の治療 化学療法, 三宅秀明, 第 99 回日本泌尿器科学会総会, 2011
4. 日本泌尿器科学会卒後教育プログラム: 筋層浸潤および転移性膀胱がんの診断と治療 (尿路変向・化学療法を含む) 膀胱全摘除術と尿路変向, 三宅秀明, 第 62 回日本泌尿器科学会中部総会, 2012
5. 日本泌尿器科学会卒後教育プログラム: 進行性前立腺癌の治療 ホルモン療法, 三宅秀明, 第 103 回日本泌尿器科学会総会, 2015
6. 日本泌尿器内視鏡・ロボティクス学会第 9 回泌尿器ロボット支援手術プロクター教育セミナー ロボット支援根治的腎摘除術および副腎摘除術のプロクターリング, 三宅秀明, 第 36 回日本泌尿器内視鏡・ロボティクス学会総会, 2022

## 教育セミナー

1. 進行性腎細胞癌における薬物治療の新展開 進行性腎細胞癌に対する IL-2 と IFN- $\alpha$  併用療法の意義, 三宅秀明, 第 97 回日本泌尿器科学会総会, 2009
2. 転移性腎癌に対する分子標的薬の使用経験 ネクサバールを中心に, 三宅秀明, 第 59 回日本泌尿器科学会中部総会, 2009
3. 腎癌治療の最新知見 mTOR 阻害剤による転移性腎癌治療の最新知見, 三宅秀明, 第 99 回日本泌尿器科学会総会, 2011
4. 腎癌薬物治療における新しい時代の幕開け 使用経験から考える最適なファーストライン治療, 三宅秀明, 第 50 回日本癌治療学会総会, 2012
5. 去勢抵抗性前立腺癌に対する薬物療法の現況と展望, 三宅秀明, 第 101 回日本泌尿器科学会総会, 2013
6. 腎癌薬物療法の最新知見に基づく最適な治療戦略とは? RCC 治療における逐次療法の考え方とその実践, 三宅秀明, 第 51 回日本癌治療学会総会, 201
7. 転移性腎細胞癌に対する薬物療法 その展望と課題, 三宅秀明, 第 27 回日本泌尿器内視鏡学会総会, 2013
8. 前立腺がん治療に関する最近の話題～限局癌から CRPC まで～, 三宅秀明, 第 28 回日本内視鏡外科学会総会, 2015
9. CRPC に対する化学療法の位置付けとマネジメント CRPC に対する逐次治療における化学療法の意義, 三宅秀明, 第 53 回日本癌治療学会総会, 2015
10. CRPC 治療におけるジェブタナの役割: 使用経験に基づく考察, 三宅秀明, 第 54 回日本癌治療学会総会, 2016
11. タキサン療法で変わる新しい前立腺癌治療 転移性去勢抵抗性前立腺癌の治療最適化におけるジェブタナの位置付け, 三宅秀明, 第 104 回日本泌尿器科学会総会, 2016
12. Global and Japanese perspectives in CRPC treatment 本邦における CRPC に対する治療の現状と展望, 三宅秀明, 第 104 回日本泌尿器科学会総会, 2016
13. 去勢抵抗性前立腺癌の標準治療を模索する～エビデンスと実臨床の結びつき～, 三宅秀明, 第 67 回日本泌尿器科学会中部総会, 2017
14. 去勢抵抗性前立腺癌の標準治療を模索する～エビデンスと実臨床の結びつき～, 三宅秀明, 第 3 回日本泌尿器腫瘍学会総会, 2017
15. M0 CRPC : エビデンスのない M0 をどのように治療すべきか?, 三宅秀明, 第 56 回日本癌治療学会総会, 2018
16. 進行前立腺癌の治療選択を考える～アピラテロンを使いこなすために～, 三宅秀明, 第 83 回日本泌尿器科学会東部総会, 2018
17. I-0 drug 導入後の腎癌薬物療法の展望, 三宅秀明, 第 68 回日本泌尿器科学会中部総会, 2018



18. CRPC に対する至適治療戦略：実臨床の経験に基づく考察，三宅秀明，第 37 回日本アンドロロジー学会総会，2018
19. Treatment of mCRPC～Experience from Real World Clinical Practice in Japan ～，三宅秀明，第 106 回日本泌尿器科学会総会，2018
20. 進行尿路上皮癌治療の現状と課題～ペムブロリズマブの役割を中心に～，三宅秀明，第 68 回日本泌尿器科学会中部総会，2019
21. MOCRPC 治療の新展開，三宅秀明，第 5 回日本泌尿器腫瘍学会総会，2019
22. MOCRPC の臨床的特徴から考えるニューベクオの至適対象患者像，三宅秀明，第 108 回日本泌尿器科学会総会，2020
23. 転移性去勢感受性癌の薬物療法に関する最近の話題，三宅秀明，第 58 回日本癌治療学会総会，2020
24. mRCC に対する至適治療戦略～1 次治療を中心に～，三宅秀明，第 58 回日本癌治療学会総会，2020
25. 複合がん免疫療法時代におけるペムブロリズマブ＋アキシチニブ併用療法の役割 ～逐次治療を含めて～，三宅秀明，第 69 回日本泌尿器科学会中部総会，2020
26. 令和時代の前立腺がん治療戦略を考える，三宅秀明，第 69 回日本泌尿器科学会中部総会，2020
27. mRCC に対する IO-TKI の位置づけ～最新データおよび実臨床経験に基づく考察～，三宅秀明，第 59 回日本癌治療学会総会，2021
28. mCSPC に対する至適薬物療法の変遷と展望，三宅秀明，第 72 回日本泌尿器科学会中部総会，2022
29. エビデンスに基づく mCRPC に対する最適な逐次治療とは？，三宅秀明，第 74 回西日本泌尿器科学会総会，2022

#### ランチョンセミナー

1. 転移性腎細胞癌に対する IFN- $\alpha$  と分子標的薬の併用療法，三宅秀明，第 59 回日本泌尿器科学会中部総会，2009
2. 進行腎癌に対する分子標的治療 スーテントを中心に，三宅秀明，第 60 回 日本泌尿器科学会中部総会，2010
3. 分子標的療法時代におけるサイトカイン療法の意義，三宅秀明，第 75 回日本泌尿器科学会東部総会，2010
4. 転移性腎細胞癌 分子標的療法時代におけるサイトカイン療法の意義と限界，三宅秀明，第 77 回日本泌尿器科学会東部総会，2012
5. 去勢抵抗性前立腺癌に対する新規治療戦略確立に向けた取り組み，三宅秀明，第 32 回日本アンドロロジー学会総会，2013
6. 腎がん薬物療法におけるファーストライン治療の重要性と継続投与の工夫，三宅秀明，第 79

回日本泌尿器科学会東部総会，2014

7. 進行前立腺癌に対する薬物療法の最新の話題，三宅秀明，第34回日本アンドロロジー学会総会，2015
8. 本邦におけるCRPC治療の展望（化学療法を中心に），三宅秀明，第103回日本泌尿器科学会総会，2015
9. 筋層非浸潤性膀胱癌の治療戦略に関する最近の話題，三宅秀明，第66回日本泌尿器科学会中部総会，2016
10. 腎細胞癌治療に関する最近の話題：低侵襲手術から薬物治療まで，三宅秀明，第30回日本泌尿器内視鏡学会総会，2016
11. 腎細胞癌治療に関する最近の話題：低侵襲手術から薬物療法まで，三宅秀明，第31回日本泌尿器内視鏡学会総会，2017
12. CRPCに対する逐次治療におけるジェブタナの役割，三宅秀明，第105回日本泌尿器科学会総会，2017
13. 転移性腎細胞癌に対する至適薬物療法：自験例に基づく考察，三宅秀明，第105回日本泌尿器科学会総会，2017
14. CRPCに対する逐次治療における新規AR標的薬の役割，三宅秀明，第105回日本泌尿器科学会総会，2017
15. 進行前立腺癌の標準治療を模索する～エビデンスと実臨床の結びつき～，三宅秀明，第29回日本性機能学会総会，2018
16. 進行腎癌に対する至適一次治療：各種併用療法の導入を見据えて，三宅秀明，第107回日本泌尿器科学会総会，2019
17. 進行前立腺癌に対する至適治療戦略確立に向けた取り組み，三宅秀明，第107回日本泌尿器科学会総会，2019
18. CRPCに対する逐次療法における化学療法の役割，三宅秀明，第85回日本泌尿器科学会東部総会，2020
19. 転移性腎細胞癌における薬物治療戦略を考える，三宅秀明，第85回日本泌尿器科学会東部総会，2020
20. mCSPCに対するアピラテロンの役割：RCTおよび実臨床からの再検証，三宅秀明，第109回日本泌尿器科学会総会，2021
21. 複合免疫療法時代を迎えた進行腎癌に対する至適治療戦略，三宅秀明，第80回日本癌学会総会，2021
22. mCRPCに対する至適治療戦略，三宅秀明，第86回日本泌尿器科学会東部総会，2021
23. 泌尿器科領域におけるロボット支援手術の現況と展望，三宅秀明，第11回日本低侵襲・内視鏡脊髄神経外科学会総会，2021

24. 進行腎癌に対する薬物療法の現況と課題：一次治療を中心に，三宅秀明，一次治療を中心に，第36回腎移植・血管外科研究会総会，2021
25. 本邦における進行前立腺癌に対する治療の現況と展望，三宅秀明，第35回日本老年泌尿器科学会総会，2022
26. 複合免疫療法時代を迎えた進行腎癌に対する至適治療戦略，三宅秀明，第36回日本泌尿器内視鏡・ロボティクス学会総会，2022
27. 複合がん免疫療法時代におけるペムブロリズマブ+レンバチニブ併用療法の位置付け，三宅秀明，第36回日本泌尿器内視鏡・ロボティクス学会総会，2022

#### サテライトシンポジウム

1. 進行腎細胞癌の薬物治療（mTOR 阻害剤を中心に）アフィニトールの使用経験と今後の課題，三宅秀明，第60回日本泌尿器科学会中部総会，2010
  2. ハイリスク前立腺癌へのアプローチ Surgical Tx & Combination，三宅秀明，藤澤正人，第63回日本泌尿器科学会中部総会，2013
  3. ケースから考える腎細胞癌の集学的治療最前線 実臨床から考える腎細胞がん治療の最適な薬剤選択とは？，三宅秀明，第64回日本泌尿器科学会中部総会，2014
-

# 業 績 目 録

## 6. 学会発表(国際会議)

No. 1

(番号, 演題名, 発表者(共同発表者を含む), 学会名, 発行年の順に記入してください。)

### Special Lecture

1. Antisense testosterone-repressed prostate message-2 oligodeoxynucleotides inhibit progression to androgen-independence in the Shionogi tumor model. Miyake H. 第 54 回 Canadian Urological Association Annual Meeting, 1999
2. Current and emerging treatment with chemotherapy options in mCRPC. Miyake H. 第 30 回 Koria-Japan Urological Congress, 2013

### Symposium

1. Surgical Treatment for Localized Prostate cancer Development of “extended radical retropubic prostatectomy (ERRP)” : a new surgical technique for improving margin status. Miyake H., Fujimoto H, Komiyama M, Takenaka A, Fujisawa M. 第 53 回 Annual Congress of the Japan Section of the International College of Surgeons, 2007
2. Systematic surgical approach for RCC with IVC thrombus. Miyake H. 第 37 回 Koria-Japan Urological Congress, 2021
3. Prognostic significance of time to castration resistance in mCSPC. Miyake H. 第 19 回 Urological Association of Asia Congress, 2021
4. Kidney Cancer Current status and future prospect of IO-TKI combined therapy for metastatic renal cell carcinoma. Miyake H. 第 7 回 East Asia Urological Oncology Society Congress, 2021

### Panel Discussion

1. Panel discussion on clinical cases: How to approach this situation?. Miyake H. 第 12 回 American Urological Association/Japanese Urological Association International Affiliate Society Meeting, 2017

### General Lecture

1. Introduction of basic fibroblast growth factor (FGF-2) gene into mouse renal cell carcinoma cell line induces progression in malignant phenotype. Miyake H., Hara I, Yoshimura K, Eto H, Arakawa S, Kamidono S. 第 91 回 American Urological Association Annual Meeting, 1996
2. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. Miyake H., Hara I, Yoshimura K, Eto H, Arakawa S, Kamidono S. 第 92 回 American Urological Association Annual Meeting, 1997
3. Antisense Bcl-2 oligonucleotides enhance the cytotoxic effect of taxol in the Shionogi tumor model. Miyake H., Nelson C, Gleave ME. American Association for Cancer Research Special Conference: New Research Approaches in the Prevention and Cure of Prostate Cancer, 1998
4. Antisense Bcl-2 oligodeoxynucleotide enhances the chemosensitivity of taxol in the Shionogi tumor model. Miyake H., Tolcher A, Gleave ME. 第 94 回 American Urological

Association Annual Meeting, 1999

5. Antisense Bcl-2 oligodeoxynucleotide inhibits progression to androgen independence and enhances the chemosensitivity of taxol in the Shionogi tumor model. Miyake H, Tolcher A, Gleave ME. 第 54 回 Canadian Urological Association Annual Meeting, 1999
6. Changes in gene expression during androgen-independent progression in the Shionogi tumor model: upregulation of multiple gene pathway precipitated by androgen ablation. Miyake H, Nelson C, Gleave ME. 第 54 回 Canadian Urological Association Annual Meeting, 1999
7. Antisense TRPM-2 oligodeoxynucleotides delay progression to androgen independence and enhance chemosensitivity in prostate cancer tumor model. Miyake H, Chi KN, Gleave ME. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery, Development and Clinical Validation, 1999
8. Castration-induced up-regulation of insulin-like growth factor binding protein-5 (IGFBP-5) potentiates IGF-I activity and accelerates progression to androgen-independence in prostate cancer. Miyake H, Nelson C, Rennie PS, Gleave ME. 第 91 回 American Association for Cancer Research Annual Meeting, 2000
9. Castration-induced up-regulation of insulin-like growth factor binding protein-5 (IGFBP-5) potentiates IGF-I activity and accelerates progression to androgen-independence in prostate cancer. Miyake H, Gleave ME. 第 95 回 American Urological Association Annual Meeting, 2000
10. Synergistic chemosensitization and inhibition of tumor growth and metastasis by antisense oligodeoxynucleotide targeting TRPM-2 gene in human bladder cancer model. Miyake H, Hara I, Hara S, Arakawa S, Gleave ME, Kamidono S. 第 96 回 American Urological Association Annual Meeting, 2001
11. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. 第 97 回 American Urological Association Annual Meeting, 2002
12. Overexpression of CD44v8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. 第 97 回 American Urological Association Annual Meeting, 2002
13. Overexpression of TRPM-2 enhances metastatic potential of human renal cell carcinoma cells. Miyake H, Hara I, Hara S, Kamidono S, Gleave M. 第 97 回 American Urological Association Annual Meeting, 2002
14. Prediction of the extent of prostate cancer by the combined use of systematic biopsy and serum level of cathepsin D. Miyake H, Hara I, Kamidono S, Eto H. 第 98 回 American Urological Association Annual Meeting, 2003
15. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin using CD44 alternative splicing patterns. Miyake H, Hara I, Kamidono S, Eto H. 第 98 回 American Urological Association Annual Meeting, 2003

16. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Miyake H, Hara I, Kamidono S, Gleave M, Eto H. 第98回 American Urological Association Annual Meeting, 2003
17. Synergistic antitumor effect of combined use of antisense clusterin oligodeoxynucleotide and adoviral-mediated p53 gene transfer in the androgen-independent human prostate PC3 tumor model. Miyake H, Hara I, Kamidono S, Eto H, Gleave M. 第98回 American Urological Association Annual Meeting, 2003
18. Overexpression of insulin-like growth factor binding protein-2 in human bladder cancer cells enhances their metastatic potential. Miyake H, Hara I, Kamidono S, Eto H. 第99回 American Urological Association Annual Meeting, 2004
19. Quantitative detection of micrometastases in pelvic lymph nodes using real-time RT-PCR in clinically localized prostate cancer. Miyake H, Kurahashi T, Hara I, Kamidono S, Eto H. 第100回 American Urological Association Annual Meeting, 2005
20. Prognostic significance of insulin-like growth factor binding protein-2 to insulin-like growth factor binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder. Miyake H, Yamanaka K, Muramaki M, Kamidono S, Hara I. 第100回 American Urological Association Annual Meeting, 2005
21. Quantitative detection of micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by using real-time reverse transcriptase polymerase chain reaction targeting prostate-specific antigen and prostate-specific membrane antigen genes. Miyake H, Kurahashi T, Inoue T, Hara I, Fujisawa M. 第101回 American Urological Association Annual Meeting, 2006
22. Induction of apoptosis and enhancement of chemosensitivity in human bladder cancer KoTCC-1 cells using small interference RNA targeting heat shock protein-70. Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. 第102回 American Urological Association Annual Meeting, 2007
23. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy following neoadjuvant hormonal therapy. Miyake H, Kurahashi T, Takenaka A, Hara I, Fujisawa M. 第102回 American Urological Association Annual Meeting, 2007
24. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. 第102回 American Urological Association Annual Meeting, 2007
25. Clinical outcome of combined immunotherapy with interferon- $\alpha$  and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Inoue T, Fujisawa M. 第25回 Japan-Korea Urological Congress, 2008

26. Long-term functional outcomes in patients with various types of orthotopic intestinal neobladder. Miyake H, Furukawa J, Takenaka A, Yamanaka N, Kamidono S, Fujisawa M. 第103回 American Urological Association Annual Meeting, 2008
27. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Miyake H, Muramaki M, Takenaka A, Kamidono S, Fujisawa M. 第103回 American Urological Association Annual Meeting, 2008
28. Which is the most optimal target gene for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase polymerase chain reaction?. Miyake H, Kurahashi T, Takenaka A, Kamidono S, Fujisawa M. 第104回 American Urological Association Annual Meeting, 2009
29. Long-term outcomes of orthotopic neobladder reconstruction after radical cystectomy for bladder cancer in Japanese men: assessment of complications, voiding patterns and quality of life. Miyake H, Furukawa J, Takenaka A, Kamidono S, Fujisawa M. 第104回 American Urological Association Annual Meeting, 2009
30. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Miyake H, Kusuda Y, Furukawa J, Muramaki M, Nakano Y, Tanaka K, Fujisawa M. 第27回 Japan-Korea Urological Congress, 2010年
31. Orthotopic neobladder reconstruction following radical cystectomy in Japanese women: comparative study between sigmoid and ileal neobladders. Miyake H, Furukawa J, Takenaka A, Fujisawa M. 第105回 American Urological Association Annual Meeting, 2010
32. Laparoscopic radical versus laparoscopic partial nephrectomy for clinical pT1 renal cell carcinoma: comparison of perioperative, pathological and functional outcomes. Miyake H, Muramaki M, Ishimura T, Nakano Tanaka K, Fujisawa M. 第8回 Annual Meeting of the East Asian Society of Endourology, 2011
33. Laparoscopic radical versus laparoscopic partial nephrectomy for clinical pT1 renal cell carcinoma: comparison of perioperative, pathological and functional outcomes. Miyake H, Muramaki M, Ishimura T, Nakano Tanaka K, Fujisawa M. 第29回 World Congress of Endourology and SWL, 2011
34. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Miyake H, Muramaki M, Kamidono S, Fujisawa M. 第106回 American Urological Association Annual Meeting, 2011
35. Orthotopic sigmoid neobladder after radical cystectomy: assessment of complications, functional outcomes and quality of life in 82 Japanese patients. Miyake H, Furukawa J, Kamidono S, Fujisawa M. 第106回 American Urological Association Annual Meeting, 2011
36. Assessment of the most optimal target gene for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction. Miyake H, Kusuda Y, Kurahashi T, Fujisawa M. 第26回 European Association of Urology Annual Meeting, 2011

37. Orthotopic sigmoid versus ileal neobladders in Japanese patients: a comparative assessment of complications, functional outcomes and quality of life. Miyake H, Furukawa J, Muramaki M, Fujisawa M. 第 32 回 Congress of the Société Internationale d'Urologie, 2012
38. Prognostic significance of tumor extension into venous system in patients undergoing surgical treatment for renal cell carcinoma with venous tumor thrombus. Miyake H, Furukawa J, Muramaki M, Fujisawa M. 第 32 回 Congress of the Société Internationale d'Urologie, 2012
39. Expression of integrin proteins in non-muscle invasive bladder cancer: significance of intravesical recurrence following transurethral resection. Miyake H, Behnsawy H, Fujisawa M. 第 107 回 American Urological Association Annual Meeting, 2012
40. Expression of epithelial-mesenchymal transition markers in localized prostate cancer: impact on clinicopathological outcomes in patients undergoing radical prostatectomy. Miyake H, Behnsawy H, Fujisawa M. 第 107 回 American Urological Association Annual Meeting, 2012
41. Long-term outcomes following radical prostatectomy in prostate cancer patients with micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction. Miyake H, Kurahashi T, Fujisawa M. 第 107 回 American Urological Association Annual Meeting, 2012
42. Expression of cell cycle-associated proteins in non-muscle invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Miyake H, Behnsawy HM, Fujisawa M. 第 27 回 European Association of Urology Annual Meeting, 2012
43. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Miyake H, Muramaki M, Fujisawa M. 第 27 回 European Association of Urology Annual Meeting, 2012
44. Impact of the primary Gleason pattern on biochemical recurrence-free survival in Japanese patients with Gleason 7 prostate cancer who underwent radical prostatectomy. Miyake H, Muramaki M, Fujisawa M. 第 108 回 American Urological Association Annual Meeting, 2013
45. Limited significance of routine excretory urography as a surveillance of the upper urinary tract in follow-up of patients with non-muscle invasive bladder cancer after transurethral resection. Miyake H, Harada K, Fujisawa M. 第 108 回 American Urological Association Annual Meeting, 2013
46. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumor cell proliferation. Miyake H, Sakai I, Fujisawa M. 第 28 回 European Association of Urology Annual Meeting, 2013
47. Expression of epithelial-mesenchymal transition markers in localized prostate cancer: Impact on clinicopathological outcomes in patients undergoing radical prostatectomy. Miyake H, Behnsawy S, Fujisawa M. 第 28 回 European Association of Urology Annual Meeting,



2013

48. Health related quality of life after radical cystectomy: Comparative study between orthotopic sigmoid versus ileal neobladders. Miyake H, Furukawa J, Muramaki M, Fujisawa M. 第28回 European Association of Urology Annual Meeting, 2013
49. Objective assessment of residual nerve tissues on radical prostatectomy specimens by immunohistochemical staining of neuronal nitric oxide synthase-positive nerves and its impact on postoperative erectile function. Miyake H, Hinata N, Fujisawa M. 第109回 American Urological Association Annual Meeting, 2014
50. Visualization of periprostatic nerve fibers before and after radical prostatectomy using diffusion tensor magnetic resonance imaging with tractography. Miyake H, Kitajima K, Takahashi S, Ueno Y, Sugimura K, Fujisawa M. 第109回 American Urological Association Annual Meeting, 2014
51. Expression profile of epithelial-mesenchymal transition markers in non-muscle invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection. Miyake H, Bing L, Fujisawa M. 第109回 American Urological Association Annual Meeting, 2014
52. Visualization of periprostatic nerve fibers before and after radical prostatectomy using diffusion tensor magnetic resonance imaging with tractography. Miyake H, Kitajima K, Takahashi S, Ueno Y, Sugimura K, Fujisawa M. 第29回 European Association of Urology Annual Meeting, 2014
53. Expression profile of epithelial-mesenchymal transition markers in non-muscle invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection. Miyake H, Bing L, Fujisawa M. 第29回 European Association of Urology Annual Meeting, 2014
54. Early tumor shrinkage under first-line tyrosine kinase inhibitor as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Miyake H, Harada K, Fujisawa M. 第110回 American Urological Association Annual Meeting, 2015
55. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real world clinical practice in Japan. Miyake H, Miyazaki A, Harada K, Fujisawa M. 第110回 American Urological Association Annual Meeting, 2015
56. Early tumor shrinkage under first-line tyrosine kinase inhibitor as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Miyake H, Harada K, Fujisawa M. 第40回 European Society of Medical Oncology Annual Meeting, 2015
57. Prognostic significance of tumor extent into the venous system in patients undergoing surgical treatment for renal cell carcinoma with venous tumor thrombus. Miyake H, Hara T, Fujisawa M. 第111回 American Urological Association Annual Meeting, 2016
58. Health-related quality of life after radical cystectomy: Comparative study between

orthotopic sigmoid versus ileal neobladders. Miyake H, Furukawa J, Fujisawa M. 第111回 American Urological Association Annual Meeting, 2016

59. Prognostic significance of early tumor shrinkage under second-line targeted therapy for metastatic renal cell carcinoma: a retrospective multiinstitutional study in Japan. Miyake H, Ozono S, Fujisawa M. 第41回 European Society of Medical Oncology Annual Meeting, 2016

60. Early tumor shrinkage under second-line targeted therapy for metastatic renal cell carcinoma as a predictor of overall survival: a retrospective multiinstitutional study in Japan. Miyake H, Tamura K, Ozono S. 第112回 American Urological Association Annual Meeting, 2017

---